


# P(A) Event Hall



## 16:30-17:15

- P-1001 .... P1-1 Cell culture experiments
- P-1007 .... P2-1 Animal models for cancer (1)
- P-1014 .... P3-1 HTLV-1, KSHV
- P-1021 .... P4-1 Wnt signaling
- P-1026 .... P4-2 Cancer basic, diagnosis and treatment
- P-1030 .... P4-3 RNA-related new oncogenes and tumor suppressor genes
- P-1034 .... P5-1 Signal transduction of cancer cells and inhibitors (1)
- P-1041 .... P7-1 Cancer genomic analysis (1)
- P-1046 .... P8-1 Cell death as therapeutic targets
- P-1053 .... P9-1 Histone modification (1)
- P-1058 .... P10-1 Molecular pathology of cancer behavior (1)
- P-1065 .... P10-2 Inter-tissue interactions in metastasis
- P-1070 .... P11-1 Cancer stem cell (1)
- P-1077 .... P11-2 Cancer stem cell (2)
- P-1084 .... P11-3 Cell differentiation and cancer progression
- P-1090 .... P11-4 Metabolism in cancer (1)
- P-1095 .... P12-1 Antibody-based therapy of gastrointestinal cancer
- P-1101 .... P13-1 Growth factor and cytokine (1)

## 17:15-18:00

- P-1200 .... P1-2 3D cell culture experiments
- P-1206 .... P3-2 Virus associated gastric cancer and hepatoma
- P-1211 .... P3-3 Inflammation and cancer (1)
- P-1216 .... P4-4 RB/p16 and p53 tumor suppressor pathways
- P-1223 .... P4-5 Oncogenes and tumor-suppressor genes (1)
- P-1230 .... P5-2 Cell proliferation
- P-1236 .... P5-3 MicroRNAs (1)
- P-1243 .... P7-2 Hereditary cancer
- P-1250 .... P9-2 Diagnostic and therapeutic application of aberrant DNA methylation
- P-1256 .... P10-3 Molecular pathology of cancer behavior (2)
- P-1263 .... P10-4 Angiogenesis
- P-1270 .... P10-5 New methods for studying invasion and metastasis
- P-1277 .... P11-5 Cancer stem cell (3)
- P-1283 .... P11-6 Cell-cell communication in cancer development
- P-1290 .... P11-7 PDX and organoid
- P-1295 .... P12-2 Tumor antigen / effector
- P-1300 .... P12-3 Novel approaches in cancer immunotherapy



## 1 Chemical carcinogenesis and radiation carcinogenesis

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

### P1-1 Cell culture experiments

培養細胞実験

Chairperson: Takao Miki (Dept. Pharmacology, Kansai Med. Univ.)

座長: 三木 貴雄 (関西医大・医薬理学講座)

- P-1001 Analysis of immunoproteasome as a therapeutic target in cisplatin-resistant small and non-small cell lung cancer**  
Tetsuaki Shoji<sup>1</sup>, Eiki Kikuchi<sup>1</sup>, Junko Kikuchi<sup>1</sup>, Yuta Takashima<sup>1</sup>, Megumi Furuta<sup>1</sup>, Ichiro Kinoshita<sup>1,2</sup>, Hirotohi Dosaka-Akita<sup>2</sup>, Jun Sakakibara-Konishi<sup>1</sup> (<sup>1</sup>Dept. Respiratory Med., Grad. Sch. of Med., Hokkaido Univ., <sup>2</sup>Dept. Med. Oncology, Grad. Sch. of Med., Hokkaido Univ.)  
シスプラチン耐性肺癌の治療標的としての免疫プロテアソームの検討  
庄司 哲明<sup>1</sup>、菊地 英毅<sup>1</sup>、菊地 順子<sup>1</sup>、高島 雄太<sup>1</sup>、古田 恵<sup>1</sup>、木下一郎<sup>1,2</sup>、秋田 弘俊<sup>2</sup>、榊原 純<sup>1</sup> (北海道大・院呼吸器内科学教室、<sup>2</sup>北海道大・院腫瘍内科学教室)
- P-1002 Murine MHC-haploidentical Transplant Model Using Cyclophosphamide-resistant Tumor Cell Lines**  
Hiroko Umezawa<sup>1</sup>, Isao Tawara<sup>1</sup>, Junya Tsuboi<sup>1</sup>, Kazuko Ino<sup>1</sup>, Kohshi Ohishi<sup>2</sup>, Masahiro Masuya<sup>1</sup>, Yoshihiro Miyahara<sup>3</sup>, Hiroshi Shiku<sup>3,4</sup>, Naoyuki Katayama<sup>1</sup> (<sup>1</sup>Dept. Hematol. & Oncol., Mie Univ., Grad. Sch. Med., <sup>2</sup>Dept. Transfusion Med. & Cell Ther., Mie Univ. Hosp., <sup>3</sup>Dept. Personalized Cancer Immunother., Mie Univ. Grad. Sch. Med., <sup>4</sup>Dept. Immuno-gene Ther., Mie Univ. Grad. Sch. Med.)  
シクロホスファミド抵抗性の腫瘍細胞株を用いたマウス MHC 半合致移植モデル  
梅澤 紘子<sup>1</sup>、依 功<sup>1</sup>、坪井 順哉<sup>1</sup>、伊野 和子<sup>1</sup>、大石 晃嗣<sup>2</sup>、榎屋 正浩<sup>1</sup>、宮原 慶裕<sup>3</sup>、珠玖 洋<sup>3,4</sup>、片山 直之<sup>1</sup> (三重大・医・血液腫瘍内科、<sup>2</sup>三重大・医・輸血細胞治療部、<sup>3</sup>三重大・医・個別化がん免疫治療、<sup>4</sup>三重大・医・免疫細胞治療)
- P-1003 Cancer associated fibroblasts display tissue heterogeneity and induce (VEGFA) in clinical perturbations**  
Ken-ichi Inoue (Ctr. for Res. Support, Dokkyo Med. Univ.)  
癌関連線維芽細胞は臓器ごとに多様な遺伝子発現を示し、治療に伴う状態変動によって VEGFA を誘導する  
井上 健一 (獨協医大・研究支援セ)
- P-1004 Sensitive and rapid technique for exosome quantification by labeling exosome markers with luciferase**  
Tomoya Hikita<sup>1</sup>, Chitose Oniyama<sup>1,2</sup> (<sup>1</sup>Div. Cancer Cell Regulation., Aichi Cancer Ctr. Res. Inst., <sup>2</sup>JST, PRESTO)  
生物発光を用いた新規エクソソーム研究基盤の構築  
疋田 智也<sup>1</sup>、小根山 千歳<sup>1,2</sup> (愛知県がん研セ・研・腫瘍制御、<sup>2</sup>JST・さきかけ)
- P-1005 Molecular mechanism of polarity switching in micropapillary carcinoma**  
Kunishige Onuma, Junpei Kondo, Masahiro Inoue (Dept. Clin. Bioresource Res. Dev. Grad. Sch. Med. Kyoto Univ.)  
Micropapillary carcinoma 病態における極性転換とその分子機構  
小沼 邦重、近藤 純平、井上 正宏 (京都大・医・CL バイオリソース研究開発講座)
- P-1006 The tropisms of SHSY-5Y neuroblastoma cells by bone marrow derived mesenchymal stem cells**  
Chia-Chu Hsieh, Dong-Ming Huang (Inst. of Biomed. Engineering & Nanomedicine, NHRI)

## 2 Experimental animal models and genetically-engineered animals

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

### P2-1 Animal models for cancer (1)

動物モデル (1)

Chairperson: Masahiro Inoue (Kyoto Univ. Grad. Sch. of Med. Dept. Clin. Bioresource Res. & Development)

座長: 井上 正宏 (京都大・院医・クリニカルバイオリソース研究開発講座)

- P-1007 Phenotypical and genotypical strain difference on the manifestation of NASH between Hsd and F344 rats fed the CDA diet**  
Kindoko Uno<sup>1</sup>, Noriko Kemuriyama<sup>2</sup>, Dai Nakae<sup>1,2</sup> (<sup>1</sup>Dept. Food & Nutr. Sci., Grad. Sch. Tokyo Univ. Agricul., <sup>2</sup>Dept. Nutr. Sci. Food Safety, Tokyo Univ. Agricul.)  
Hsd ラットと F344 ラットにおける CDA 食誘発性 NASH の表現型及び遺伝子型の系統差  
宇野 絹子<sup>1</sup>、煙山 紀子<sup>2</sup>、中江 大<sup>1,2</sup> (東京農業大・院・食品栄養学専攻、<sup>2</sup>東京農業大・食品安全健康学科)
- P-1008 Histological assessment of intratumoral lymphoplasmacytic infiltration as a prediction way of LPL incidence in PDX model**  
Angeline Ping Ping Tch<sup>1</sup>, Mie Naruse<sup>1</sup>, Masako Ochiai<sup>2</sup>, Mami Takahashi<sup>1</sup>, Toshio Imai<sup>1,2</sup> (<sup>1</sup>Natl. Cancer Ctr. Res. Inst., Ctr. Anim. Div., <sup>2</sup>Natl. Cancer Ctr. Res. Inst., Dept. Anim. Exp.)  
PDX モデルにおける LPL 発生率の予測法としての腫瘍内リンパ形質細胞浸潤の組織学的評価  
テ アンジェリンピンピン<sup>1</sup>、成瀬 美衣<sup>1</sup>、落合 雅子<sup>2</sup>、高橋 真美<sup>1</sup>、今井 俊夫<sup>1,2</sup> (国立がん研セ・研・動物実験施設、<sup>2</sup>国立がん研セ・研・動物実験部門)
- P-1009 Faithful expression of stem cell genes in PDX and organoids reproduced features of individual original colorectal cancer**  
Mie Naruse<sup>1</sup>, Masako Ochiai<sup>2</sup>, Atsushi Ochiai<sup>3</sup>, Toshio Imai<sup>1,2,3</sup> (<sup>1</sup>Ctr. Anim. Div., Natl. Cancer Ctr. Res. Inst., <sup>2</sup>Dept. Anim. Exp., Natl. Cancer Ctr. Res. Inst., <sup>3</sup>EPOC, Natl. Cancer Ctr.)  
大腸がん手術検体由来の PDX およびオルガノイドは、症例特異的な幹細胞のマーカー遺伝子の発現を維持している  
成瀬 美衣<sup>1</sup>、落合 雅子<sup>2</sup>、落合 淳志<sup>3</sup>、今井 俊夫<sup>1,2,3</sup> (国立がん研セ・研・動物実験施設、<sup>2</sup>国立がん研セ・研・動物実験部門、<sup>3</sup>国立がん研セ・先端医療開発セ)
- P-1010 Engraftment rate of patient-derived xenograft in various patients' status: lung cancer analysis of J-PDX library project**  
Masayuki Shirasawa<sup>1</sup>, Hidehito Horinouchi<sup>1</sup>, Midori Tanaka<sup>2</sup>, Yuki Shinno<sup>3</sup>, Yuji Matsumoto<sup>1,2</sup>, Tatsuya Yoshida<sup>1</sup>, Yasushi Goto<sup>1</sup>, Noboru Yamamoto<sup>1</sup>, Noriko Moto<sup>3</sup>, Shunichi Watanabe<sup>4</sup>, Shigehiro Yagishita<sup>3</sup>, Akinobu Hamada<sup>3</sup>, Yuichiro Ohe<sup>1</sup> (<sup>1</sup>Dept. Thorac. Oncol. Natl. Cancer Ctr. Hosp., <sup>2</sup>Dept. Endosc. Natl. Cancer Ctr. Hosp., <sup>3</sup>Dept. Path. Natl. Cancer Ctr. Hosp., <sup>4</sup>Dept. Thorac. Surg. Natl. Cancer Ctr. Hosp., <sup>5</sup>Div. Mol. Pharmacol. Natl. Cancer Ctr. Res. Inst.)  
肺癌患者の背景による PDX 生着率: J-PDX ライブラリープロジェクトの肺癌コホート  
白澤 昌之<sup>1</sup>、堀之内 秀仁<sup>1</sup>、田中 緑<sup>2</sup>、新野 祐樹<sup>1</sup>、松元 祐司<sup>1,2</sup>、吉田 達哉<sup>1</sup>、後藤 倂<sup>1</sup>、山本 昇<sup>1</sup>、元井 紀子<sup>3</sup>、渡辺 俊一<sup>4</sup>、柳下 薫寛<sup>5</sup>、濱田 哲暢<sup>5</sup>、大江 裕一郎<sup>1</sup> (国立がん研セ・中央病院・呼吸器内科、<sup>2</sup>国立がん研セ・中央病院・内視鏡科、<sup>3</sup>国立がん研セ・中央病院・病理診断科、<sup>4</sup>国立がん研セ・中央病院・呼吸器外科、<sup>5</sup>国立がん研セ・研・分子薬理)
- P-1011 Incidence of graft-versus-host diseases in the establishment of patient-derived xenograft model**  
Shigehiro Yagishita<sup>1</sup>, Ako Takahashi<sup>1</sup>, Megumi Umeda<sup>1</sup>, Mitsuhiro Hayashi<sup>1</sup>, Angeline The Ping Ping<sup>2</sup>, Rikako Ishigamori<sup>2</sup>, Mami Takahashi<sup>2</sup>, Toshio Imai<sup>2</sup>, Akinobu Hamada<sup>1</sup> (<sup>1</sup>Div. Mol. Pharm., NCCRI, <sup>2</sup>Cen. Anim. Div., NCCRI)  
患者腫瘍移植モデル樹立過程における移植片対宿主病の発生頻度  
柳下 薫寛<sup>1</sup>、高橋 亜子<sup>1</sup>、梅田 愛<sup>1</sup>、林 光博<sup>1</sup>、テピンピン アンジェリン<sup>2</sup>、石ケ守 里加子<sup>2</sup>、高橋 真美<sup>2</sup>、今井 俊夫<sup>2</sup>、濱田 哲暢<sup>1</sup> (国立がん研セ・研・分子薬理、<sup>2</sup>国立がん研セ・研・動物実験施設)
- P-1012 Exome sequencing identifies a distinct mutational landscape in SFN-transgenic mice bearing human lung adenocarcinoma**  
Yunjung Kim, Aya Shiba, Masayuki Noguchi (Dept. Pathol., Univ. of Tsukuba)
- P-1013 Withdrawn**

## 3 Virus, infection, inflammation and cancer

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

P3-1

## HTLV-1, KSHV

ヒトT細胞白血病ウイルス1型、カポジ肉腫ウイルス

Chairperson: Jun-ichiro Yasunaga (Lab of Virus Control, INFRONT, Kyoto Univ.)

座長: 安永 純一郎 (京都大・ウイルス・再生医科学研)

## P-1014 Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma

Yoshihiro Komohara<sup>1</sup>, Baghdadi Muhammad<sup>2</sup>, Ken-ichiro Seino<sup>2</sup>, Yutaka Okuno<sup>3</sup>, Kisato Nosaka<sup>3</sup>, Masao Matsuoka<sup>3</sup> (<sup>1</sup>Dept. Cell athology, Kumamoto Univ., <sup>2</sup>Institute for Genetic Med., Hokkaido Univ., <sup>3</sup>Dept. Hematology, Kumamoto Univ.)

## ATLL における M-CSFR 発現と M-CSFR 阻害剤の有効性

孤原 義弘<sup>1</sup>、Baghdadi Muhammad<sup>2</sup>、清野 研一郎<sup>2</sup>、奥野 豊<sup>3</sup>、野坂 生郷<sup>3</sup>、松岡 雅雄<sup>3</sup> (<sup>1</sup>熊本大・生命科学・細胞病理学、<sup>2</sup>北海道大・遺伝子制御研、<sup>3</sup>熊本大・血液内科)

## P-1015 CADM1 enhances organ infiltration of adult T-cell leukemia/lymphoma cells

Yutaka Kasai, Takeshi Ito, Yoshinori Murakami (Div. Mol. Pathol., Inst. Med. Sci., Univ. Tokyo)

細胞接着分子 CADM1 は成人 T 細胞白血病/リンパ腫細胞の臓器浸潤を促進する

笠井 優、伊東 剛、村上 善則 (東京大・医科研・人癌病因遺伝子)

## P-1016 K1 gene transformation activities in AIDS-related and classic Kaposi's sarcoma: Correlation with clinical presentation

Takao Kinjo<sup>1</sup>, Shinichiro Kina<sup>2</sup>, Hirofumi Arakawa<sup>3</sup> (<sup>1</sup>Morphol. Pathol., Faculty of Med. Univ. of the Ryukyus, <sup>2</sup>Mol. Pharmacol. Oncol., Sch of Med., Gunma Univ., <sup>3</sup>Cancer Biol., Nat. Cancer Ctr. Res. Inst.)

HHV-8 の K1 遺伝子の形質転換能の違いは古典型カポジ肉腫と AIDS 関連型カポジ肉腫の臨床像の違いに関与する

金城 貴夫<sup>1</sup>、喜名 振一郎<sup>2</sup>、荒川 博文<sup>3</sup> (<sup>1</sup>琉球大・医・形態病理、<sup>2</sup>群馬大・医・病態腫瘍薬理、<sup>3</sup>国立がん研セ・腫瘍生物学)

## P-1017 Dynamic changes of HTLV-1 infected cell clones under different clinical conditions

Izaki Mkiko<sup>1</sup>, Jun-Ichiro Yasunaga<sup>2</sup>, Takafumi Shichijo<sup>1,2</sup>, Kisato Nosaka<sup>1</sup>, Youko Suehiro<sup>3</sup>, Masao Matsuoka<sup>1,2</sup> (<sup>1</sup>Dept. Hematol., Kumamoto Med. Univ., <sup>2</sup>Inst. Virus. Res., Kyoto Univ., <sup>3</sup>Dept. Hematol., Natl. Kyoshu Cancer Ctr.)

異なる臨床病態における HTLV-1 感染クローンの動態

井崎 幹子<sup>1</sup>、純一郎 安永<sup>2</sup>、七條 敬文<sup>1,2</sup>、野坂 生郷<sup>1</sup>、末廣 陽子<sup>3</sup>、松岡 雅雄<sup>1,2</sup> (<sup>1</sup>熊本大・医・血液膠原病感染症内科、<sup>2</sup>京都大・ウイルス・再生研、<sup>3</sup>NHO九州がんセ・血液細胞治療)

## P-1018 DNA damage response are modulated during the KSHV latency

Atsuko Sugimoto<sup>1,2</sup>, Yuichi Abe<sup>3,4</sup>, Jun Adachi<sup>3</sup>, Takayuki Murata<sup>1</sup>, Masahiro Fujimuro<sup>2</sup> (<sup>1</sup>Dept. Virol&Parasitol., Fujita Health Med., Sch. Med., <sup>2</sup>Dept. Cell Biol., Kyoto Pharm Univ., <sup>3</sup>Lab. Proteome Res., NIBIHN, <sup>4</sup>Div. Mol. Diagn., Aichi Cancer Ctr., Res. Inst.)

カポジ肉腫関連ヘルペスウイルス潜伏感染時に抑制される DNA 損傷応答の解析

杉本 温子<sup>1,2</sup>、阿部 雄一<sup>3,4</sup>、足立 淳<sup>3</sup>、村田 貴之<sup>1</sup>、藤室 雅弘<sup>2</sup> (<sup>1</sup>藤田医大・医・ウイルス・寄生虫学、<sup>2</sup>京都薬大・細胞生物学、<sup>3</sup>医薬基盤研・プロテオームリサーチ、<sup>4</sup>愛知県がんセ・分子診断 TR)

## P-1019 Growth inhibition of HTLV-1-infected cells by regulation of IRF4 is accompanied by increased SOCS3 expression

Yoshiko Nagano, Jianchun Zhang, Atsuhiko Hasegawa, Takao Masuda, Mari Kannagi (Dept. ImmunoTherap., Tokyo Med. &amp; Dent. Univ.)

IRF4 制御による HTLV-1 感染細胞の増殖抑制は SOCS3 発現の増加を伴う

永野 佳子、Jianchun Zhang、長谷川 温彦、増田 貴夫、神奈木 真理 (東京医歯大・免疫治療学分野)

## P-1020 Epitope-based universal vaccine for Human T-lymphotropic virus-1(HTLV-1)

Shah Md. Shahik (Biomed. Res. Foundation, Dhaka, Bangladesh.)

## 4 Oncogenes and tumor-suppressor genes

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

P4-1

## Wnt signaling

Wnt シグナル

Chairperson: Mari Masuda (Div. Cell. Signaling, Natl. Cancer Ctr. Res. Inst.)

座長: 増田 万里 (国立がん研セ・研・細胞情報学分野・連携研究室)

## P-1021 Identification of odontogenic ameloblast associated (ODAM) as a novel target gene of the Wnt signaling pathway

Chiaki Horie, Kiyoshi Yamaguchi, Kiyoko Takane, Tsuneo Ikenoue, Yoichi Furukawa (Div. Clin. Genome Res., Inst. Med. Sci., Univ. Tokyo)

Wnt シグナル経路の新規標的遺伝子 odontogenic ameloblast associated (ODAM) の同定

堀江 千晶、山口 貴世志、高根 希世子、池上 恒雄、古川 洋一 (東京大・医科研・臨床ゲノム)

## P-1022 The effect of Wnt3a on CSC-like properties of colorectal tumor cells

Juri Ichige, Atsushi Tanabe, Akihiro Kawanami, Hitoshi Yamaga, Hiroeki Sahara (Lab. Biol., Azabu Univ. Sch. Vet. Med.)

大腸癌の幹細胞形質における Wnt3a の影響

市毛 樹梨、田辺 敦、河南 輝大、山我 仁志、佐原 弘益 (麻布大・獣医・生物学)

## P-1023 Two-faced effects of Claudin-2 on Wnt signaling in liver cancer cells

Hironori Koga<sup>1,2</sup>, Hideki Iwamoto<sup>1,2</sup>, Takahiko Sakae<sup>1,2</sup>, Takuji Torimura<sup>1,2</sup> (<sup>1</sup>Div. Gastroenterol., Dept. Med., Kurume Univ. Sch. Med., <sup>2</sup>Liver Cancer, Kurume Univ. Res. Ctr. Innovative Cancer Therapy)

肝癌細胞における Claudin-2 の Wnt シグナルに対する 2 面的効果

古賀 浩徳<sup>1,2</sup>、若本 英希<sup>1,2</sup>、阪上 尊彦<sup>1,2</sup>、鳥村 拓司<sup>1,2</sup> (久留米大・医・消化器内科、<sup>2</sup>久留米大・先端癌治療研究セ・肝癌部門)

## P-1024 Perturbation of non-canonical Wnt/Planar Cell Polarity signaling by the Helicobacter pylori CagA oncoprotein

Atsushi Takahashi-Kanemitsu<sup>1</sup>, Mengxue Lu<sup>1</sup>, Masanori Taira<sup>2</sup>, Masanori Hatakeyama<sup>1</sup> (<sup>1</sup>Div. Microbiology, Grad. Sch. Med., Univ. Tokyo, <sup>2</sup>Dept. Biological Sci., Fac. Sci. & Engineering, Chuo Univ.)

ヘリコバクター・ピロリ菌がんタンパク質 CagA による非古典的 Wnt/平面内細胞極性シグナル伝達の攪乱

高橋 昌史<sup>1</sup>、盧 夢雪<sup>1</sup>、平良 眞規<sup>2</sup>、島山 昌則<sup>1</sup> (東京大・医・微生物学分野、<sup>2</sup>中央大・理工・生物科学科)

## P-1025 Image based siRNA screening for the regulation of intra cellular translocation of CTNBN1 in colon cancers

Sung Ung Moon, Sukjoon Yoon (Sci. building 404. Dept. Biological Sci., Sookmyung Women's Univ.)

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

P4-2

## Cancer basic, diagnosis and treatment

肉腫・白血病

Chairperson: Miwa Tanaka (Div., Carcinogenesis, Cancer Inst., JFCR)

座長: 田中 美和 ((公財) がん研・研・発がん)

## P-1026 A novel mouse model for mesenchymal chondrosarcoma expressing HEY1-NCOA2

Yasuyo Teramura, Miwa Tanaka, Yukari Yamazaki, Takuro Nakamura (Div., Carcinogenesis, Cancer Inst., JFCR)

HEY1-NCOA2 融合遺伝子を発現する間葉系軟骨肉腫モデルマウスの確立

寺村 易予、田中 美和、山崎 ゆかり、中村 卓郎 ((公財) がん研・研・発がん)

## P-1027 Stabilization of oncoprotein BCR-ABL by its deubiquitylation promotes cell proliferation in chronic myelogenous leukemia

Norihito Shibata, Nobumichi Ohoka, Mikihiko Naito (Div. Mol. Target &amp; Gene Thera. Pro., NIHS)

脱ユビキチン化による発がん因子 BCR-ABL の安定化は慢性骨髄性白血病細胞の増殖を促進する

柴田 識人、大岡 伸通、内藤 幹彦 (国立衛研・遺伝子医薬部)

## P-1028 Targeting BIG3-PHB2 protein interaction to suppress osteosarcoma progression

Shunichi Toki<sup>1,2</sup>, Tetsuro Yoshimaru<sup>1</sup>, Yosuke Matsushita<sup>1</sup>, Hitoshi Aibara<sup>1</sup>, Toyomasa Katagiri<sup>1</sup> (<sup>1</sup>Div. Genome Med., Inst. for Genome Res., Tokushima Univ., <sup>2</sup>Div. Orthopedic surgery, Tokushima Univ.)

骨肉腫細胞悪性化における BIG3 の役割解明と分子間相互作用阻害ペプチド薬による抗腫瘍効果

土岐 俊一<sup>1,2</sup>、吉丸 哲郎<sup>1</sup>、松下 洋輔<sup>1</sup>、相原 仁<sup>1</sup>、片桐 豊雅<sup>1</sup> (徳島大・先端酵素学研・ゲノム制御学分野、<sup>2</sup>徳島大・院医歯薬・整形外科)

- P-1029 Application of pluripotent stem cells for in vitro sarcomagenesis**  
Sakura Tamaki<sup>1</sup>, Sanae Nagata<sup>2</sup>, Aya Yukawa<sup>1</sup>, Megumi Nishio<sup>2</sup>, Yonghui Jin<sup>3</sup>, Hiroyuki Yoshitomi<sup>1,2,4</sup>, Junya Toguchida<sup>1,2,4</sup> (<sup>1</sup>Inst. Frontier Life & Med. Sci., Kyoto Univ., <sup>2</sup>Dept. Cell Growth & Diff., CiRA, Kyoto Univ., <sup>3</sup>Inst. Advancement Clin. & Translational Sci., Kyoto Univ. Hosp., <sup>4</sup>Dept. Orthopaedic Surg., Grad. Sch. Med., Kyoto Univ.)  
**多能性幹細胞を用いた In vitro 肉腫発生機序解明への試み**  
玉置 さくら<sup>1</sup>、永田 早苗<sup>2</sup>、湯川 愛友<sup>1</sup>、西尾 恵<sup>2</sup>、金 永輝<sup>3</sup>、吉富 啓之<sup>1,2,4</sup>、戸口田 淳也<sup>1,2,4</sup> (京都大・ウイルス・再生研、<sup>2</sup>京都大・iPS 研、<sup>3</sup>京都大・医・臨床総合研究セ、<sup>4</sup>京都大・医・整形)

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P4-3 RNA-related new oncogenes and tumor suppressor genes**  
RNA 関連がん遺伝子・がん抑制遺伝子

Chairperson: Yohei Shimono (Dept. Biochem., Fujita Health Univ. Sch. of Med.)  
座長: 下野 洋平 (藤田医大・医・生化学講座)

- P-1030 Identification of molecular signatures involved in prostate cancer progression by comprehensive transcriptome analysis**  
Ken-ichi Takayama<sup>1</sup>, Yutaka Suzuki<sup>2</sup>, Tetsuya Fujimura<sup>3</sup>, Satoshi Inoue<sup>1,4</sup> (<sup>1</sup>Dept. Func. Biogeront., Tokyo Metro. Inst. of Geront., <sup>2</sup>Dept. Med. Gen. Sci., Grad. Sch. Front. Sci., Univ. Tokyo, <sup>3</sup>Dept. Uro., Jichi Med. Univ., <sup>4</sup>Div. Gene Reg., Res. Cent. Genom. Med., Saitama Med. Univ.)  
**網羅的トランスクリプトーム解析による前立腺癌進展に関わる新規分子マーカーの同定**  
高山 賢一<sup>1</sup>、鈴木 稔<sup>2</sup>、藤村 哲也<sup>3</sup>、井上 聡<sup>1,4</sup> (1 老化制御・東京都健康長寿医療セ、<sup>2</sup>メディカル情報・新領域・東京大、<sup>3</sup>腎泌尿器・自治医大、<sup>4</sup>遺伝子情報・ゲノム・埼玉医大)
- P-1031 Clinical significance of RNA export 1 (RAE1), a mitotic checkpoint regulator, expression in colorectal cancer**  
Yuta Kobayashi<sup>1</sup>, Takaaki Masuda<sup>1</sup>, Yusuke Tsuruda<sup>1</sup>, Yoshihiro Matsumoto<sup>1</sup>, Hajime Ootsu<sup>1</sup>, Hiroki Uchida<sup>1</sup>, Tsunekazu Mizushima<sup>2</sup>, Yuichiro Doki<sup>2</sup>, Masaki Mori<sup>3</sup>, Koshi Mimori<sup>1</sup> (<sup>1</sup>Dept. Surg. Beppu Hosp. Kyushu Univ., <sup>2</sup>Dept. Gastroenterological Surg. Osaka Univ., <sup>3</sup>Dept. Surg. & Sci. Grad. Sch. Med. Sci. Kyushu Univ.)  
**大腸癌における有糸分裂チェックポイント遺伝子 RNA export 1 (RAE1) 発現の臨床的意義**  
小林 雄太<sup>1</sup>、増田 隆明<sup>1</sup>、鶴田 祐介<sup>1</sup>、松本 佳大<sup>1</sup>、大津 甫<sup>1</sup>、内田 博喜<sup>1</sup>、水島 恒和<sup>2</sup>、土岐 祐一郎<sup>2</sup>、森 正樹<sup>3</sup>、三森 功士<sup>1</sup> (九州大・病院・別府病院、<sup>2</sup>大阪大・院・消化器外科学、<sup>3</sup>九州大・院・消化器・総合外科)
- P-1032 Profiling of Hypoxia induced non-coding RNAs in colorectal cancer**  
Naohiro Nishida<sup>1</sup>, Shiki Fujino<sup>1</sup>, Takayuki Ogino<sup>1</sup>, Daisuke Sakai<sup>2</sup>, Norikatsu Miyoshi<sup>1</sup>, Hidekazu Takahashi<sup>1</sup>, Mamoru Uemura<sup>1</sup>, Chu Matsuda<sup>1</sup>, Taroh Satoh<sup>2</sup>, Tsunekazu Mizushima<sup>1</sup>, Masaki Mori<sup>3</sup>, Yuichiro Doki<sup>1</sup> (<sup>1</sup>Dept. Gastroenterological Surg., Osaka Univ., <sup>2</sup>Dept. Frontier Sci. for Cancer & Chemother., Osaka Univ., <sup>3</sup>Dept. Surg. & Sci., Kyushu Univ.)  
**大腸癌における低酸素誘導性ノンコーディング RNA のプロファイリング**  
西田 尚弘<sup>1</sup>、藤野 志季<sup>1</sup>、荻野 崇之<sup>1</sup>、坂井 大介<sup>2</sup>、三吉 範克<sup>1</sup>、高橋 秀和<sup>1</sup>、植村 守<sup>1</sup>、松田 宙<sup>1</sup>、佐藤 太郎<sup>2</sup>、水島 恒和<sup>1</sup>、森 正樹<sup>3</sup>、土岐 祐一郎<sup>1</sup> (大阪大・院・消化器外科学、<sup>2</sup>大阪大・先進薬物療法開発学、<sup>3</sup>九州大・院・消化器・総合外科)
- P-1033 Novel lncRNA LINC00844 regulates migration and invasion in hepatocellular carcinoma through p53 signaling**  
Yang Kong, Weilin Wang (The Second Affiliated Hosp. of Zhejiang Univ. Sch. of Med.)

**5 Signal transduction and gene expression**

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P5-1 Signal transduction of cancer cells and inhibitors (1)**  
シグナル伝達と阻害剤 (1)

Chairperson: Atsushi Enomoto (Dept. Pathol. Nagoya Univ. Grad. Sch. Med.)  
座長: 榎本 篤 (名古屋大・院医・腫瘍病理学)

- P-1034 IL-17A derived mast cells contributes EMT via STAT3 phosphorylation in gastric cancer progression and tumor fibrosis**  
Sachio Fushida<sup>1</sup>, Katsuya Gunjigake<sup>1</sup>, Jun Kinoshita<sup>1</sup>, Takahisa Yamaguchi<sup>1</sup>, Hiroto Saito<sup>1</sup>, Koichi Okamoto<sup>1</sup>, Tomoharu Miyashita<sup>1</sup>, Hidaharu Tajima<sup>1</sup>, Itasu Ninomiya<sup>1</sup>, Tetsuo Ohta (Gastroenterol. Surg. Kanazawa Univ. Grad. Sch. Med. Sci.)  
**肥満細胞が分泌する IL-17A は STAT3 のリン酸化を介して胃癌の進展・腫瘍線維化に関与する**  
伏田 幸夫、郡司掛 勝也、木下 淳、山口 貴久、齋藤 裕人、岡本 浩一、宮下 智治、田島 秀治、二宮 致、太田 哲生 (金沢大・医・消化器・腫瘍・再生外科)
- P-1035 Regulation of accelerated membrane trafficking by PKC eta via the phosphorylation of Rab 11 in lung cancer cells**  
Motoi Ohba<sup>1</sup>, Toshimitsu Yamaoka<sup>1</sup>, Fumihiro Ishikawa<sup>3</sup>, Etsuko Toya<sup>4</sup>, Yoshinori Murakami<sup>2</sup> (<sup>1</sup>Adv. Cancer Trans. Res. Inst., Showa Univ., <sup>2</sup>Div. Mol. Path., Inst. Med. Sci., Univ. Tokyo, <sup>3</sup>Div. Cancer Cell, Dept. Pharm. Sci., Showa Univ., <sup>4</sup>Clin. Res. Inst. Clin. Pharm., Showa Univ.)  
**PKCη による肺がん特異的な増殖因子受容体膜輸送の亢進機構**  
大場 基<sup>1</sup>、山岡 利光<sup>1</sup>、石川 文博<sup>3</sup>、外谷 衣都子<sup>4</sup>、村上 善則<sup>2</sup> (昭和 大・先端がん研、<sup>2</sup>東京大・医科研・人癌、<sup>3</sup>昭和大・薬・腫瘍細胞、<sup>4</sup>昭和大・臨床薬理研)
- P-1036 Identification and functional analysis of FGFR2 binding proteins in diffuse-type gastric carcinoma**  
Takuya Shirakihara<sup>1</sup>, Ryuichi Sakai (Dept. Biochem., Kitasato Univ. Med.)  
**びまん性胃がんの進展に関わる FGFR2 結合タンパク質の探索と機能解析**  
白木原 琢哉、堺 隆一 (北里大・医・生化学)
- P-1037 Large-scale phosphoproteomics of oesophageal squamous cell carcinoma cell lines reveals potential therapeutic targets**  
Jun Adachi<sup>1</sup>, Yuichi Abe<sup>1</sup>, Takeshi Tomonaga (Lab. Proteome Res., Natl. Inst. Biomed. Innovation, Health, Nutrition)  
**食道扁平上皮癌培養細胞株の大規模リン酸化プロテオミクス解析に基づく治療標的候補の探索**  
足立 淳、阿部 雄一、朝長 毅 (医薬基盤健康栄研・プロテオームリサーチ)
- P-1038 Crosstalk between the estrogen receptor and ErbB signaling pathways in breast cancer cells**  
Suxiang Zhang<sup>1</sup>, Shigeyuki Magi<sup>1</sup>, Mariko Okada<sup>1,2</sup> (<sup>1</sup>Inst. Prot. Res., Osaka Univ., <sup>2</sup>IMS, RIKEN)  
**乳がんにおけるエストロゲン受容体と ErbB シグナル伝達経路のクロストーク**  
張 素香<sup>1</sup>、間木 重行<sup>1</sup>、岡田 眞里子<sup>1,2</sup> (大阪大・蛋白研、<sup>2</sup>理研・生命医科学研究セ)
- P-1039 EndoMT Cells promote CRC Cell Stemness through Notch-lncRNA Signal Activation**  
Chi-Hsuan Fan (Inst. of Cancer Res., Natl. Health Res. Inst.)
- P-1040 The p21 activated kinases 1 (PAK1)-Stat3 signal axis maintains human breast cancer stem cells**  
Dong-Sun Lee<sup>1,2</sup>, Ji-Hyang Kim<sup>1</sup>, Su-Lim Kim<sup>1</sup>, Hack Sun Choi<sup>1,2</sup> (<sup>1</sup>Dept. Biotechnology, Jeju Natl. Univ., <sup>2</sup>Subtropical/tropical organism gene bank, Jeju Natl. Univ.)

## 7 Cancer genome/genetics

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

P7-1 Cancer genomic analysis (1)  
がんゲノム解析 (1)Chairperson: Masashi Fujita (RIKEN Ctr. for Integrative Med. Sci.)  
座長: 藤田 征志 (理研・生命医科学研究七)

## P-1041 Time-series analysis of tumorigenesis in a murine skin carcinogenesis model

Yoshimasa Aoto<sup>1</sup>, Kazuhiro Okumura<sup>2</sup>, Yuichi Wakabayashi<sup>3</sup>, Fuyuki Ishikawa<sup>3</sup>, Yasubumi Sakakibara<sup>1</sup> (<sup>1</sup>Dept. BioSci. Info., Keio Univ., <sup>2</sup>Div. Exp. Anim. Res., Chiba Cancer Ctr. Rse. Inst., <sup>3</sup>Grad. Sch. of Biostudies, Kyoto Univ.)

## がん進展過程の経時的ゲノム解析

青戸 良賢<sup>1</sup>、奥村 和弘<sup>2</sup>、若林 雄一<sup>2</sup>、石川 冬木<sup>3</sup>、榊原 康文<sup>1</sup> (<sup>1</sup>慶應大・理工・生命情報、<sup>2</sup>千葉県がんセンター・研・動物実験、<sup>3</sup>京都大・生命)P-1042 Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene *Mlh1*Kazuhiro Daino<sup>1</sup>, Atsuko Ishikawa<sup>1</sup>, Yi Shang<sup>1</sup>, Mayumi Nishimura<sup>1</sup>, Akifumi Nakata<sup>2</sup>, Mitsuki Yoshida<sup>3</sup>, Takashi Imai<sup>4</sup>, Yoshiya Shimada<sup>5,6</sup>, Shizuko Kakinuma<sup>1</sup> (<sup>1</sup>Dept. Radiat. Eff. Res., NIRS, OST, <sup>2</sup>Fac. Pharm. Sci., Hokkaido Univ. Sci., <sup>3</sup>Dept. Radiat. Biol., IREM, Hirosaki Univ., <sup>4</sup>QST Hosp., NIRS, QST, <sup>5</sup>QST, <sup>6</sup>IES)

## Mlh1 欠損マウスに発生する T 細胞リンパ腫の遺伝子変異

臺野 和広<sup>1</sup>、石川 敦子<sup>1</sup>、尚 奕<sup>1</sup>、西村 まゆみ<sup>1</sup>、中田 章史<sup>2</sup>、吉田 光明<sup>3</sup>、今井 高志<sup>4</sup>、島田 義也<sup>5,6</sup>、柿沼 志津子<sup>1</sup> (<sup>1</sup>量研・放医研・放射線影響、<sup>2</sup>北科大・薬・薬学、<sup>3</sup>弘前大・被ばく医療研・放射線生物、<sup>4</sup>量研・QST 病院、<sup>5</sup>量研、<sup>6</sup>環境研)

## P-1043 The impact of germline mutations on cancer risk

Kazuki Takahashi<sup>1,2</sup> (<sup>1</sup>Lab. of Plant Genetics, Grad. Sch. of Agriculture, Kyoto Univ., <sup>2</sup>Dept. Evolutionary Studies of Biosystems, SOKENDAI)

## ガン化に関与する集団内での超低頻度変異

高橋 数牙<sup>1,2</sup> (<sup>1</sup>京都大・院農・応用生物科学専攻、<sup>2</sup>総合研究大・先端科学科)

## P-1044 Analysis of SVA retrotransposon insertions in Mismatch repair genes

Gou Yamamoto<sup>1</sup>, Yoshiko Arai<sup>1</sup>, Hideyuki Ishida<sup>2</sup>, Kiwamu Akagi<sup>1</sup> (<sup>1</sup>Dept. Mol. Diag. Cancer Prev. Saitama Cancer Ctr., <sup>2</sup>Dept. Surg. Saitama Med. Ctr. Saitama Med. Univ.)

## ミスマッチ修復遺伝子における SVA 型レトロトランスポゾン挿入リアントの解析

山本 剛<sup>1</sup>、新井 吉子<sup>1</sup>、石田 秀行<sup>2</sup>、赤木 究<sup>1</sup> (<sup>1</sup>埼玉県がんセンター・腫瘍診断・予防科、<sup>2</sup>埼玉医大・総合医セ・外科)

## P-1045 The VNTR polymorphism of DC-SIGN and DC-SIGNR and susceptibility to nasopharyngeal carcinoma in a Chinese population

Ying Xie<sup>1</sup>, Sisi Ning<sup>1</sup>, Mengwei Yao<sup>1</sup>, Yuan Wu<sup>1</sup>, Xunzhao Zhou<sup>1</sup>, Changtao Zhou<sup>2</sup>, Kui Yan<sup>2</sup>, Zhengbo Wei<sup>2</sup> (<sup>1</sup>Life Sci. Inst. of Guangxi Med. Univ., Nanning, China, <sup>2</sup>Affiliated Tumor Hosp. of Guangxi Med. Univ., Nanning, China)

## 8 Cell death/immortalization

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

P8-1 Cell death as therapeutic targets  
治療標的としての細胞死

Chairperson: Shingo Dan (Div. Mol. Pharmacology, Cancer Chemother. Ctr., Japanese Foundation for Cancer Res.)

座長: 旦 慎吾 ((公財) がん研・化療セ・分子薬理部)

## P-1046 Therapeutic effects and antitumor mechanism of trehalose liposomes against breast adenocarcinoma

Keiji Kuwabara, Hideaki Ichihara, Yoko Matsumoto (Div. Appl. Life Sci., Grad. Sch. Eng., Sojo Univ.)

## トレハロースリポソームを用いた乳がんに対する治療効果と制がん機構

桑原 啓司、市原 英明、松本 陽子 (崇城大・院・応用生命)

## P-1047 Targeting for sphingosine kinase 1 in oral squamous cell carcinoma based on analysis of TCGA data

Masakazu Hamada, Narikazu Uzawa (Dept. Oral &amp; Maxillofac. Surg2 Osaka Univ.)

TCGA データの解析に基づく口腔扁平上皮癌におけるスフィンゴシンキナーゼ 1 の標的化  
濱田 正和、鶴澤 成一 (大阪大・院歯・口外 2)

## P-1048 Rational combination therapy for melanoma with CDK2/9 inhibition by targeting BAK-dependent cell death

Xiaoou Xu<sup>1</sup>, Satoru Yokoyama<sup>2</sup>, Yoshihiro Hayakawa<sup>1</sup> (<sup>1</sup>Div. Pathogenic Biochem., Int. Nat. Med., Toyama Univ., <sup>2</sup>Dept. Cancer Cell Bio., Sch. Med. Pharm. Sci., Toyama Univ.)

## BAK 依存性細胞死を標的とした CDK2/9 阻害による悪性黒色腫の合理的併用療法

徐 小鷗<sup>1</sup>、横山 悟<sup>2</sup>、早川 芳弘<sup>1</sup> (<sup>1</sup>富山大・和漢研・病態生化学、<sup>2</sup>富山大・薬・がん細胞生物学)

## P-1049 Combination therapies with BH3 mimetic drugs for prostate cancer

Seiji Arai<sup>1,2</sup>, Akira Otsu<sup>2</sup>, Kazuhiro Suzuki<sup>2</sup> (<sup>1</sup>Harvard Med. Sch., <sup>2</sup>Dept. of Urol. Gunma Univ., Grad., Sch. Med.)抗アポトーシス蛋白阻害剤併用による前立腺癌新規治療法の開発  
新井 誠二<sup>1,2</sup>、大津 晃<sup>2</sup>、鈴木 和浩<sup>2</sup> (<sup>1</sup>ハーバード医学校、<sup>2</sup>群馬大・医・泌尿器科)

## P-1050 Efficacy of MCL1 inhibitor in small cell lung cancer in vitro and in vivo

Yuto Yasuda<sup>1</sup>, Hiroaki Ozasa<sup>1</sup>, Takahiro Tsuji<sup>1</sup>, Tomoko Yamamoto<sup>1</sup>, Hitomi Ajimizu<sup>1</sup>, Masatoshi Yamazoe<sup>1</sup>, Hironori Yoshida<sup>1</sup>, Yuichi Sakamori<sup>2</sup>, Toyohiro Hirai<sup>1</sup>, Young Hak Kim<sup>1</sup> (<sup>1</sup>Dept. Respir. Grad. Sch. of Med., Kyoto Univ., <sup>2</sup>Dept. Med. Onc. Grad. Sch. of Med., Kyoto Univ.)

## in vitro および in vivo での小細胞肺癌における MCL1 阻害剤の有効性

安田 有斗<sup>1</sup>、小笹 裕晃<sup>1</sup>、辻 貴宏<sup>1</sup>、山本 智子<sup>1</sup>、味水 瞳<sup>1</sup>、山添 正敏<sup>1</sup>、吉田 博徳、阪森 優一<sup>2</sup>、平井 豊博<sup>1</sup>、金 永学<sup>1</sup> (<sup>1</sup>京都大・医・呼吸器内科、<sup>2</sup>京都大・医・腫瘍内科)

## P-1051 The anti-cancer effects and molecular mechanisms of Tanshinone IIA in human lymphoma HT cells

Wan-Yu Zeng<sup>1</sup>, Chin-Cheng Su<sup>1,2,3</sup> (<sup>1</sup>Tumor Res. Ctr. of Integrative Med. Institution, <sup>2</sup>Dept. surgery Institution, <sup>3</sup>Comprehensive Breast Cancer Ctr. Institution)

## P-1052 Combination of 5-ASA/hyperthermia synergistically enhances cancer cell death via nitric oxide/peroxynitrite generation

Rohan Moniruzzaman<sup>1,2</sup>, Kei Tomihara<sup>1</sup>, Qing-Li Zhao<sup>2</sup>, Wataru Heshiki<sup>1</sup>, Makoto Noguchi<sup>1</sup> (<sup>1</sup>Dept. Oral Surg., Grad. Sch. Med. & Pharm., Toyama Univ., <sup>2</sup>Dept. Radiobiol., Grad. Sch. of Med. & Pharm., Toyama Univ.)

## 9 Epigenetics

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

P9-1 Histone modification (1)  
ヒストン修飾 (1)

Chairperson: Reo Maruyama (Project for Cancer Epigenomics, Cancer Inst., JFCR)

座長: 丸山 玲緒 ((公財) がん研・研・がんエピゲノム)

## P-1053 Setdb1 is required for formation of pancreatic cancer by inhibiting apoptosis through the regulation of p53 expression

Satoshi Ogawa, Akihisa Fukuda, Hiroshi Seno (Dept. Gastro. &amp; Hepato., Kyoto Univ., Gradu. Sch. Med.)

Setdb1 は p53 発現制御を介してアポトーシスを阻害することにより膵臓癌の形成に必要である  
小川 智、福田 晃久、妹尾 浩 (京都大・医・消化器内科)

## P-1054 Low KMT2D expression correlates with poor prognosis in esophageal squamous cell carcinoma

Kazuki Odagiri<sup>1</sup>, Koji Tanaka<sup>1</sup>, Takuro Saito<sup>1</sup>, Kotaro Yamashita<sup>1</sup>, Tomoki Makino<sup>1</sup>, Tsuyoshi Takahashi<sup>1</sup>, Yukinori Kurokawa<sup>1</sup>, Makoto Yamasaki<sup>1</sup>, Kiyokazu Nakajima<sup>1</sup>, Masaki Mori<sup>2</sup>, Yuichiro Doki<sup>1</sup> (<sup>1</sup>Dept. Gastro. Surg., Osaka Univ. Grad. Sch. Med., <sup>2</sup>Dept. Surg. Sci., Grad. Sch. Med. Sci., Kyushu Univ.)

## 食道扁平上皮癌における KMT2D 低発現の意義

小田切 数基<sup>1</sup>、田中 晃司<sup>1</sup>、西塔 拓郎<sup>1</sup>、山下 公太郎<sup>1</sup>、牧野 知紀<sup>1</sup>、

高橋 剛<sup>1</sup>、黒川 幸典<sup>1</sup>、山崎 誠<sup>1</sup>、中島 清一<sup>1</sup>、森 正樹<sup>2</sup>、土岐 祐一郎<sup>1</sup> (<sup>1</sup>大阪大・消化器外科、<sup>2</sup>九州大・消化器・総合外科)

- P-1055 **Deregulation of the histone demethylase LSD1 is involved in hepatocellular carcinoma**  
Sangchul Kim<sup>1,2</sup>, Amina Bolatkan<sup>1</sup>, Syuzo Kaneko<sup>1</sup>, Shinya Hayami<sup>3</sup>, Hiroki Yamae<sup>3</sup>, Ryuji Hamamoto<sup>1,4</sup> (<sup>1</sup>Div. Mol. Mod. Cancer Biol., Natl. Cancer Ctr. Res. Inst., <sup>2</sup>Dept. Surg., Sch. Med., Kyorin Univ., <sup>3</sup>2nd Dept. Surg., Wakayama Med. Univ., <sup>4</sup>Cancer Transl. Res. Team, RIKEN Ctr. for AIP project)

HCCにおけるヒストン脱メチル化酵素LSD1の機能解析  
金 翔哲<sup>1,2</sup>、Amina Bolatkan<sup>1</sup>、金子 修三<sup>1</sup>、速水 晋也<sup>3</sup>、山上 裕機<sup>3</sup>、浜本 隆二<sup>1,4</sup> (<sup>1</sup>国立がん研セ・研・がん分子修飾制御学、<sup>2</sup>杏林大・外科、<sup>3</sup>和歌山医大・第2外科、<sup>4</sup>理研AIP)

- P-1056 **SETDB1 regulates SMAD7 expression for breast cancer metastasis**  
Tae Young Ryu, Mi-Young Son, Dae-Soo Kim, Hyun-Soo Cho (Korea Res. Inst. of Biosci. & Biotechnology)

- P-1057 **Downregulation of PRMT1 by sodium propionate induced cell apoptosis in colon cancer**  
Kwangho Kim, Myung Jin Son, Dae-Soo Kim, Mi-Young Son (Korea Res. Inst. of Biosci. & Biotechnology)

## 10 Invasion and metastasis

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

### P10-1 Molecular pathology of cancer behavior (1) がんの浸潤と転移のメカニズム (1)

Chairperson: Michiru Nishita (Dept. Biochem., Fukushima Med. Univ. Sch. of Med.)

座長: 西田 満 (福島県医大・医・生科学講座)

- P-1058 **Identification and characterization of TGFBI in circulating tumor cell subline from pancreatic cancer cell line**  
Tomoki Muramatsu<sup>1,2</sup>, Taku Sato<sup>1,2</sup>, Minoru Tanabe<sup>2</sup>, Johji Inazawa<sup>1,3</sup> (<sup>1</sup>Dept. Mol. Cytogenet., MRI, Tokyo Med. I & Dent. Univ. (TMDU), <sup>2</sup>Dept. Hepatobiliary & Pancreatic Surg., Grad. Sch. Med. TMDU, <sup>3</sup>Bioresource Res. Ctr., TMDU, <sup>4</sup>Lab. for Integrated Res. Projects on Intractable Diseases, MRI, TMDU)

循環腫瘍細胞亜株 (Panc-1-CTC)の発現解析から見出したTGFBIの機能解析

村松 智輝<sup>1,4</sup>、佐藤 拓<sup>1,2</sup>、田邊 稔<sup>2</sup>、稲澤 譲治<sup>1,3</sup> (<sup>1</sup>東京医歯大・難研・分子細胞遺伝学、<sup>2</sup>東京医歯大・肝胆脾外科、<sup>3</sup>東京医歯大・疾患バイオリソースセ、<sup>4</sup>東京医歯大・難研・難病基盤プロジェクト)

- P-1059 **Soluble RANKL contributes to bone metastasis of RANK+ tumor cells without directly affecting tumor growth and osteoclast**  
Kazuo Okamoto<sup>1</sup>, Tatsuo Asano<sup>2</sup>, Kyoko Hashimoto<sup>2</sup>, Shogo Ehata<sup>3</sup>, Hiroshi Takayanagi<sup>2</sup> (<sup>1</sup>Dept. Osteoimmunology, Grad. Sch. Med., Univ. of Tokyo, <sup>2</sup>Dept. Immunol., Grad. Sch. Med., Univ. of Tokyo, <sup>3</sup>Dept. Mol. Pathol., Grad. Sch. Med., Univ. of Tokyo)

可溶性RANKLは腫瘍増殖と破骨細胞に直接影響せずにRANK陽性腫瘍細胞の骨への転移に寄与する

岡本 一男<sup>1</sup>、浅野 達雄<sup>2</sup>、橋本 恭子<sup>2</sup>、江幡 正悟<sup>3</sup>、高柳 広<sup>2</sup> (<sup>1</sup>東京大・院医・骨免疫学、<sup>2</sup>東京大・院医・免疫学、<sup>3</sup>東京大・院医・分子病理)

- P-1060 **The biological role of CD44v9 in EMT induction and distant metastasis of gastric cancer**  
Shichao Qiu<sup>1</sup>, Keitaro Edahiro<sup>1</sup>, Akihiro Sakai<sup>1</sup>, Yoshiaki Fujimoto<sup>1</sup>, Makoto Iimori<sup>2</sup>, Eiji Oki<sup>1</sup>, Hiroyuki Kitao<sup>2</sup>, Masaki Mori<sup>1</sup> (<sup>1</sup>Dept. Surg. & Sci., Kyushu Univ., Sch. Med., <sup>2</sup>Dept. Mol. Cancer Biol., Kyushu Univ., Sch. Pharm. Sci.)

胃がん転移におけるEMTと抗酸化能の寄与

邱 仕超<sup>1</sup>、枝廣 圭太郎<sup>1</sup>、酒井 陽玄<sup>1</sup>、藤本 禎明<sup>1</sup>、飯森 真人<sup>2</sup>、沖 英次<sup>1</sup>、北尾 洋之<sup>2</sup>、森 正樹<sup>1</sup> (<sup>1</sup>九州大・医・消化器・総合外科、<sup>2</sup>九州大・薬・抗がん剤薬研)

- P-1061 **Function analysis of MITF in epithelial ovarian cancer**  
Kazuhiisa Kitami<sup>1</sup>, Yoshihiro Koya<sup>2</sup>, Hiroaki Kajiyama<sup>1</sup>, Mai Sugiyama<sup>2</sup>, Shohei Yoshi<sup>1</sup>, Kaname Uno<sup>1</sup>, Masato Yoshihara<sup>1</sup>, Akihiro Nawa<sup>2</sup>, Fumitaka Kikkawa<sup>1</sup> (<sup>1</sup>Dept. Obstet. Gynecol. Univ. Nagoya Sch. Med., <sup>2</sup>Bell Res. Ctr., Dept. Obstet. Gynecol. Univ. Nagoya Sch. Med.)

上皮性卵巣癌におけるMITFの機能的役割

北見 和久<sup>1</sup>、小屋 美博<sup>2</sup>、梶山 広明<sup>1</sup>、杉山 麻衣<sup>2</sup>、伊吉 祥平<sup>1</sup>、宇野 枢<sup>1</sup>、吉原 雅人<sup>1</sup>、那波 明宏<sup>2</sup>、吉川 史隆<sup>1</sup> (<sup>1</sup>名古屋大・院医・産婦人科、<sup>2</sup>名古屋大・ペルリサーチセ)

- P-1062 **Anti-metastatic ability of designed peptide on breast cancer cell in vitro and in vivo**  
Yan Jun Pan<sup>1</sup>, Hao-Jen Hsu<sup>1</sup>, Shinn-Jong Jiang<sup>2</sup> (<sup>1</sup>Dept. LS., NCI, <sup>2</sup>Dept. Bic., NCI)

- P-1063 **Overexpression of CLEC4M in HLEC activates adhesion, migration and invasion of nasopharyngeal carcinoma cell**  
Xi Yao<sup>2</sup>, Ying Xie<sup>1</sup>, Zhengbo Wei<sup>2</sup> (<sup>1</sup>Life Sci. Inst. of Guangxi Med. Univ., <sup>2</sup>Affiliated Tumor Hosp. of Guangxi Med. Univ.)

- P-1064 **Comparison of de novo designed peptides on the interactions of inflammatory cytokines and their cognate receptors**  
Ting Han Lin<sup>1</sup>, Ting-han Lin<sup>1</sup>, Hao-Jen Hsu<sup>1</sup>, Shinn-Jong Jiang<sup>2</sup> (<sup>1</sup>Dept. Biosci., TCU, <sup>2</sup>Dept. Biochem., TCU)

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

### P10-2 Inter-tissue interactions in metastasis 転移における組織間相互作用

Chairperson: Yasunori Okada (Juntendo Univ. Grad. Sch. of Med.)

座長: 岡田 保典 (順天堂大・院医)

- P-1065 **Premetastatic niche formation of the lymph nodes in a mouse model of mammary cancer**  
Masa-Aki Shibata<sup>1</sup>, Yuko Ito<sup>2</sup>, Hitomi Hamaoka<sup>1</sup>, Kohei Taniguchi<sup>2,3</sup> (<sup>1</sup>Dept. Anatomy & Cell Biol., Osaka Med. College, <sup>2</sup>Dept. General Gastroenterol. Surg. Osaka Med. College, <sup>3</sup>Transl. Res. Program, Osaka Med. College)

マウス乳癌転移モデルにおけるリンパ節の転移前ニッチの形成

柴田 雅朗<sup>1</sup>、伊藤 裕子<sup>2</sup>、濱岡 仁美<sup>1</sup>、谷口 高平<sup>2,3</sup> (<sup>1</sup>大阪医大・医・解剖学、<sup>2</sup>大阪医大・医・一般消化器外科、<sup>3</sup>大阪医大・医・TR部門)

- P-1066 **Peritoneal dissemination of rectal cancer cells from patient-derived xenograft induced distant metastasis**  
Tomoki Yamano<sup>1</sup>, Shuji Kubo<sup>2</sup>, Tomoko Kominato<sup>1</sup>, Kei Kimura<sup>1</sup>, Masataka Ikeda<sup>1</sup>, Naohiro Tomita<sup>1</sup> (<sup>1</sup>Div. Lower GI Surg., Hyogo College of Med., <sup>2</sup>Dept. Med. Innovation, Inst. Advanced Med. Sci., Hyogo College Med.)

腹腔内へのPDX由来直腸癌細胞播種は肝・脾への遠隔転移を起こす  
山野 智基<sup>1</sup>、久保 秀司<sup>2</sup>、小湊 智子<sup>1</sup>、木村 慶<sup>1</sup>、池田 正孝<sup>1</sup>、富田 尚裕<sup>1</sup> (<sup>1</sup>兵庫医大・下部消化管外科、<sup>2</sup>兵庫医大・先端研・分子遺伝治療学)

- P-1067 **Investigation of molecular mechanisms regulating bone metastasis by mesenchymal stem cells**  
Satoshi Fujimori, Shinae Kizaka-Kondoh (Life Sci. & Tech. Sch, Tokyo Inst. of Tech.)

間葉系幹細胞による骨転移巣の形成促進メカニズムの解析  
藤森 慧、近藤 科江 (東京工業大・生命理工学院)

- P-1068 **Withdrawn**

- P-1069 **Removal of lymph nodes increases the incidence of metastasis**  
Ariunbuyan Sukhbaatar<sup>1,2</sup>, Mori Shiro<sup>1,2,3</sup>, Kodama Tetsuya<sup>1,2</sup> (<sup>1</sup>Lab. Biomed. Eng. for Cancer, Tohoku Univ., <sup>2</sup>Biomed. Eng. Cancer Res. Ctr. Sch. Biomed. Eng., Tohoku Univ., <sup>3</sup>Dept. Oral & Maxillofacial Surg., Sch. Dent., Tohoku Univ. Hosp.)

## 11 Characteristics of cancer cells

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

### P11-1 Cancer stem cell (1) がん幹細胞 (1)

Chairperson: Hideki Izumi (Life Sci. Inst. Saga Med. Ctr.)

座長: 泉 秀樹 (佐賀医療セ・ライフサイエンス部)

- P-1070 **Morphological features and chemosensitivity of cancer stem cells (CSCs) derived from a mouse tumor**  
Jiro Fujimoto (Hyogo Prefecture Health Promotion Association)  
マウスがん幹細胞の形態学的特徴と抗がん剤抵抗性について  
藤本 二郎 (兵庫県健康財団)

- P-1071** **CD133 induces EMT and peritumoral fibrosis of pancreatic cancer**  
Shyuichiro Matsubara<sup>1</sup>, Koichiro Tsukasa<sup>1</sup>, Yumi Miyazaki<sup>1</sup>, Toru Obara<sup>1</sup>, Takami Matsuyama<sup>1</sup>, Sonshin Takao<sup>1,2</sup> (<sup>1</sup>Cancer & Regenerative Med. Kagoshima Univ. Sch. Med., <sup>2</sup>Tanegashima Med. Ctr.)  
**CD133は膵癌細胞のEMTを誘導し腫瘍周囲の線維化と相関する**  
松原 修一郎<sup>1</sup>、政 幸一郎<sup>1</sup>、宮崎 優美<sup>1</sup>、小原 徹<sup>1</sup>、松山 隆美<sup>1</sup>、高尾 尊身<sup>1,2</sup> (鹿児島大・院・歯医学・癌再生医療学、<sup>2</sup>種子島医療セ)
- P-1072** **SNAIL2 is a critical factor for the cancer stem cell (CSC) properties in pancreatic cancer**  
Kenji Masuo<sup>1</sup>, Shigeo Takaishi<sup>1,3</sup>, Akitada Yogo<sup>2,3</sup>, Ru Chen<sup>1,3</sup>, Akihisa Fukuda<sup>1</sup>, Toshihiko Masui<sup>1</sup>, Hiroshi Seno<sup>1,3</sup> (<sup>1</sup>Dept. Gastroenterology & Hepatology, Kyoto Univ., Sch. Med., <sup>2</sup>Dept. Surg., Kyoto Univ., Sch. Med., <sup>3</sup>DSK Project, Med. Innovation Ctr., Kyoto Univ., Sch. Med.)  
**SNAIL2は膵癌の幹細胞性維持において重要である**  
増尾 謙志<sup>1</sup>、高石 繁生<sup>1,3</sup>、余語 寛匡<sup>2,3</sup>、Ru Chen<sup>1,3</sup>、福田 晃久<sup>1</sup>、増井 俊彦<sup>2</sup>、妹尾 浩<sup>1,3</sup> (<sup>1</sup>京都大・医・消化器内科、<sup>2</sup>京都大・医・肝胆膵・移植外科/小児外科、<sup>3</sup>京都大・MIC DSK プロジェクト)
- P-1073** **Single-cell originated spheroids from colorectal cancer show a phenotypic heterogeneity among tumor-initiating cells**  
Roberto Coppo, Jumpei Kondo, Masahiro Inoue (Dept. Clin. Bio-resource Res. Dev. Grad. Sch. Med. Kyoto Univ.)  
**大腸癌由来の単一の腫瘍始原細胞から作製したスフェロイドによって示される表現型の不均一性**  
コッポ ロベルト、近藤 純平、井上 正宏 (京都大・医・CLバイオリソース研究開発講座)
- P-1074** **Adaptation to acidic extracellular pH induces cancer stem cell like phenotype**  
Yasumasa Kato, Atsuko Suzuki, Toyonobu Maeda (Dept. Oral Fxn & Mol. Biol., Ohu Univ. Sch. Dent.)  
**酸性細胞外pHへの耐性化は癌幹細胞様性質を誘導する**  
加藤 靖正、鈴木 厚子、前田 豊信 (奥羽大・歯・口腔機能分生)
- P-1075** **Establishment of Glioma-initiating cell and growth suppression of Eva1 positive cell by genome editing**  
Naoki Ohtsu (Div. Stem Cell, IGM, Hokkaido Univ.)  
**ゲノム編集を用いたグリオーマ幹細胞の樹立及びEva1陽性細胞の検出と増殖抑制**  
大津 直樹 (北海道大・遺制研・幹細胞)
- P-1076** **Hematopoietic Like Cells Derived From Cancer Stem Cells Generated From Mouse Induced Pluripotent Stem Cells**  
Ghmkin Hassan<sup>1,2</sup>, Said M Afify<sup>3</sup>, Kazuki Kumon<sup>3</sup>, Shunsuke Ueno<sup>1</sup>, Maram H Zahra<sup>1</sup>, Nobuhiro Okada<sup>1</sup>, Akimasa Seno<sup>1,4</sup>, Masaharu Seno<sup>1,4</sup> (<sup>1</sup>GS-ISEHS, Okayama Univ., <sup>2</sup>Faculty of Pharm., Damascus Univ., Damascus, Syria, <sup>3</sup>GS-NST, Okayama Univ., <sup>4</sup>OU-SCEED, IBIO, Wayne State Univ., Detroit, MI 48202, USA)
- P-1079** **High CD44 gastric cancer stem cells are suppressed by voltage gated Ca2+ channel blocker**  
Keita Katsurahara, Atsushi Shiozaki, Michihiro Kudou, Katsutoshi Shoda, Tomohiro Arita, Toshiyuki Kosuga, Hirotaka Konishi, Ryo Morimura, Yasutoshi Murayama, Takeshi Kubota, Masayoshi Nakanishi, Hitoshi Fujiwara, Eigo Otsuji (Div. Dig. Surg., Kyoto Pref. Univ. Med.)  
**CD44陽性胃癌幹細胞に対する電位依存性Caチャンネルブロッカーの抗腫瘍効果の検討**  
葛原 啓太、塩崎 敦、工藤 道弘、庄田 勝俊、有田 智洋、小菅 敏幸、小西 博貴、森村 玲、村山 康利、窪田 健、中西 正芳、藤原 斉、大辻 英吾 (京都府医大・消化器外科)
- P-1080** **EGFR inhibitors suppress drug-tolerant CD44v+ gastric cancer cell growth and enhance the antitumor effect of irinotecan**  
Tetsuo Mashima<sup>1</sup>, Risa Iwasaki<sup>1,2</sup>, Ryuhei Kawakami<sup>1,2</sup>, Koshi Kumagai<sup>3</sup>, Toshiro Migita<sup>1</sup>, Takeshi Sano<sup>3</sup>, Kensei Yamaguchi<sup>4</sup>, Hiroyuki Seimiya<sup>1,2</sup> (<sup>1</sup>Div. Mol. Biother., Cancer Chemother. Ctr., JFCR, <sup>2</sup>Dept. Med. Sci, Grad. Sch. of Frontier Sci., The Univ. Tokyo, <sup>3</sup>Dept. Gastroent. Surg., Cancer Inst. Host., JFCR, <sup>4</sup>Dept. Gastroent. Med., Cancer Inst. Host., JFCR)  
**EGFR阻害剤による胃がん薬剤抵抗性CD44v発現細胞の増殖抑制とイリノテカンによる治療効果の増強**  
馬島 哲夫<sup>1</sup>、岩崎 里紗<sup>1,2</sup>、川上 隆兵<sup>1,2</sup>、熊谷 厚志<sup>3</sup>、右田 敏郎<sup>1</sup>、佐野 武<sup>3</sup>、山口 研成<sup>4</sup>、清宮 啓之<sup>1,2</sup> (<sup>1</sup>(公財)がん研・化療セ・分子生物治療、<sup>2</sup>東京大・院・新領域・メディ・がん分子標的、<sup>3</sup>(公財)がん研・有明病院・消化器外科、<sup>4</sup>(公財)がん研・有明病院・消化器内科)
- P-1081** **EGCG reduces stemness markers of human lung cancer cells by targeting AXL receptor tyrosine kinase**  
Pattama Wongsirisin<sup>1,2</sup>, Motoi Sato<sup>1,2</sup>, Masami Suganuma<sup>1,2</sup> (<sup>1</sup>Grad. Sch. Sci. Eng., Saitama Univ., <sup>2</sup>Res. Inst. Clin. Oncol., Saitama Cancer Ctr.)  
**緑茶カテキンEGCGはAXLチロシンキナーゼを標的として肺がん細胞の幹細胞を抑制する**  
ウォンシリシン パタマ<sup>1,2</sup>、佐藤 元威<sup>1,2</sup>、菅沼 雅美<sup>1,2</sup> (<sup>1</sup>埼玉大・院・理工、<sup>2</sup>埼玉がんセ・臨床腫瘍研)
- P-1082** **Tankyrase inhibitors target colorectal cancer stem-like cells through an AXIN2-dependent mechanism**  
Myungkyu Jang<sup>1,2</sup>, Tetsuo Mashima<sup>1</sup>, Hiroyuki Seimiya<sup>1,2</sup> (<sup>1</sup>Cancer Chemother. Ctr., JFCR, <sup>2</sup>Dept. Med. Sci Grad Sch Frontier Sci Univ. Tokyo)  
**タンキラーゼ阻害剤によるAXIN2を介した大腸がん幹細胞のターゲットニング**  
張 明奎<sup>1,2</sup>、馬島 哲夫<sup>1</sup>、清宮 啓之<sup>1,2</sup> (<sup>1</sup>(公財)がん研・化療セ・分子生物治療、<sup>2</sup>東京大・院・新領域・メディ・がん分子標的)
- P-1083** **Therapeutic interaction of mesenchymal stem cells with glioblastoma cells by glycogen synthase kinase (GSK)3β inhibition**  
Ilya Pyklo<sup>1,2</sup>, Takahiro Domoto<sup>1</sup>, Mitsutoshi Nakada<sup>2</sup>, Toshinari Minamoto<sup>1</sup> (<sup>1</sup>Div. Transl. Clin. Oncol., Cancer Res. Inst., Kanazawa Univ., <sup>2</sup>Dept. Neurosurg., Grad. Sch. Med. Sci., Kanazawa Univ.)

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P11-2** **Cancer stem cell (2)**  
がん幹細胞 (2)Chairperson: Takahiro Ito (Inst. for Frontier Life & Med. Sci., Kyoto Univ.)  
座長: 伊藤 貴浩 (京都大・ウイルス・再生研)**P-1077** **Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer treatment**

Toru Narusaka, Toshiaki Ohara, Yuki Katsura, Kazuhiro Noma, Noriyuki Nishiwaki, Satoshi Komoto, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara (Dept. Gastroenterological Surg., Okayama Univ. Grad. Sch. Med.)

**鉄キレート剤による幹細胞性制御による新規食道癌治療法**  
鳴坂 徹、大原 利章、桂 佑貴、野間 和広、西脇 紀之、河本 慧、田澤 大、香川 俊輔、藤原 俊義 (岡山大・院医・消化器外科)**P-1078** **GLO1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive CSCs**Shoma Tamori<sup>1</sup>, Yuka Nozaki<sup>1</sup>, Hitomi Motomura<sup>1</sup>, Chotaro Onaga<sup>1</sup>, Ryo Abe<sup>3</sup>, Ryoko Takasawa<sup>1</sup>, Sei-ichi Tanuma<sup>2</sup>, Kazunori Akimoto<sup>1</sup> (<sup>1</sup>Fac. Pharm. Sci., Tokyo Univ. Sci., <sup>2</sup>RIST, Tokyo Univ. Sci., <sup>3</sup>SIRC, Teikyo Univ.)**解糖系代謝酵素GLO1はBasal-like型乳癌において高発現し、ALDH1陽性乳癌幹細胞の生存に関与する**  
多森 翔馬<sup>1</sup>、野崎 優香<sup>1</sup>、本村 瞳<sup>1</sup>、翁長 朝太郎<sup>1</sup>、安部 良<sup>3</sup>、高澤 涼子<sup>1</sup>、田沼 靖一<sup>2</sup>、秋本 和憲<sup>1</sup> (<sup>1</sup>東京理大・薬、<sup>2</sup>東京理大・RIST、<sup>3</sup>帝京大・SIRC)

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P11-3** **Cell differentiation and cancer progression**  
細胞分化とがん発生Chairperson: Chiaki Takahashi (Cancer Res. Inst. Kanazawa Univ.)  
座長: 高橋 智聡 (金沢大・がん進展制御研)**P-1084** **Numerical simulation of tumor growth and angiogenesis-from development to growth-**Katsuya Nagayama<sup>1</sup>, Ichiro Miura<sup>2</sup> (<sup>1</sup>Kyushu Inst. of Tech., <sup>2</sup>Obihiro Kyokai Hosp., Juntendo Univ.)**腫瘍増殖と血管新生の数値シミュレーション—発生から成長まで—**  
永山 勝也<sup>1</sup>、三浦 一郎<sup>2</sup> (<sup>1</sup>九州工業大・情報工学部、<sup>2</sup>帯広協会病院、順天堂大)**P-1085** **Expression level of superoxide dismutase 3 and tumorigenicity**Kaho Jinsei<sup>1</sup>, Isao Tawara<sup>1</sup>, Junya Tsuboi<sup>1</sup>, Daisuke Kato<sup>2</sup>, Masahiro Masuya<sup>1</sup>, Hideyuki Tanabe<sup>3</sup>, Yoshihiro Miyahara<sup>4</sup>, Naohiro Seo<sup>5</sup>, Toshimichi Yoshida<sup>2</sup>, Satoru Miyano<sup>6</sup>, Hiroshi Shiku<sup>4,5</sup>, Naoyuki Katayama<sup>1</sup> (<sup>1</sup>Dept. Hematol. & Oncol., Mie Univ., Grad. Sch. Med., <sup>2</sup>Dept. Pathol. & Matrix Biol., Mie Univ. Grad. Sch. Med., <sup>3</sup>Dept. Evol. Stud. Biosys., Sch. Adv. Sci., SOKENDAI, <sup>4</sup>Dept. Personalized Cancer Immunotherapy, Mie Univ. Grad. Sch. Med., <sup>5</sup>Dept. Immuno-gene Ther., Mie Univ. Grad. Sch. Med., <sup>6</sup>Human Genome Ctr. IMS. Univ. of Tokyo)**SOD3の発現レベルと腫瘍形成**



神生 夏帆<sup>1</sup>、儀 功<sup>1</sup>、坪井 順哉<sup>1</sup>、加藤 大祐<sup>2</sup>、榎屋 正浩<sup>1</sup>、田辺 秀之<sup>3</sup>、宮原 慶裕<sup>4</sup>、瀬尾 尚宏<sup>5</sup>、吉田 利通<sup>2</sup>、宮野 悟<sup>6</sup>、珠玖 洋<sup>4,5</sup>、片山 直之<sup>1</sup> (<sup>1</sup>三重大・医・血液腫瘍内科、<sup>2</sup>三重大・医・修復再生病理、<sup>3</sup>総合研究大・進化生物学、<sup>4</sup>三重大・医・個別化がん免疫治療学、<sup>5</sup>三重大・医・遺伝子・免疫細胞治療学、<sup>6</sup>東京大・医科研・ヒトゲノム解析セ)

**P-1086 Crucial contribution of leukemia cell-derived extracellular vesicles to the development of donor cell-derived leukemia**  
Tomohisa Baba, Naofumi Mukaida (Cancer Res. Inst., Kanazawa Univ.)  
白血球細胞由来細胞外小胞によるドナー細胞由来白血病の発症  
馬場 智久、向田 直史 (金沢大・がん研)

**P-1087 Differentiation of Hodgkin lymphoma cells by reactive oxygen species and its regulation by Heme oxygenase-1 via HIF-1 $\alpha$**   
Makoto Nakashima<sup>1</sup>, Mariko Watanabe<sup>2</sup>, Kazumi Nakano<sup>1</sup>, Kaoru Uchimaru<sup>1</sup>, Ryouichi Horie<sup>2</sup> (<sup>1</sup>Grad. Sch. of Frontier Sci., Tokyo Univ., <sup>2</sup>Sch. of Allied Health Sci., Kitasato Univ.)  
活性酸素種によるホジキンリンパ腫細胞の分化とHIF-1 $\alpha$ を介したHeme Oxygenase 1による分化制御機構  
中島 誠<sup>1</sup>、渡邊 真理子<sup>2</sup>、中野 和民<sup>1</sup>、内丸 薫<sup>1</sup>、堀江 良一<sup>2</sup> (<sup>1</sup>東京大・院・新領域創成科学研究科、<sup>2</sup>北里大・医療衛生・血液学)

**P-1088 NFYA regulates the acquisition of drug resistance in breast cancer**  
Nobuhiro Okada<sup>1</sup>, Hayato Muranaka<sup>2</sup>, Kiyotsugu Yoshikawa<sup>3</sup>, Masaharu Seno<sup>1</sup>, Chiaki Takahashi<sup>2</sup> (<sup>1</sup>Grad. Sch. of ISEHS, Okayama Univ., <sup>2</sup>Div. Oncol. Mol. Biol., Cancer Res. Inst., Kanazawa Univ., <sup>3</sup>Nagahama Inst. Bio-Sci. & Tech.)  
乳がん治療薬抵抗性獲得機構におけるNFYAの機能解明  
岡田 宣宏<sup>1</sup>、村中 勇人<sup>2</sup>、吉川 清次<sup>3</sup>、妹尾 昌治<sup>1</sup>、高橋 智聡<sup>2</sup> (<sup>1</sup>岡山大・ヘルスシステム、<sup>2</sup>金沢大・がん研・腫瘍分子、<sup>3</sup>長浜バイオ大・バイオサイエンス)

**P-1089 The CRISPR/Cas9-mediated gene knockout screening to analyze EMT-MET plasticity in triple-negative breast cancer**  
Mizuki Yamamoto<sup>1</sup>, Kiyoshi Yamaguchi<sup>2</sup>, Yoichi Furukawa<sup>2</sup>, Jun-ichiro Inoue<sup>1</sup> (<sup>1</sup>Div. Cell. Mol. Biol., Inst. Med. Sci., Univ. Tokyo, <sup>2</sup>Div. Clin. Genome Res., Inst. Med. Sci., Univ. Tokyo)  
CRISPR/Cas9システムを用いたトリプルネガティブ乳癌におけるEMT/MET可塑性制御機構の解析  
山本 瑞生<sup>1</sup>、山口 貴世志<sup>2</sup>、古川 洋一<sup>2</sup>、井上 純一郎<sup>1</sup> (<sup>1</sup>東京大・医科研・分子発癌、<sup>2</sup>東京大・医科研・臨床ゲノム)

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P11-4 Metabolism in cancer (1)**  
がんにおける代謝 (1)

Chairperson: Yoji Andrew Minamishima (Dept. Biochem., Gunma Univ. Grad. Sch. of Med.)  
座長: 南嶋 洋司 (群馬大・医・生化学)

**P-1090 Gene expression analysis of lysophospholipid acyltransferases in mouse metastatic variant cell lines**  
Yoko Nemoto-Sasaki<sup>1</sup>, Tatsuro Irimura<sup>2</sup>, Atsushi Yamashita<sup>1</sup> (<sup>1</sup>Fac. Pharma-Sci., Teikyo Univ., <sup>2</sup>Intractable Disease Res. Ctr., Juntendo Univ. Grad. Sch. Med. Sci.)  
マウスの低転移性および高転移性がん細胞株におけるリゾリン脂質アシルトランスフェラーゼ発現量の解析  
佐々木 洋子<sup>1</sup>、入村 達郎<sup>2</sup>、山下 純<sup>1</sup> (<sup>1</sup>帝京大・薬、<sup>2</sup>順天堂大・院医)

**P-1091 Impact of mitochondrial complex I activity on cancer cell proliferation: importance of NAD<sup>+</sup> levels**  
Kazunori Mori, Masato Higrashi, Fumihiko Ishikawa, Motoko Shibamura (Div. Cancer Cell Biol., Showa Univ. Sch. Pharm.)  
呼吸鎖複合体Iによるミトコンドリア内NAD<sup>+</sup>の供給と癌細胞増殖  
森 一憲、日暮 大渡、石川 文博、柴沼 質子 (昭和大・薬・腫瘍細胞生物学)

**P-1092 ER-mitochondria tethering by PDZD8 regulates mitochondrial ATP-ROS balance in osteosarcoma cells**  
Shingo Kishi<sup>1</sup>, Shiori Mori<sup>1</sup>, Rina Fujiwara-Tani<sup>1</sup>, Yoshihiro Miyagawa<sup>1</sup>, Takuya Mori<sup>1</sup>, Yi Luo<sup>1</sup>, Takamitsu Sasaki<sup>1</sup>, Kanya Honoki<sup>2</sup>, Hiroki Kuniyasu<sup>1</sup> (<sup>1</sup>Dept. molc. patho. Nara Med. Univ., <sup>2</sup>Dept. Ortho. surg. Nara. Med. Univ.)  
PDZD8による小胞体-ミトコンドリアの繫留は骨肉腫細胞においてミトコンドリアの活性を制御する  
岸 真五<sup>1</sup>、森 汐莉<sup>1</sup>、谷 里奈<sup>1</sup>、宮川 良博<sup>1</sup>、森 拓也<sup>1</sup>、羅 奕<sup>1</sup>、佐々木 隆光<sup>1</sup>、朴木 寛弥<sup>2</sup>、國安 弘基<sup>1</sup> (<sup>1</sup>奈良県医大・分子病理学教室、<sup>2</sup>奈良県医大・整形外科)

**P-1093 The role of sterol regulatory element binding protein (SREBP) in the growth and progression of oral cancer**  
Masakatsu Fukuda, Hideaki Sakashita (Div. Oral Maxillfac. Surg., Meikai Univ., Sch, Dent.)

口腔癌の増殖と進展におけるsterol regulatory element binding protein (SREBP) の役割  
福田 正勝、坂下 英明 (明海大・歯・口外 2)

**P-1094 Frequent spontaneous tumor development in ACLY transgenic mouse**  
Hiroaki Kanda<sup>1,2</sup>, Kimie Nomura<sup>1,2</sup>, Yuichi Ishikawa<sup>2</sup>, Toshiro Migita<sup>3</sup> (<sup>1</sup>Dept. Pathol. Saitama Cancer Ctr., <sup>2</sup>Dept. Pathol. JFCR Cancer Inst., <sup>3</sup>Dept. Mol. biotherapy, JFCR Cancer Chemo. Ctr.)

ACLYトランスジェニックマウスに発生する自発腫瘍の解析  
神田 浩明<sup>1,2</sup>、野村 起美恵<sup>1,2</sup>、石川 雄一<sup>2</sup>、右田 敏郎<sup>3</sup> (<sup>1</sup>埼玉がん・病理、<sup>2</sup>(公財)がん研・研・病理、<sup>3</sup>(公財)がん研・化療・分子治療)

**12 Cancer immunity**

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P12-1 Antibody-based therapy of gastrointestinal cancer**  
消化器がんの抗体療法

Chairperson: Masahiko Shibata (Dept. Advanced Cancer Immunotherapy & Gastrointestinal Tract Surg., Fukushima Med. Univ.)

座長: 柴田 昌彦 (福島県医大・先端癌免疫療法研究講座・消化管外科学)

**P-1095 COMBINATION OF CETUXIMAB AND ONCOLYTIC VIRUS CANERAPATUREV SYNERGISTICALLY INHIBITS HUMAN COLORECTAL CANCER GROWTH**  
Shigeru Matsumura<sup>1</sup>, Zhiwen Wu<sup>1,3</sup>, Ibrahim Eissa<sup>1</sup>, Yoshinori Naoe<sup>1</sup>, Yasuhiro Kodera<sup>2</sup>, Maki Tanaka<sup>2</sup>, Hideki Kasuya<sup>1</sup> (<sup>1</sup>Cancer Immun. Therapy, Nagoya Univ., Grad. Sch. Med., <sup>2</sup>Takara Bio Inc., <sup>3</sup>Dept. Surg. II, Nagoya Univ. Grad. Sch. Med.)

大腸癌モデルにおけるセツキシマブとC-REVとの併用治療効果について  
松村 繁<sup>1</sup>、Zhiwen Wu<sup>1,3</sup>、Ibrahim Eissa<sup>1</sup>、直江 吉則<sup>1</sup>、小寺 泰弘<sup>3</sup>、田中 舞紀<sup>2</sup>、粕谷 英樹<sup>1</sup> (<sup>1</sup>名古屋大・医・癌免疫治療、<sup>2</sup>タカラバイオ (株)、<sup>3</sup>名古屋大・医・第二外科)

**P-1096 Antitumor activity of novel anti-HER2 monoclonal antibodies in a mouse xenograft model of colon cancer**  
Shinji Yamada<sup>1</sup>, Tomokazu Ohishi<sup>2</sup>, Mika Kaneko<sup>1</sup>, Manabu Kawada<sup>2</sup>, Yukinari Kato<sup>1,3</sup> (<sup>1</sup>Dept. Antibody Drug Development, Tohoku Univ., Grad. Sch. Med., <sup>2</sup>Inst. of Microbial Chemistry (BIKAKEN), Numazu, <sup>3</sup>New Industry Creation Hatchery Ctr., Tohoku Univ.)

新規HER2モノクローナル抗体の大腸がんxenograftモデルにおける抗腫瘍効果  
山田 慎二<sup>1</sup>、大石 智一<sup>2</sup>、金子 美華<sup>1</sup>、川田 学<sup>2</sup>、加藤 幸成<sup>1,3</sup> (<sup>1</sup>東北大・院医・抗体創薬、<sup>2</sup>微化研・沼津支所、<sup>3</sup>東北大・未来科学)

**P-1097 Characterization of HER3/MET-KO human colon cancer cells**  
Rikuto Miyake, Akitaka Yamasaki, Yuta Hara, Yoshiya Ono, Takashi Masuko (Cell Biol. Lab., Sch. Pharm., Kindai Univ.)

HER3/METノックアウト(KO)大腸癌細胞の性状解析  
三宅 陸斗、山崎 晶貴、原 雄大、大野 喜也、益子 高 (近畿大・薬・細胞生物)

**P-1098 Elucidation of mechanisms for MET phosphorylation stimulated by neuregulin-1 in human colorectal cancer cells**  
Akitaka Yamasaki, Natsumi Hayashi, Takashi Masuko (Cell Biol. Lab., Pharm., Kindai Univ., Sch.)

Neuregulin-1刺激がヒト大腸癌細胞で誘導するMETリン酸化の機構について  
山崎 晶貴、林 奈津美、益子 高 (近畿大・薬・細胞生物)

**P-1099 5-FU induces up-regulation of PD-L1 expression in gastric cancer**  
Kohei Yamashita, Masaaki Iwatsuki, Kojiro Eto, Yukiharu Hiyoshi, Takatsugu Ishimoto, Yohei Nagai, Shiro Iwagami, Yuji Miyamoto, Naoya Yoshida, Hideo Baba (Dept. GE Surg., Kumamoto Univ.)

5FUが胃癌細胞のPD-L1発現に与える影響の検討  
山下 晃平、岩根 政晃、江藤 弘二郎、日吉 幸晴、石本 崇胤、長井 洋平、岩上 志朗、宮本 裕士、吉田 直矢、馬場 秀夫 (熊本大・医・消化器外科)

**P-1100 Anti-CD4 depleting Ab IT1208 exerts antitumor effects by replacing TCR repertoire in gastrointestinal cancer patients**

Satoshi Ueha<sup>1</sup>, Manami Shimomura<sup>2</sup>, Toshihiro Suzuki<sup>2</sup>, Tetsuya Nakatsura<sup>3</sup>, Makiko Yamashita<sup>3</sup>, Shigehisa Kitano<sup>3</sup>, Satoru Ito<sup>1,4</sup>, Toshihiko Doi<sup>5</sup>, Kouji Matsushima<sup>1</sup> (<sup>1</sup>MRIID, Res. Inst. Biomed. Sci., Tokyo. Univ. Sci., <sup>2</sup>Div. Cancer Immunothera., Explor. Onco\_Res. Clinic\_Trial Ctr., Natl. Cancer Ctr., <sup>3</sup>Dept. Exp. Therap., Natl. Cancer Ctr. Hosp., <sup>4</sup>IDAC Theranostics Inc., <sup>5</sup>Dept. Exp. Therap., Natl. Cancer Ctr. Hosp. East)

消化器がん患者に対する抗ヒトCD4抗体IT1208投与はT細胞受容体レバトアを入れ替え抗腫瘍効果を発揮する

上羽 悟史<sup>1</sup>、下村 真菜美<sup>2</sup>、鈴木 利宙<sup>2</sup>、中面 哲也<sup>2</sup>、山下 万貴子<sup>3</sup>、北野 滋久<sup>3</sup>、伊藤 哲<sup>1,4</sup>、土井 俊彦<sup>5</sup>、松島 綱治<sup>1</sup> (<sup>1</sup>東京理科大・生命研・炎症免疫難病制御、<sup>2</sup>国立がん研セ・先端医・免疫療法開発、<sup>3</sup>国立がん研セ・中央病院・先端医療科、<sup>4</sup>IDAC セラノスティクス(株)、<sup>5</sup>国立がん研セ・東病院・先端医療科)

**P-1106 TGF-beta blockade enhances the immunotherapeutic effect of CpG DNA in cancer**

Sho Umegaki, Hidekazu Shirota, Chikashi Ishioka (Dept. Med. Oncology, Inst. Development, Aging & Cancer, Tohoku Univ.)

CpG DNA と TGF-β 中和抗体を併用する新規がん免疫療法の開発  
梅垣 翔、城田 英和、石岡 千加史 (東北大・加齢研・臨床腫瘍学分野)

**P-1107 Myc contributes to hepatocyte proliferation following a partial hepatectomy in mice**

Masanori Goto, Takako Ooshio, Masahiro Yamamoto, Yuki Kamikokura, Lingrong Meng, Yoko Okada, Yuji Nishikawa (Div. Tumor Pathol., Dept. Pathol., Asahikawa Med. Univ.)

Myc は部分肝切除後のマウス肝細胞増殖に寄与する  
後藤 正憲、大塩 貴子、山本 雅大、上小倉 祐機、孟 玲童、岡田 陽子、西川 祐司 (旭川医大・医・病理学・腫瘍病理)

**13 Growth factors/cytokines/hormones**

Room P(A) Sep. 26 (Thu.) 16:30-17:15

E/J

**P13-1 Growth factor and cytokine (1)**  
増殖因子・サイトカイン (1)

Chairperson: Keiji Miyazawa (Univ. of Yamanashi)

座長: 宮澤 恵二 (山梨大・医)

**P-1101 The transcriptional co-factor VGLL3 promotes EMT progression in TGF-β signaling**

Noritaka Yamaguchi<sup>1,2</sup> (<sup>1</sup>Lab. Mol. Cell Biol., Grad. Sch. Pharm. Sci., Chiba Univ., <sup>2</sup>Dept. Mol. Cardiovasc. Pharmacol., Grad. Sch. Pharm. Sci., Chiba Univ.)

TGF-β シグナルにおける転写共役因子VGLL3による上皮間葉転換誘導

山口 憲孝<sup>1,2</sup> (<sup>1</sup>千葉大・院薬・分子細胞生物学、<sup>2</sup>千葉大・院薬・分子心血管薬理学)

**P-1102 Smad3 suppresses epithelial cell migration and proliferation via the clock gene Dec1**

Fuyuki Sato<sup>1</sup>, Ujjarl Bhawal<sup>2</sup>, Kosuke Oikawa<sup>1</sup>, Yasuteru Muragaki<sup>1</sup> (<sup>1</sup>Dept. Pathol., Wakayama Med., <sup>2</sup>Dept. Biochem., Nihon Univ., Matsudo)

Smad3は時計遺伝子Dec1を介して細胞増殖や遊走を抑制する  
佐藤 冬樹<sup>1</sup>、パワール ウジャール<sup>2</sup>、及川 恒輔<sup>1</sup>、村垣 泰光<sup>1</sup> (和歌山医大・医・病理、<sup>2</sup>日本大・歯・生化・松戸)

**P-1103 Ubiquitin C-terminal hydrolase-L1 enhances TGF-β signaling and potentiates lung tumorigenesis**

Asami Nagata, Fumiko Itho, Yuta Fujikawa, Hideshi Inoue (Sch. Life Sci., Tokyo Univ. Pharm. Life Sci.)

脱ユビキチン化酵素UCH-L1はTGF-βシグナルを増強し、肺がん形成に関与する

永田 麻未、伊東 史子、藤川 雄太、井上 英史 (東京薬大・生命)

**P-1104 RUNX3 expression mediates cross-talk between TGF-β and SDF-1 signaling and WNT-β-catenin signaling in human breast CAFs**

Yu Koyama<sup>1,2</sup>, Go Yoshida<sup>2</sup>, Yasuhiko Ito<sup>2</sup>, Yoshihiro Mezawa<sup>2</sup>, Takumi Koyama<sup>1,2</sup>, Keisuke Sugahara<sup>1</sup>, Akira Katakura<sup>1</sup>, Akira Orimo<sup>2</sup> (<sup>1</sup>Dept. Oral Pathobiological Sci. & Surg., Tokyo Dent. Col., <sup>2</sup>Dept. Path. & Oncol., Juntendo Univ. Faculty of Med.)

乳腺癌関連線維芽細胞におけるRUNX3の発現はTGF-βとSDF-1のクロストークおよびWNT-β-cateninシグナルを媒介する

小山 侑<sup>1,2</sup>、吉田 剛<sup>2</sup>、伊藤 恭彦<sup>2</sup>、目澤 義弘<sup>2</sup>、小山 拓洋<sup>1,2</sup>、菅原 圭亮<sup>1</sup>、片倉 朗、折茂 彰<sup>2</sup> (<sup>1</sup>東京歯科大・口腔病態外科学講座、<sup>2</sup>順天堂大・病理・腫瘍学講座)

**P-1105 Diagnosis of activated TGF-β signaling in head and neck cancer by ambient mass spectrometry with machine learning**

Hiroki Ishii<sup>1</sup>, Masao Saitoh<sup>2</sup>, Kaname Sakamoto<sup>1</sup>, Keiji Miyazawa<sup>2</sup>, Sen Takeda<sup>3</sup>, Kentaro Yoshimura<sup>3</sup> (<sup>1</sup>Dept. Otolaryngo. H&N surg. Yamanashi Univ., <sup>2</sup>Dept. Biochem. Yamanashi Univ., <sup>3</sup>Dept. Anatomy & Cell Biol. Yamanashi Univ.)

頭頸部がん脂質代謝に基づくTGF-βシグナルの学習機械を用いた腫瘍内迅速診断予測

石井 裕貴<sup>1</sup>、斎藤 正夫<sup>2</sup>、坂本 要<sup>1</sup>、宮澤 恵二<sup>2</sup>、竹田 扇<sup>3</sup>、吉村 健太郎<sup>3</sup> (<sup>1</sup>山梨大・医・耳鼻咽喉科、<sup>2</sup>山梨大・医・生化2、<sup>3</sup>山梨大・医・解剖学講座細胞生物学)

## 14 Cancer basic, diagnosis and treatment

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

### P14-1 Gastric cancer: pathology

胃がん：病理

Chairperson: Kazuhiro Sentani (Dept. Mol. Pathol., Hiroshima Univ. Grad. Sch. Biomed. Health Sci.)

座長：仙谷 和弘 (広島大・院医・分子病理)

### P-1108 Endoscopic and pathologic motifs for the clinical diagnosis of Epstein-Barr virus-associated gastric cancer

Hideo Yanai<sup>1</sup>, Tomoyuki Murakami<sup>2</sup>, Jun Nishikawa<sup>3</sup> (<sup>1</sup>Dept. Clin. Res. Natl. Hosp. Org. Kanmon Med. Cent., <sup>2</sup>Dept. Pathol. Natl. Hosp. Org. Kanmon Med. Cent., <sup>3</sup>Dept. Lab. Sci. Yamaguchi Univ. Grad. Sch. Med.)

#### EB ウイルス関連胃癌診断の内視鏡的および組織学的契機

柳井 秀雄<sup>1</sup>、村上 知之<sup>2</sup>、西川 潤<sup>3</sup> (<sup>1</sup>国立病院機構関門医療セ・臨床研究部、<sup>2</sup>国立病院機構関門医療セ・病理、<sup>3</sup>山口大・院・基礎検査学)

### P-1109 RHOA mutations contribute to the histopathological features of RHOA-mutated diffuse gastric cancer

Etsuko Fujii<sup>1,2</sup>, Kiyotaka Nakano<sup>1</sup>, Daisuke Komura<sup>3,4</sup>, Hiroyuki Aburatani<sup>5</sup>, Shumpei Ishikawa<sup>3,4</sup>, Masami Suzuki<sup>1,2</sup> (<sup>1</sup>Forerunner Pharma Res. Co., Ltd., <sup>2</sup>Chugai Pharm. Co., Ltd., <sup>3</sup>Tokyo Med. & Dent. Univ. Genomic Path., <sup>4</sup>Univ. of Tokyo, Dept. Preventive Med., <sup>5</sup>Univ. of Tokyo, RCAST Genome Sci. Div.)

#### RHOA 変異び慢性胃癌における変異 RHOA の病理組織学的形質への影響

藤井 悦子<sup>1,2</sup>、中野 清孝<sup>1</sup>、河村 大輔<sup>3,4</sup>、油谷 浩幸<sup>5</sup>、石川 俊平<sup>3,4</sup>、鈴木 雅実<sup>1,2</sup> (<sup>1</sup>(株) 未来創薬研、<sup>2</sup>中外製薬(株)、<sup>3</sup>東京医歯大・ゲノム病理分野、<sup>4</sup>東京大・医・衛生学分野、<sup>5</sup>東京大・先端研・ゲノムサイエンス)

### P-1110 Clinicopathological and molecular analysis of foveolar type gastric adenocarcinoma

Noriyuki Uesugi<sup>1</sup>, Ryo Sugimoto<sup>1</sup>, Makoto Eizuka<sup>1</sup>, Yasuko Fujita<sup>1</sup>, Mitsumasa Osakabe<sup>1</sup>, Kazuyuki Ishida<sup>1</sup>, Takayuki Matsumoto<sup>2</sup>, Tamotsu Sugai<sup>1</sup> (<sup>1</sup>Det. Mol. Diag. Pathol., Iwate Med. Univ., Sch. Med., <sup>2</sup>Div. Gastroenterol, Det. Int. Med., Iwate Med. Univ., Sch. Med.)

#### 腺窩上皮型胃癌における臨床病理学および分子生物学的解析

上杉 憲幸<sup>1</sup>、杉本 亮<sup>1</sup>、永塚 真<sup>1</sup>、藤田 泰子<sup>1</sup>、刑部 光正<sup>1</sup>、石田 和之<sup>1</sup>、松本 主之<sup>2</sup>、菅井 有<sup>1</sup> (<sup>1</sup>岩手医大・医・分子診断病理、<sup>2</sup>岩手医大・医・内科)

### P-1111 Molecular Pathological Features of Signet Ring Cell Gastric Cancer

Ryo Saito, Suguru Maruyama, Naoki Ashizawa, Yuko Nakayama, Hiroki Shimizu, Daisuke Ichikawa (1st Dept. Surg., Med., Yamanashi Univ.)

#### 印鑑細胞胃癌のもつ分子病理学的特徴に関する検討

齋藤 亮、丸山 傑、芦沢 直樹、中山 裕子、清水 浩紀、市川 大輔 (山梨大・医・第1外科)

### P-1112 Clinicopathological features and molecular analysis of crawling-type early gastric cancers

Yasuko Fujita<sup>1</sup>, Noriyuki Uesugi<sup>1</sup>, Ryo Sugimoto<sup>1</sup>, Makoto Eizuka<sup>1</sup>, Mitsumasa Osakabe<sup>1</sup>, Kazuyuki Ishida<sup>1</sup>, Takayuki Matsumoto<sup>2</sup>, Tamotsu Sugai<sup>1</sup> (<sup>1</sup>Dept. Mol. Diag. Path., Iwate Med. Univ., <sup>2</sup>Div. Gastroenterol., Dept. Int. Med., Iwate Med. Univ.)

#### 手繫ぎ型早期胃癌における臨床病理学および分子病理学的解析

藤田 泰子<sup>1</sup>、上杉 憲幸<sup>1</sup>、杉本 亮<sup>1</sup>、永塚 真<sup>1</sup>、刑部 光正<sup>1</sup>、石田 和之<sup>1</sup>、松本 主之<sup>2</sup>、菅井 有<sup>1</sup> (<sup>1</sup>岩手医大・医・病理診断学、<sup>2</sup>岩手医大・医・消化器内科消化管分野)

### P-1113 Clinicopathological Significance of Thrombospondin 4 Expression in Gastric Cancer Stroma

Kenji Kuroda<sup>1,2</sup>, Masakazu Yashiro<sup>1,2</sup>, Shingo Togano<sup>1,2</sup>, Syuhei Kushiya<sup>1,2</sup>, Sadaaki Nishimura<sup>1,2</sup>, Atsushi Sugimoto<sup>1,2</sup>, Tomoo Sera<sup>1,2</sup>, Yukako Kushitani<sup>1,2</sup>, Yurie Yamamoto<sup>1,2</sup>, Takahiro Toyokawa<sup>1</sup>, Hiroaki Tanaka<sup>1</sup>, Kazuya Muguruma<sup>1</sup>, Masaichi Ohira<sup>1</sup> (<sup>1</sup>Dept. Gastroenterol. Surg., Osaka City Univ. Grad., <sup>2</sup>Mol. Oncology & Therap., Osaka City Univ. Grad.)

#### 胃癌間質における Thrombospondin 4 発現の臨床病理学的検討

黒田 顕慈<sup>1,2</sup>、八代 正和<sup>1,2</sup>、梶野 真吾<sup>1,2</sup>、榎山 周平<sup>1,2</sup>、西村 貞徳<sup>1,2</sup>、杉本 敦史<sup>1,2</sup>、瀬良 知央<sup>1,2</sup>、榎谷 友佳子<sup>1,2</sup>、山本 百合恵<sup>1,2</sup>、豊川 貴弘<sup>1</sup>、田中 浩明<sup>1</sup>、六車 一哉<sup>1</sup>、大平 雅一<sup>1</sup> (<sup>1</sup>大阪市大・消化器外科、<sup>2</sup>大阪市大・癌分子病態制御学)

### P-1114 Primary gastric melanoma: Surgical treatment of tow cases and review of the literature

Hong Fu, Mingzhe Ma, Yakai Huang (Dept. of Gastric Surg. Fudan Univ. Shanghai Cancer Ctr. FUSCC)

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

### P14-2 Colorectal cancer: diagnosis method

大腸がん：診断技術

Chairperson: Nobuyuki Onishi (Tech. Res. Lab., SHIMADZU CORPORATION)

座長：大西 伸幸 (島津製作所・基盤研)

### P-1115 EGFR-targeted molecular imaging for detection and treatment evaluation of colorectal tumors in animal model

Yoshihiko Miyamoto<sup>1</sup>, Naoki Muguruma<sup>1</sup>, Yasuyuki Okada<sup>1</sup>, Hironori Tanaka<sup>1</sup>, Jun Okazaki<sup>1</sup>, Koichi Okamoto<sup>1</sup>, Yasushi Sato<sup>2</sup>, Tetsuji Takayama<sup>1</sup> (<sup>1</sup>Dept. Gastroenterol. Oncol., Tokushima Univ., <sup>2</sup>Dept. Commun. Med. for Gastroenterol. Oncol., Tokushima Univ.)

#### 動物モデルにおける結腸直腸腫瘍の検出と治療評価のための EGFR 標的分子イメージング

宮本 佳彦<sup>1</sup>、六車 直樹<sup>1</sup>、岡田 泰行<sup>1</sup>、田中 宏典<sup>1</sup>、岡崎 潤<sup>1</sup>、岡本 耕一<sup>1</sup>、佐藤 康史<sup>2</sup>、高山 哲治<sup>1</sup> (<sup>1</sup>徳島大・医・消化器内科学、<sup>2</sup>徳島大・医・地域消化器・総合内科学)

### P-1116 Rapid detection of metastatic lymph nodes of colorectal cancer with a GGT-activatable fluorescence probe

Hidemasa Kubo<sup>1</sup>, Yasutoshi Murayama<sup>1</sup>, Soichiro Ogawa<sup>1</sup>, Tatsuya Matsumoto<sup>1</sup>, Tomohiro Arita<sup>1</sup>, Yoshiaki Kuriu<sup>1</sup>, Takeshi Kubota<sup>1</sup>, Masayoshi Nakanishi<sup>1</sup>, Kazuma Okamoto<sup>1</sup>, Mako Kamiya<sup>2</sup>, Yasuteru Urano<sup>2,3,4</sup>, Eigo Otsuji<sup>1</sup> (<sup>1</sup>Digest., Surg., Kyoto Pref. Univ. of Med., <sup>2</sup>Grad. Sch. Med., The Univ. Tokyo, <sup>3</sup>Grad. Sch. Pharm. Sci., The Univ. Tokyo, <sup>4</sup>CREST, AMED)

GGT 活性検出蛍光プローブによる大腸癌リンパ節転移の迅速診断  
久保 秀正<sup>1</sup>、村山 康利<sup>1</sup>、小川 聡一郎<sup>1</sup>、松本 辰也<sup>1</sup>、有田 智洋<sup>1</sup>、栗生 宣明<sup>1</sup>、窪田 健<sup>1</sup>、中西 正芳<sup>1</sup>、岡本 和真<sup>1</sup>、神谷 真子<sup>2</sup>、浦野 泰照<sup>2,3,4</sup>、大辻 英吾<sup>1</sup> (<sup>1</sup>京都府医大・消化器外科、<sup>2</sup>東京大・院医・生体情報学、<sup>3</sup>東京大・院薬・薬品代謝化学、<sup>4</sup>AMED・CREST)

### P-1117 New technology for colorectal cancer detection using Membrane-type Surface stress Sensor (MSS) plus AI data analysis

Masao Miyashita<sup>1</sup>, Marina Yamada<sup>3</sup>, Genki Yoshikawa<sup>4</sup>, Junko Watanabe<sup>3</sup>, Riki Eto<sup>3</sup>, So Yamada<sup>3</sup>, Hiroshi Yoshida<sup>2</sup>, Akihisa Matsuda<sup>1,2</sup>, (<sup>1</sup>Dept. Surg., Nippon Med. Sch. Chiba Hokusoh Hosp., <sup>2</sup>Dept. Surg., Nippon Med. Sch., <sup>3</sup>Dept. Emerg & Crit Care Med., Nippon Med. Sch., <sup>4</sup>Cent. Functional Sensor & Actuator, NIMS, <sup>5</sup>Data Sci. Res. Labs., NEC)

#### 膜型表面応力センサによる新規大腸癌スクリーニング法

宮下 正夫<sup>1</sup>、山田 真史奈<sup>3</sup>、吉川 元起<sup>4</sup>、渡辺 純子<sup>5</sup>、江藤 力<sup>5</sup>、山田 聡<sup>3</sup>、吉田 寛<sup>2</sup>、松田 明久<sup>1,2</sup> (<sup>1</sup>日本医大・千葉北総・外科、<sup>2</sup>日本医大・消化器外科、<sup>3</sup>日本医大・救急医学、<sup>4</sup>センサ・アクチュエータ研開セ、<sup>5</sup>NEC データサイエンス研)

### P-1118 Prognostic role of baseline and end-of-treatment metabolic PET/CT features to NACR with thermal therapy in rectal cancer

Hisanori Shoji<sup>1</sup>, Yoji Ogoshi<sup>2</sup>, Takeo Takahashi<sup>2</sup>, Takayuki Asao<sup>4</sup>, Ken Shirabe<sup>5</sup> (<sup>1</sup>Div. Surg., Hidaka Hosp., <sup>2</sup>Div. Clin. Oncol., Hidaka Hosp., <sup>3</sup>Dept. Rad. Oncol. Saitama Med. Ctr., <sup>4</sup>Saitama Med. Univ., <sup>5</sup>Gunma Univ. Initiative Advanced Res., <sup>6</sup>Dept. General Surg. Sci., Gunma Univ. Grad. Sch. Med.)

#### 温熱療法を用いた直腸癌 NACR における、ベースラインおよび治療終了時の PET/CT metabolic parameter による予後予測

東海林 久紀<sup>1</sup>、生越 高二<sup>2</sup>、高橋 健夫<sup>3</sup>、浅尾 高行<sup>4</sup>、調 憲<sup>5</sup> (<sup>1</sup>日高病院・外科、<sup>2</sup>日高病院・臨床腫瘍科、<sup>3</sup>埼玉医大・総合医療セ・放射線腫瘍科、<sup>4</sup>群馬大・未来先端、<sup>5</sup>群馬大・院・病態総合外科学)

### P-1119 RAS mutation analysis using cell-free DNA in urine from patients with colorectal cancer

Makoto Kusakabe<sup>1</sup>, Takeshi Yamada<sup>1</sup>, Michihiro Koizumi<sup>1</sup>, Seiichi Shinji<sup>1</sup>, Akihisa Matsuda<sup>1</sup>, Goro Takahashi<sup>1</sup>, Takuma Iwai<sup>3</sup>, Kouki Takeda<sup>1</sup>, Kouji Ueda<sup>1</sup>, Yasuyuki Yokoyama<sup>2</sup>, Masahiro Hotta<sup>1</sup>, Keisuke Hara<sup>1</sup>, Hiroshi Yoshida<sup>1</sup> (<sup>1</sup>Dept. Gastroenterological Surg., Nippon Med. Sch. Hosp., <sup>2</sup>Dept. Gastroenterological Surg., Nippon Med. Sch. Musashi-kosugi Hosp., <sup>3</sup>Dept. Gastroenterological Surg., Nippon Med. Sch. Tama-nagayama Hosp.)

#### 結腸直腸癌症例における尿中 cell-free DNA の抽出および RAS 遺伝子変異の解析の試み

日下部 誠<sup>1</sup>、山田 岳史<sup>1</sup>、小泉 岐博<sup>1</sup>、進士 誠一<sup>1</sup>、松田 明久<sup>1</sup>、高橋 吾郎<sup>1</sup>、岩井 拓磨<sup>3</sup>、武田 幸樹<sup>1</sup>、上田 康二<sup>1</sup>、横山 康行<sup>2</sup>、堀田 正啓<sup>1</sup>、原 敬介<sup>1</sup>、吉田 寛<sup>1</sup> (<sup>1</sup>日本医大・付属病院・消化器外科、<sup>2</sup>日本

医大・武蔵小杉病院・消化器外科、<sup>3</sup>日本医大・多摩永山病院・消化器外科

P-1120 **Withdrawn**

Room **P(B)** Sep. 26 (Thu.) 16:30-17:15

E/J

**P14-3 Hepatocellular carcinoma (1)**  
肝がん (1)

Chairperson: Hidenori Ojima (Dept. Path., Keio Univ. Sch. of Med.)  
座長: 尾島 英知 (慶應大・医・病理学)

P-1121 **Comprehensive molecular and immunological characterization of hepatocellular carcinoma**  
Shu Shimada, Yoshimitsu Akiyama, Shinji Tanaka (Dept. Mol. Oncol., Tokyo Med. & Dent. Univ.)

肝細胞癌の分子生物学的および免疫学的分類

島田 周、秋山 好光、田中 真二 (東京医歯大・院医歯学総合・分子腫瘍医学)

P-1122 **Fatty liver promotes liver tumor growth and recombinant thrombomodulin suppresses liver tumor growth**

Megumi Yamaguchi<sup>1,2</sup>, Hirotaka Tashiro<sup>1</sup>, Sho Okimoto<sup>3</sup>, Hideki Ohdan<sup>2</sup> (<sup>1</sup>Natl. Hosp. Organization Kure Med. Ctr., <sup>2</sup>Dept. Gastroenterological & Transplant Surg., Hiroshima Univ.)

脂肪肝は肝腫瘍を促進し、トロンボモジュリン製剤が肝腫瘍を抑制する

山口 恵美<sup>1,2</sup>、田代 裕尊<sup>1</sup>、沖本 将<sup>2</sup>、大段 秀樹<sup>2</sup> (<sup>1</sup>国立病院機構呉医療セ、<sup>2</sup>広島大・消化器移植外科)

P-1123 **The SNP allele corresponding to higher IRF5 expression reduces susceptibility to HBV-related hepatocellular carcinoma**

Daiki Miki<sup>1,2</sup>, Masataka Tsuge<sup>1,2</sup>, Masami Yamauchi<sup>1</sup>, Atsushi Ono<sup>1</sup>, Hiroshi Aikata<sup>1,2</sup>, Tatsuhiko Tsunoda<sup>3,4</sup>, Kazuaki Chayama<sup>1,2,4</sup> (<sup>1</sup>Dept. Gastroenterol. & Metab., Hiroshima Univ., <sup>2</sup>Res. Ctr. for Hepatol. & Gastroenterol., Hiroshima Univ., <sup>3</sup>Dept. Med. Sci. Math., Tokyo Med. & Dent. Univ., <sup>4</sup>RIKEN Ctr. for Integrative Med. Sci.)

IRF5 高発現に関連する SNP アレルは HBV 関連肝臓の発症リスクを低下させる

三木 大樹<sup>1,2</sup>、柘植 雅貴<sup>1,2</sup>、山内 理海<sup>1</sup>、大野 敦司<sup>1</sup>、相方 浩<sup>1,2</sup>、角田 達彦<sup>3,4</sup>、茶山 一彰<sup>1,2,4</sup> (<sup>1</sup>広島大・消化器・代謝内科、<sup>2</sup>広島大・肝臓・消化器研究拠点、<sup>3</sup>東京医歯大・医科学数理分野、<sup>4</sup>理研・生命医科学研究セ)

P-1124 **Association of tumor-infiltrating CD8-T cells with programmed cell death-ligand 1 expression in hepatocellular carcinoma**

Shinji Itoh, Tomoharu Yoshizumi, Masaki Mori (Dept. Surg. & Sci., Kyushu Univ.)

肝細胞癌における PD-L1 発現と浸潤性 CD8 陽性 T リンパ球の関連

伊藤 心二、吉住 朋晴、森 正樹 (九州大・医・消化器・総合外科)

P-1125 **The function and mechanism of HNF1A-AS1 in the development of hepatocellular carcinoma**

Lufei Zhang (The second affiliated Hosp. zhejiang Univ.)

P-1126 **Establishment of preoperative predictive nomogram for hepatocellular carcinoma with microvascular invasion**

Liang Zhi Yin, Chen Chang Zhi, Huang Tao, Qi Ya Peng, Zhang Jie, Yuan Wei Ping, Xiang Bang De, Li Le Qun (Affiliated Cancer Hosp. of Guangxi Med. Univ.)

P-1127 **Preoperative hypoglycemia is a poorer prognostic for hepatocellular carcinoma patients following curative hepatectomy**

Jia Hao Liang, Ya Peng Qi, Jie Zhang, Jun Wen Hu, Bang De Xiang (Affiliated Cancer Hosp. of Guangxi Med. Univ.)

Room **P(B)** Sep. 26 (Thu.) 16:30-17:15

E/J

**P14-4 Pancreatic cancer (1)**  
膵がん (1)

Chairperson: Akihisa Fukuda (Kyoto Univ. Hosp., Dept. Gastroenterology & Hepatology)

座長: 福田 晃久 (京都市大・医付属病院・消化器内科)

P-1128 **Cell-free KRAS mutant allele predicts the micrometastasis in pancreatic cancer patients with curative-intent resection**

Tatsuo Hata, Masamichi Mizuma, Fuyuhiko Motoi, Tatsuyuki Takadate, Kyohei Ariake, Shuichi Aoki, Kei Kawaguchi, Hideo Ohtsuka, Hiroki Hayashi, Shinobu Ohnuma, Michiaki Unno (Dept. Surg. Tohoku Univ.)

切除企図膵癌の微小転移診断における血中 KRAS 変異 DNA 測定の有用性

畠 達夫、水間 正道、元井 冬彦、高舘 達之、有明 恭平、青木 修一、川口 桂、大塚 英郎、林 洋毅、大沼 忍、海野 倫明 (東北大・医・消化器外科)

P-1129 **Fetal bovine serum enlarges the size of pancreatic cancer spheres with an increase in the cancer stem cell markers**

Toshiyuki Ishiwata<sup>1</sup>, Norihiko Sasaki<sup>2</sup>, Masashi Toyoda<sup>2</sup>, Fumio Hasegawa<sup>1</sup>, Fujiya Gomi<sup>1</sup> (<sup>1</sup>Res. Team for Geriatric Pathol., Tokyo Met. Inst. Gerontol., <sup>2</sup>Res. Team for Geriatric Med., Tokyo Met. Inst. Gerontol.)

胎児ウシ血清による、膵癌のスフェア増大効果と癌幹細胞マーカーの増加

石渡 俊行<sup>1</sup>、佐々木 紀彦<sup>2</sup>、豊田 雅士<sup>2</sup>、長谷川 文雄<sup>1</sup>、五味 不二也<sup>1</sup> (<sup>1</sup>東京都健康長寿医療セ・高齢者がん、<sup>2</sup>東京都健康長寿医療セ・血管医学)

P-1130 **Prosaposin, tumor-secreted glycoprotein, regulates metastasis of pancreatic cancer**

Yoji Miahara<sup>1</sup>, Shigetsugu Takano<sup>1</sup>, Kazuyuki Sogawa<sup>2</sup>, Hideyuki Yoshitomi<sup>1</sup>, Masayuki Ohtsuka<sup>1</sup> (<sup>1</sup>Dept. General Surg., Sch., Med., Chiba Univ., <sup>2</sup>Dept. Biochem., Sch., Life Environ., Azabu Univ.)

分泌糖蛋白 prosaposin の膵癌転移における役割

宮原 洋司<sup>1</sup>、高野 重紹<sup>1</sup>、曾川 一幸<sup>2</sup>、吉富 秀幸<sup>1</sup>、大塚 将之<sup>1</sup> (千葉大・医・臓器制御外科、<sup>2</sup>麻布大・生命・環境部・臨床検査技術学)

P-1131 **Genetic alterations in pancreatic cancer cells affect the mechanism of cancer immunoediting**

Shingo Kato<sup>1</sup>, Tomohiko Tamura<sup>2</sup>, Atsushi Nakajima<sup>1</sup> (<sup>1</sup>Dept. Gastroenterology & Hepatology, Yokohama City Univ. Sch. Med., <sup>2</sup>Dept. Immuno., Yokohama City Univ.)

膵癌細胞における遺伝子変異は癌細胞の腫瘍免疫編集機構に影響を与える

加藤 真吾<sup>1</sup>、田村 智彦<sup>2</sup>、中島 淳<sup>1</sup> (横浜市大・医・肝胆膵消化器病学、<sup>2</sup>横浜市大・医・免疫学)

P-1132 **The role of pancreatic cancer associated fibroblasts to construct immune suppressive microenvironment**

Eri Sawai<sup>1,2</sup>, Hironori Fukuda<sup>1</sup>, Makiko Yamashita<sup>1,3</sup>, Yurin Sawada<sup>1</sup>, Yukihiko Mizoguchi<sup>1</sup>, Kazunori Aoki<sup>1</sup> (<sup>1</sup>Natl. Cancer Ctr. Res. Inst., Dept. Immune Med., <sup>2</sup>Lab. of Immune Regulation Sch. of Life Science., <sup>3</sup>Natl. Cancer Ctr. Hosp. Dept. Exp. Therapeutics.)

免疫抑制性微小環境を構築するための膵がん関連線維芽細胞の役割

澤井 瑛里<sup>1,2</sup>、福田 洋典<sup>1</sup>、山下 万貴子<sup>1,3</sup>、沢田 悠梨亜<sup>1</sup>、溝口 幸宏<sup>1</sup>、青木 一教<sup>1</sup> (<sup>1</sup>国立がん研セ・研・免疫創薬、<sup>2</sup>東大・生命科学・免疫制御、<sup>3</sup>国立がん研セ・中央病院・先端医療科)

P-1133 **Anti-tumor activity of cediranib, an inhibitor of VEGF receptors, in pancreatic ductal adenocarcinoma cells**

Majid Momeny (Shariati Hosp., Tehran, Iran)

P-1134 **Tumor suppressor LKB1 regulate glutamine metabolism in pancreatic ductal adenocarcinoma with gemcitabine resistance**

Ji Min Park<sup>1,2</sup>, Chia-Ying Lin<sup>2</sup>, Chien-Chao Chiu<sup>3</sup>, Shao-Wen Hung<sup>3,4</sup>, Ching-Feng Chiu<sup>1,2</sup> (<sup>1</sup>Sch. of Nutrition&Health Sci, College of Nutrition, Taipei Med. Univ., <sup>2</sup>Grad. Inst. of Metabolism&Obesity Sci, Taipei Med. Univ., <sup>3</sup>Div. Animal Industry, Animal Tech. Lab., Agricultural Tech. Res. Inst., <sup>4</sup>Nursing Dept. Yuanpei Univ.)

### P14-5 Molecular pathogenesis and treatment of lung cancer (1) 肺がんの分子病態と治療 (1)

Chairperson: Hiromichi Ebi (Aichi Cancer Ctr. Res. Inst., Div. Mol. Therap.)

座長: 衣斐 寛倫 (愛知県がんセンター標的治療トランスレーショナルリサーチ分野)

- P-1135 Somatic mutations specific to micropapillary element in EGFR-mutated lung adenocarcinoma**  
Mai Matsumura<sup>1</sup>, Koji Okudela<sup>1</sup>, Chihiro Koike<sup>1</sup>, Jun Nakabayashi<sup>2</sup>, Hideaki Mitsui<sup>1</sup>, Takehisa Suzuki<sup>1</sup>, Toshiaki Kataoka<sup>1</sup>, Shigeaki Umeda<sup>1</sup>, Yoko Tateishi<sup>1</sup>, Hiromasa Arai<sup>3</sup>, Kenichi Ohashi<sup>1</sup> (1Dept. Pathol., Yokohama City Univ., Sch. Med., 2Advanced Med. Res. Ctr. Yokohama City Univ., 3Dept. Surg., Kanagawa Cardiovasc & Respir Cent Hosp.)  
EGFR 変異型肺腺癌の微小乳頭状型に特異的な体細胞遺伝子変異  
松村 舞依<sup>1</sup>, 奥寺 康司<sup>1</sup>, 小池 千尋<sup>1</sup>, 中林 潤<sup>2</sup>, 三井 秀昭<sup>1</sup>, 鈴木 健久<sup>1</sup>, 片岡 俊朗<sup>1</sup>, 梅田 茂明<sup>1</sup>, 立石 陽子<sup>1</sup>, 荒井 宏雅<sup>3</sup>, 大橋 健一<sup>1</sup> (1横浜市大・医・病態病理, 2横浜市大・先端研バイオインフォマテイクス, 3神奈川循環呼吸・胸部一般外科)
- P-1136 Expression of intratumoral GFPT2 in lung adenocarcinoma**  
Yukihisa Inoue<sup>1</sup>, Hiroyuki Shimada<sup>1</sup>, Yasuto Jin<sup>1</sup>, Osamu Matsubara<sup>2</sup> (1Hiratsuka Kyosai Hosp., Dept. Resp. Med., 2Hiratsuka Kyosai Hosp., Dept. Diag. Pathol.)  
肺腺癌組織中の GFPT2 の発現  
井上 幸久<sup>1</sup>, 島田 裕之<sup>1</sup>, 神 靖人<sup>1</sup>, 松原 修<sup>2</sup> (1平塚共済病院・呼吸器内科, 2平塚共済病院・病理診断科)
- P-1137 A subpopulation of airway epithelial cells that express HNF 4alfaand non-TRU lung adenocarcinoma**  
Koji Okudela<sup>1</sup>, Hiromasa Arai<sup>2</sup>, Mai Matsumura<sup>2</sup>, Tomohisa Baba<sup>3</sup>, Hideaki Mitsui<sup>1</sup>, Takehisa Suzuki<sup>1</sup>, Yoko Tateishi<sup>1</sup>, Kenichi Ohashi<sup>1</sup> (1Dept. Pathol. Yokohama City Univ. Med., 2Div. General Thoracic Surg., Kanagawa CRC, 3Div. Resp. Int. Med., Kanagawa CRC)  
HNF 4alfa 陽性気道上皮細胞と non-TRU lung adenocarcinoma の発生の関係性  
奥寺 康司<sup>1</sup>, 荒井 宏雅<sup>2</sup>, 松村 舞依<sup>2</sup>, 馬場 智尚<sup>3</sup>, 三井 秀昭<sup>1</sup>, 鈴木 健久<sup>1</sup>, 立石 陽子<sup>1</sup>, 大橋 健一<sup>1</sup> (1横浜市大・医・病理, 2神奈川循環呼吸・胸部一般外科, 3神奈川循環呼吸・呼吸器内科)
- P-1138 A mRNA expression profile specific to micropapillary element in EGFR-mutated lung adenocarcinoma**  
Chihiro Koike<sup>1</sup>, Koji Okudela<sup>1</sup>, Mai Matsumura<sup>1</sup>, Hideaki Mitsui<sup>1</sup>, Takehisa Suzuki<sup>1</sup>, Toshiaki Kataoka<sup>1</sup>, Shigeaki Umeda<sup>1</sup>, Yoko Tateishi<sup>1</sup>, Hiromasa Arai<sup>2</sup>, Kenichi Ohashi<sup>1</sup> (1Dept. Pathol., Yokohama City Univ., Sch. Med., 2Dept. Surg., Kanagawa Cardiovasc & Respir Cent Hosp.)  
EGFR 変異型肺腺癌における微小乳頭状組織型に特徴的な mRNA 発現プロファイル  
小池 千尋<sup>1</sup>, 奥寺 康司<sup>1</sup>, 松村 舞依<sup>1</sup>, 三井 秀昭<sup>1</sup>, 鈴木 健久<sup>1</sup>, 片岡 俊朗<sup>1</sup>, 梅田 茂明<sup>1</sup>, 立石 陽子<sup>1</sup>, 荒井 宏雅<sup>2</sup>, 大橋 健一<sup>1</sup> (1横浜市大・医・病態病理, 2神奈川循環呼吸・胸部外科)
- P-1139 Overcoming EMT-mediated drug resistance with Monensin-based combined therapy in non-small cell lung cancer**  
Kosuke Ochi<sup>1</sup>, Ken Suzawa<sup>1</sup>, Shuta Tomida<sup>2</sup>, Kota Araki<sup>1</sup>, Shunsaku Miyachi<sup>1</sup>, Akihiro Miura<sup>1</sup>, Tatsuki Takeda<sup>1</sup>, Kei Namba<sup>1</sup>, Kazuhiko Shien<sup>1</sup>, Hiromasa Yamamoto<sup>1</sup>, Mikio Okazaki<sup>1</sup>, Tadahiko Shien<sup>1</sup>, Shinichi Toyooka<sup>1</sup> (1Dept. Thoracic Surg., Okayama Univ. Grad. Sch., 2Dept. Biobank, Okayama Univ. Grad. Sch. Med. Dent. & Pharm. Sci.)  
非小細胞肺癌におけるモノニン併用療法による EMT 関連薬剤耐性の克服  
大智 宏祐<sup>1</sup>, 諏澤 憲<sup>1</sup>, 富田 秀太<sup>2</sup>, 荒木 恒太<sup>1</sup>, 宮内 俊策<sup>1</sup>, 三浦 章博<sup>1</sup>, 武田 達明<sup>1</sup>, 難波 圭<sup>1</sup>, 枝園 和彦<sup>1</sup>, 山本 寛齊<sup>1</sup>, 岡崎 幹生<sup>1</sup>, 枝園 忠彦<sup>1</sup>, 豊岡 伸一<sup>1</sup> (1岡山大学・医・呼吸器・乳腺内分泌外科, 2岡山大学・バイオバンク)
- P-1140 Identification of altered metabolic pathways in osimertinib-resistant non-small-cell lung cancer cells**  
Rina Umehara<sup>1</sup>, Eriko Miyawaki<sup>2</sup>, Hirotugu Kenmotsu<sup>3</sup>, Keiichi Yamashita<sup>4</sup>, Kenichi Urakami<sup>5</sup>, Kyoichi Kaira<sup>6</sup>, Toshiaki Takahashi<sup>7</sup>, Ken Yamaguchi<sup>7</sup>, Masakuni Serizawa<sup>1</sup> (1Drug Discovery & Development Div. Shizuoka Cancer Ctr. Res. Inst., 2Thoracic Oncology Div. Shizuoka Cancer Ctr. Hosp., 3Med. Genetics Div. Shizuoka Cancer Ctr. Hosp., 4Med. Genetics Div. Shizuoka Cancer Ctr. Res. Inst., 5Cancer Diagnostics Res. Div., Shizuoka Cancer Ctr. Res. Inst., 6Respiratory Med. Dept. International Med. Ctr. Saitama Med. Univ., 7Shizuoka Cancer Ctr.)  
オシメルチニブ耐性非小細胞肺癌細胞において活性の変化を示す代謝経路の同定  
梅原 里奈<sup>1</sup>, 宮脇 英里子<sup>2</sup>, 釘持 広知<sup>3</sup>, 大島 啓一<sup>4</sup>, 浦上 研一<sup>5</sup>, 解

良 恭一<sup>6</sup>, 高橋 利明<sup>7</sup>, 山口 建<sup>7</sup>, 芹澤 昌邦<sup>1</sup> (1静岡がんセンター・研・新規薬剤開発評価, 2静岡がんセンター・病・呼吸器内科, 3静岡がんセンター・病・ゲノム医療推進部, 4静岡がんセンター・研・遺伝子診療, 5静岡がんセンター・研・診断技術開発, 6埼玉医大・国際医療センター・呼吸器内科, 7静岡がんセンター)

### P14-6 Uterine corpus cancer 子宮体がん

Chairperson: Katsutoshi Oda (Dept. Ob. &amp; Gyn., The Univ. of Tokyo)

座長: 織田 克利 (東京大・院医・産婦人科学講座・生殖腫瘍学)

- P-1141 Proliferation of poorly differentiated endometrial cancer through autocrine activation of FGF and expression of HES1**  
Michihiro Mori<sup>1,2</sup> (1Dept. Med. Life Sci, Kurashiki Univ., Sci & the Arts, 2Kake Inst. of Cytopathology)  
FGF オートクラインと HES1 遺伝子発現に関連した低分化型子宮体癌の増殖機構  
森 康浩<sup>1,2</sup> (1倉敷芸術科学大学・生命医科学科, 2加計細胞病理学研)
- P-1142 Establishment of patient-derived endometrial cancer cells by spheroid culture and application to preclinical models**  
Kazuhiro Ikeda<sup>1</sup>, Kuniko Horie<sup>1</sup>, Satoshi Inoue<sup>1,2</sup> (1Div. Gene Reg. Sig. Trans., RCGM, Saitama Med. Univ., 2Dept. Systems Aging Sci. Med., Tokyo Metropol. Inst. Gerontol.)  
スフェロイド培養系による患者由来子宮体がん細胞の樹立と前臨床モデルへの応用  
池田 和博<sup>1</sup>, 堀江 公仁子<sup>1</sup>, 井上 聡<sup>1,2</sup> (1埼玉医大・ゲノム医学センター・遺伝子情報制御, 2東京都健康長寿医療センター・研・システム加齢医学)
- P-1143 Clinicopathological characteristics of POLE-mutated endometrial cancer in Japanese patients**  
Munekage Yamaguchi<sup>1</sup>, Fumitaka Saito<sup>1</sup>, Hironori Tashiro<sup>1</sup>, Hidetaka Katabuchi<sup>1</sup> (Dept. OBGYN, Kumamoto Univ.)  
POLE 変異型子宮内膜癌の日本人の臨床病理学的特徴の検討  
山口 宗影<sup>1</sup>, 齋藤 文誉<sup>1</sup>, 田代 浩徳<sup>1</sup>, 片淵 秀隆<sup>1</sup> (熊本大・産科婦人科)
- P-1144 Evaluation of the utility of liquid-based genetic diagnosis for screening of endometrial cancer**  
Tsuneo Ikenoue<sup>1</sup>, Motoki Matsuura<sup>2</sup>, Kiyoko Takane<sup>1</sup>, Kiyoshi Yamaguchi<sup>1</sup>, Tsuyoshi Saito<sup>2</sup>, Yoichi Furukawa<sup>1</sup> (1Div. Clin. Genome Res., Inst. Med. Sci., Univ. Tokyo, 2Dept. Obstetrics & Gynecol., Sapporo Med. Univ.)  
子宮体がんスクリーニングにおける子宮内膜液状化細胞診検体を用いた遺伝子解析の有用性  
池上 恒雄<sup>1</sup>, 松浦 基樹<sup>2</sup>, 高根 希世子<sup>1</sup>, 山口 貴世志<sup>1</sup>, 齋藤 豪<sup>2</sup>, 古川 洋一<sup>1</sup> (1東京大・医科研・臨床ゲノム腫瘍学, 2札幌医大・婦人科)
- P-1145 Profile of genetic alterations in recurrent grade I-2 endometrial cancer patients**  
Yuka Asami<sup>1</sup>, Daisuke Takayanagi<sup>1</sup>, Mayumi Kobayashi Kato<sup>2</sup>, Ikumi Kuno<sup>1,2</sup>, Tsuyuka Ohtsuki<sup>1</sup>, Sou Hirose<sup>1,3</sup>, Naoya Murakami<sup>4</sup>, Masaaki Komatsu<sup>5</sup>, Takashi Kohno<sup>1</sup>, Tomoyasu Kato<sup>3</sup>, Kouya Shiraisi<sup>1</sup>, Hiroshi Yoshida<sup>6</sup> (1Div. Genome Biol., Natl. Cancer Ctr. Res. Inst., 2Dept. Gynecol., Natl. Cancer Ctr. Hosp., 3Dept. Obstetrics & Gynecol., The Jikei Univ. Sch. of Med., 4Dept. Radiation Oncology, Natl. Cancer Ctr. Hosp., 5Div. Mol. Modification Biol., Natl. Cancer Ctr. Res. Inst., 6Dept. Diagnostic Path., Natl. Cancer Ctr. Hosp.)  
再発子宮体部類内膜癌 grade 1-2 の早期癌患者におけるゲノム変異プロファイル  
朝見 友香<sup>1</sup>, 高柳 大輔<sup>1</sup>, 加藤 小林 真弓<sup>2</sup>, 久野 育美<sup>1,2</sup>, 大槻 露華<sup>1</sup>, 廣瀬 宗<sup>1,3</sup>, 村上 直也<sup>4</sup>, 小松 正明<sup>5</sup>, 河野 隆志<sup>1</sup>, 加藤 友康<sup>1</sup>, 白石 航也<sup>6</sup>, 吉田 裕<sup>6</sup> (1国立がん研センター・研・ゲノム生物学研究分野, 2国立がん研センター・中央病院・婦人腫瘍科, 3東京慈恵会医大・産婦人科学講座, 4国立がん研センター・中央病院・放射線治療科, 5国立がん研センター・がん分子修飾制御学, 6国立がん研センター・中央病院・病理診断科)
- P-1146 Immune Microenvironment of Uterine and Ovarian Carcinomas**  
Osamu Gotoh<sup>1,2,3</sup>, Yuko Sugiyama<sup>1,2,3</sup>, Nobuhiro Takeshima<sup>3</sup>, Yutaka Takazawa<sup>4</sup>, Kosei Hasegawa<sup>5</sup>, Keiichi Fujiwara<sup>5</sup>, Tetsuo Noda<sup>1</sup>, Seiichi Mori<sup>1</sup> (1Cancer Proteomics, CPM Ctr., JFCR, 2JFCR. Ariake Hosp. Dept. Cytopath., 3JFCR. Ariake Hosp. Dept. Gynecol., 4JFCR. Cancer Inst. Dept. Path., 5Saitama Med. Univ. Intl. Med. Ctr. Dept. Gynecol. Oncol.)  
子宮・卵巣がん肉腫における免疫微小環境  
後藤 理<sup>1</sup>, 杉山 裕子<sup>1,2,3</sup>, 竹島 信宏<sup>3</sup>, 高澤 豊<sup>4</sup>, 長谷川 幸清<sup>5</sup>, 藤原 恵一<sup>5</sup>, 野田 哲生<sup>1</sup>, 森 誠一<sup>1</sup> (1(公財)がん研・CPM セ, 2(公

財) がん研・有明病院・細胞診断部、<sup>3</sup>(公財) がん研・有明病院・婦人科、<sup>4</sup>(公財) がん研・がん研・病理部、<sup>5</sup>埼玉医大・国際医療セ・婦人科腫瘍科)

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

## P14-7 Gynecological cancer

婦人科がん

Chairperson: Yutaka Ueda (Dept. Obstetrics & Gynecol., Osaka Univ. Grad. Sch. of Med.)

座長: 上田 豊 (大阪大・院医・産科学婦人科学)

P-1147 **Anti-tumor effect of 9-oxo-10,12-ODA on human cervical cancer cells**

Yoshihiro Koya<sup>1,2</sup>, Mai Sugiyama<sup>1,2</sup>, Masato Yoshihara<sup>3</sup>, Kiyosumi Shibata<sup>4</sup>, Takeshi Senga<sup>5</sup>, Akihiro Nawa<sup>1,2</sup>, Fumitaka Kikkawa<sup>3</sup>, Hiroaki Kajiyama<sup>3</sup> (1 Bell Res. Ctr., Nagoya Univ., Sch. Med., 2 Bell Res. Ctr. Reproduction & Cancer, 3 Dept. Ob. & Gynecol., Nagoya Univ., Grad. Sch. Med., 4 Dept. Ob. & Gynecol., Fujita Health Univ., Banbuntane Hotokukai Hosp., 5 Yahagigawa Hosp.)

## 9-oxo-10,12-ODA のヒト子宮頸癌細胞に対する抗腫瘍効果の解析

小屋 美博<sup>1,2</sup>、杉山 麻衣<sup>1,2</sup>、吉原 雅人<sup>3</sup>、柴田 清住<sup>4</sup>、千賀 威<sup>5</sup>、那波 明宏<sup>1,2</sup>、吉川 史隆<sup>3</sup>、梶山 広明<sup>3</sup> (1名古屋大・医・ペルリサーチセ、2(医) 葵鐘会・研究開発部、3名古屋大・医・産婦人科、4藤田保健衛大・坂文種報徳會病院・産婦人科、5矢作川病院)

P-1148 **Prediction of recurrence in cervical cancer patients treated with radiation-based therapy: A Random Forest Model**

Ayumi Taguchi<sup>1,2</sup>, Yusuke Toyohra<sup>2</sup>, Kenbun Sone<sup>2</sup>, Akiko Furusawa<sup>1</sup>, Katsutoshi Oda<sup>2</sup>, Yutaka Osuga<sup>2</sup>, Tomoyuki Fujii<sup>2</sup>, Toshiharu Yasugi<sup>1</sup> (1 Dept. Gynecol., Komagome Hosp., 2 Dept. OB & Gynecol., Univ. of Tokyo)

## ランダムフォレストモデルによる、子宮頸がん放射線療法患者の再発予測

田口 歩<sup>1,2</sup>、豊原 佑典<sup>2</sup>、曾根 献文<sup>2</sup>、古澤 啓子<sup>1</sup>、織田 克利<sup>2</sup>、大須 賀穰<sup>2</sup>、藤井 知行<sup>2</sup>、八杉 利治<sup>1</sup> (1駒込病院・婦人科、2東京大・医・産婦人科)

P-1149 **Clinical significance of CD8+ and Foxp3+ lymphocytes in cervical adenocarcinoma treated with carbon ion radiotherapy**

Moito Iijima<sup>1,2</sup>, Kouji Banno<sup>2</sup>, Yusuke Kobayashi<sup>2</sup>, Eiichiro Tominaga<sup>2</sup>, Daisuke Aoki<sup>2</sup>, Sumitaka Hasegawa<sup>1</sup> (1 NIRS, QST, 2 Dept. Obstetrics & Gynecol., Keio Univ. Sch. of Med.)

## 子宮頸部腺癌に浸潤する CD8+ および Foxp3+ リンパ球の臨床的意義

飯島 茂異人<sup>1,2</sup>、阪埜 浩司<sup>2</sup>、小林 佑介<sup>2</sup>、富永 英一郎<sup>2</sup>、青木 大輔<sup>2</sup>、長谷川 純崇<sup>1</sup> (1量研・放医研、2慶應大・産婦人科)

P-1150 **A Study to Establish Method of Prognostic Prediction for Uterine Mesenchymal Tumor by Immunohistological Biomarkers**

Takuma Hayashi<sup>1,4</sup>, Hiroyuki Aburatani<sup>2</sup>, Nobuo Yaegashi<sup>1,5</sup>, Ikuro Konishi<sup>1</sup> (1 Natl. Hosp. Organization Kyoto Med. Ctr., 2 CRAFT, The Univ. of Tokyo, 3 Tohoku Univ. Hosp., 4 Promoting Business using Advanced Tech., JST, 5 Tohoku Gynecological Cancer Unit)

## 免疫組織学的バイオマーカーによる子宮間葉性腫瘍の予後予測法の確立に関する研究

林 琢磨<sup>1,4</sup>、油谷 浩幸<sup>2</sup>、八重樫 伸生<sup>3,5</sup>、小西 郁生<sup>1</sup> (1京都医療セ、2東京大・先端科学技術研究セ、3東北大・病院、4日本科学技術振興機構、5東北婦人科がんユニット)

P-1151 **Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma**

Daichi Nogawa<sup>1</sup>, Aihemaiti Gulinisha<sup>1</sup>, Akiko Yamamoto<sup>1</sup>, Ichiroh Onishi<sup>1</sup>, Morito Kurata<sup>1</sup>, Naoyuki Miyasaka<sup>2</sup>, Kohei Yamamoto<sup>1</sup>, Masanobu Kitagawa<sup>1</sup> (1 Dept. Comprehensive path., Tokyo Med. & Dent. Univ., 2 Dept. Gynecol., Tokyo Med. & Dent. Univ.)

## 卵巣癌における MCM2 タンパクの細胞内局在に着目した臨床病理学的検討

野川 大地<sup>1</sup>、グリニサ アヒマティ<sup>1</sup>、山本 阿紀子<sup>1</sup>、大西 威一郎<sup>1</sup>、倉田 盛人<sup>1</sup>、宮坂 尚幸<sup>2</sup>、山本 浩平<sup>1</sup>、北川 昌伸<sup>1</sup> (1東京医歯大・医・包括病理学、2東京医歯大・医・生殖機能協同学)

P-1152 **Machine Learning Algorithm Using Blood Biomarkers for Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer**

Junya Tabata, Nozomu Yanai, Aikou Okamoto (Dept. OBGYN., Jikei Univ., Sch. Med.)

## AI(機械学習)による血液検査結果を用いた上皮性卵巣癌の術前診断および予後予測モデル

田畑 潤哉、矢内原 臨、岡本 愛光 (慈恵医大・医・産婦人科)

P-1153 **Estrogen/GPR30 contributes to malignant potentials of uterine cervical adenocarcinoma via claudin-1 expression**

Akira Takasawa, Kumi Takasawa, Makoto Osanai (Dept. Path., Sapporo Med. Univ., Sch. of Med.)

子宮頸部腺癌におけるエストロゲン/GPR30 を介したがん悪性化機構  
高澤 啓、高澤 久美、小山内 誠 (札幌医大・医・病理学第二講座)

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

## P14-8 Renal cell carcinoma (1)

腎がん(1)

Chairperson: Wataru Obara (Dept. Urology, Iwate Med. Univ.)

座長: 小原 航 (岩手医大・泌尿器科)

P-1154 **The expression profile of phosphatidylinositol phosphates in clinical renal cell carcinoma**

Shintaro Narita<sup>1</sup>, Hiroki Nakanishi<sup>3</sup>, Yoshinori Matsuda<sup>1</sup>, Atsushi Koizumi<sup>1</sup>, Satoshi Eguchi<sup>2</sup>, Syunsuke Takasuga<sup>2</sup>, Mingguo Huang<sup>1</sup>, Takamitsu Inoue<sup>1</sup>, Jyunko Sasaki<sup>1</sup>, Hiroshi Nanjo<sup>3</sup>, Tomonori Habuchi<sup>1</sup>, Takechiko Sasaki<sup>2</sup> (1 Dept. Urol., Akita Univ. Med., 2 Dept., Med. Biol., Akita Univ. Med., 3 Res. Cent for Biosignal, Akita Univ. Med., 4 Dept. Biochem Pathophysiol/Lipid, 5 Dept. Pathol., Akita Univ. Hosp)

## 腎癌におけるイノシトールリン脂質発現プロファイル

成田 伸太郎<sup>1</sup>、中西 広樹<sup>3</sup>、松田 淳<sup>1</sup>、小泉 淳<sup>1</sup>、江口 賢史<sup>2</sup>、高須 賀 俊輔<sup>2</sup>、黄 明国<sup>1</sup>、井上 高光<sup>1</sup>、佐々木 純子<sup>4</sup>、南条 博<sup>5</sup>、羽淵 友則<sup>1</sup>、佐々木 雄彦<sup>5</sup> (1秋田大・医・泌尿器科、2秋田大・医・微生物学教室、3秋田大・生体情報研究セ、4東京医歯大・病態生理化学分野、5秋田大・附属病院・病理部)

P-1155 **The role of CCL20 in the development of renal cell carcinoma in the presence of macrophages**

Suguru Kadomoto<sup>1</sup>, Kouji Izumi<sup>1</sup>, Tomoyuki Makino<sup>1</sup>, Renato Naito<sup>1</sup>, Hiroaki Iwamoto<sup>1</sup>, Ariunbold Natsagdorj<sup>1</sup>, Yuta Takezawa<sup>2</sup>, Yoshifumi Kadono<sup>1</sup>, Atsushi Mizokami<sup>1</sup> (1 Uro., Kanazawa Univ., Sch. Med., 2 Uro., Toyama Pref. Hosp.)

## マクロファージ共存下での腎細胞癌進展における CCL20 の役割

門本 卓<sup>1</sup>、泉 浩二<sup>1</sup>、牧野 友幸<sup>1</sup>、内藤 伶奈人<sup>1</sup>、岩本 大旭<sup>1</sup>、Ariunbold Natsagdorj<sup>1</sup>、武澤 雄太<sup>2</sup>、角野 佳史<sup>1</sup>、溝上 敦<sup>1</sup> (1金沢大・泌尿器科、2富山県立中央病院・泌尿器科)

P-1156 **Discovery of urinary lipid biomarkers contributing to diagnosis of clear cell renal cell carcinoma**

Keita Tamura<sup>1,2</sup>, Hideaki Miyake<sup>1</sup>, Mitsutoshi Setou<sup>2</sup> (1 Dept. Urology, Hamamatsu Univ. Sch. Med., 2 Dept. Cell. & Mol. Anatomy, Hamamatsu Univ. Sch. Med.)

透明細胞型腎細胞癌の診断に寄与する尿中脂質バイオマーカーの発見  
田村 啓多<sup>1,2</sup>、三宅 秀明<sup>1</sup>、瀬藤 光利<sup>2</sup> (1浜松医大・泌尿器科学、2浜松医大・細胞分子解剖学)

P-1157 **miR-92b-3p promotes the proliferation of renal cell carcinoma through mTOR signaling pathway by targeting TSC1**

Cong Wang<sup>1</sup>, Kentaro Jingushi<sup>1</sup>, Eisuke Tomiyama<sup>1</sup>, Youko Koh<sup>1</sup>, Makoto Matsushita<sup>1</sup>, Yu Ishizuya<sup>1</sup>, Taigo Kato<sup>1,2</sup>, Koji Hatano<sup>1</sup>, Atsunari Kawashima<sup>1</sup>, Takeshi Ujike<sup>1</sup>, Kazutoshi Fujita<sup>1</sup>, Motohide Uemura<sup>2</sup>, Norio Nonomura<sup>1</sup> (1 Dept. Urology, Osaka Univ. Grad. Sch. Med., 2 Dept. Urological Immunology, Osaka Univ. Grad. Sch. Med., 3 Lab. Cell Biol. Physiol. Grad. Sch. Pharm. Sci., Osaka Univ.)

## miR-92b-3p の高発現は TSC1-mTOR 経路を介して、腎細胞癌の増殖を促進する

王 聡<sup>1</sup>、神宮司 健太郎<sup>1</sup>、富山 栄輔<sup>1</sup>、洪 陽子<sup>1</sup>、松下 慎<sup>1</sup>、石津 谷 祐<sup>1</sup>、加藤 大悟<sup>1,2</sup>、波多野 浩士<sup>1</sup>、河嶋 厚成<sup>1</sup>、氏家 剛<sup>1</sup>、藤田 和利<sup>1</sup>、植村 元秀<sup>2</sup>、野々村 祝夫<sup>1</sup> (1大阪大・院医・泌尿器科講座、2大阪大・院医・泌尿器癌免疫治療学講座、3大阪大・薬・細胞生理学講座)

P-1158 **Clinicopathological significance of claspin and its association with CSC markers in renal cell carcinoma**

Go Kobayashi<sup>1,2</sup>, Kazuhiro Sentani<sup>1</sup>, Takashi Babasaki<sup>1,3</sup>, Yohei Sekino<sup>3</sup>, Yoshinori Shigematu<sup>2</sup>, Tetsutaro Hayashi<sup>2</sup>, Naohide Oue<sup>1</sup>, Jun Teshima<sup>1</sup>, Akio Matsubara<sup>2</sup>, Naomi Sasaki<sup>2</sup>, Wataru Yasui<sup>1</sup> (1 Dept. Mol. Pathol., Hiroshima Univ., 2 Dept. Pathol., Kure-Kyosai Hp., 3 Dept. Urol., Hiroshima Univ.)

## 腎癌における claspin の臨床病理学的意義と癌幹細胞マーカーとの関連性

小林 剛<sup>1,2</sup>、仙谷 和弘<sup>1</sup>、馬場崎 隆志<sup>1,3</sup>、関野 陽平<sup>3</sup>、重松 慶紀<sup>3</sup>、林 哲太郎<sup>3</sup>、大上 直秀<sup>3</sup>、亭島 淳<sup>3</sup>、松原 昭郎<sup>3</sup>、佐々木 なおみ<sup>2</sup>、安井 弥<sup>1</sup> (1広島大・院医歯薬保・分子病理、2共済組合連合会・呉共済病院・病理診断科、3広島大・院医歯薬保・腎泌尿器)

P-1159 **Relationship between expression of microRNA related to clear cell renal cell carcinoma and clinicopathological factors**

Ei Shiomi<sup>1,2</sup>, Renpei Kato<sup>1</sup>, Mitsugu Kanehira<sup>1</sup>, Ryo Takata<sup>1</sup>, Atsushi Sugimura<sup>1</sup>, Atsushi Sugimura<sup>1</sup>, Tamotsu Sugai<sup>2</sup>, Wataru Obara<sup>1</sup> (<sup>1</sup>Dept. Urology, Iwate Med. Univ., <sup>2</sup>Dept. Mol. Diagnostic Path., Iwate Med. Univ.)

淡明細胞型腎細胞癌に関連する microRNA の発現と臨床病理学的因子との関連

塩見 聡<sup>1,2</sup>、加藤 廉平<sup>1</sup>、兼平 貢<sup>1</sup>、高田 亮<sup>1</sup>、杉村 淳<sup>1</sup>、杉村 淳<sup>1</sup>、菅井 有<sup>2</sup>、小原 航<sup>1</sup> (<sup>1</sup>岩手医大・医泌尿器科学講座、<sup>2</sup>岩手医大・医病理診断学講座)

P-1160 **Elevated expression of ELOVL2 is associated with progression of renal cell carcinoma**

Ken Tanaka, Shuya Kandori, Takahiro Kojima, Takashi Kawahara, Koji Kawai, Hiroyuki Nishiyama (Dept. Urol., Med., Tsukuba Univ.)

ELOVL2 の発現亢進は腎癌の進展に関与する

田中 建、神島 周也、小島 崇宏、河原 貴史、河合 弘二、西山 博之 (筑波大・医・腎泌尿器外科)

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

P14-9 **Central nervous system tumors (1)**  
中枢神経系腫瘍 (1)

Chairperson: Toshihiko Wakabayashi (Dept. Neurosurg., Grad. Sch. of Med., Nagoya Univ.)

座長：若林 俊彦 (名古屋大・院医・脳神経外科)

P-1161 **Profile changes of mRNA and miRNA correlating with CD24 silencing in glioblastoma cells**

Tsuyoshi Fukushima, Makiko Kawaguchi, Koji Yamamoto, Hiroyuki Tanaka, Hiroaki Kataoka (Dept. Pathol., Faculty of Med., Univ. Miyazaki)

膠芽腫における CD24 抑制による遺伝子・miRNA 発現プロファイルの変化

福島 剛、川口 真紀子、山本 晃士、田中 弘之、片岡 寛章 (宮崎大・医・病理学講座)

P-1162 **Super enhancer-associated long non-coding RNAs (lncRNAs) in glioblastoma**

H. Phillip Koeffler<sup>1,2,3</sup>, Ye Chen<sup>1</sup>, Liang Xu<sup>1</sup> (<sup>1</sup>Cancer Sci. Inst. of Singapore, Natl. Univ. of Singapore, <sup>2</sup>Dept. Med., Cedars-Sinai Med. Ctr., Los Angeles, USA, <sup>3</sup>Natl. Univ. Cancer Inst. of Singapore, Natl. Univ. Hosp., Singapore)

P-1163 **Texture analysis serving as diagnostic factor in discriminating primary CNS lymphoma from metastatic brain tumors**

Wen Guo<sup>1</sup>, Xuelei Ma<sup>2</sup> (<sup>1</sup>West China Sch. of Med., <sup>2</sup>Dept. Biotherapy, State Key Lab. of Biotherapy)

P-1164 **Comparison of machine-learning classifiers in discrimination of lesions located in skull base with 3D MRI features**

Chaoyue Chen<sup>1</sup>, Xuelei Ma<sup>2</sup> (<sup>1</sup>West China Sch. of Med., Sichuan Univ., <sup>2</sup>Dept. Biotherapy, State Key Lab. of Biotherapy)

P-1165 **The role played by SLUG, an EMT factor, in invasion and therapeutic resistance of malignant glioma**

Jae Hyuk Lee<sup>1</sup>, Kyung Hwa Lee<sup>1</sup>, Kyung Sub Moon<sup>2</sup> (<sup>1</sup>Dept. Path., Chonnam Natl. Univ. Med. Sch., <sup>2</sup>Dept. Neurosurgery, Chonnam Natl. Univ. Med. Sch.)

P-1166 **MGMT promoter methylation regions correlating to gene expression in glioblastomas after temozolomide treatment**

Jin-Wun Fang<sup>1</sup>, Hsin-Yi Pan<sup>1</sup>, Shih-Han Hsu<sup>1</sup>, Chun-Hei Cheung<sup>2</sup>, Kwang-Yu Chang<sup>1</sup>, Jang-Yang Chang<sup>2</sup>, Shang-Hung Chen<sup>1</sup> (<sup>1</sup>Natl. Health Res. Inst., Taiwan, <sup>2</sup>Natl. Cheng Kung Univ., Taiwan)

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

P14-10 **Head and neck cancer, carcinogenesis / progression**  
頭頸部がん、がん化・増殖

Chairperson: Masahiro Kikuchi (Dept. Otolaryngology, Head & Neck Surg., Grad. Sch. of Med., Kyoto Univ.)

座長：菊地 正弘 (京都大・院医・耳鼻咽喉科・頭頸部外科)

P-1167 **Bone marrow-derived cells contribute to develop squamous cell carcinoma**

Tomonori Hasegawa<sup>1</sup>, Ryouta Kamimura<sup>1</sup>, Yuta Sawatani<sup>1</sup>, Michiko Shimura<sup>1</sup>, Yusuke Komiyama<sup>1,2</sup>, Chonji Fukumoto<sup>1</sup>, Atsushi Fujita<sup>1</sup>, Hitoshi Kawamata<sup>1</sup> (<sup>1</sup>Dept. Oral. Max. Sur., Dokkyo Med. Univ., Sch. Med., <sup>2</sup>Sec. Dent., Oral. Max. Sur., Kamitsuga Gen. Hosp.)

骨髄由来細胞は扁平上皮癌になりうる

長谷川 智則<sup>1</sup>、上村 亮太<sup>1</sup>、澤谷 祐大<sup>1</sup>、志村 美智子<sup>1</sup>、小宮山 雄介<sup>1,2</sup>、福本 正知<sup>1</sup>、藤田 温志<sup>1</sup>、川又 均<sup>1</sup> (<sup>1</sup>獨医大・医・口腔外科、<sup>2</sup>上都賀総合病院・歯科口腔外科)

P-1168 **Long noncoding RNA DLEU1 is associated with oral squamous cell carcinoma development via regulating the HA-CD44 pathway**

Yui Hatanaka<sup>1,2</sup>, Takeshi Niinuma<sup>2</sup>, Koyo Nishiyama<sup>1</sup>, Hiroshi Kitajima<sup>2</sup>, Eiichiro Yamamoto<sup>2</sup>, Masahiro Kai<sup>2</sup>, Kazuhiro Ogi<sup>1</sup>, Akihiro Miyazaki<sup>1</sup>, Hiromu Suzuki<sup>2</sup> (<sup>1</sup>Dept. Oral Surg., Sapporo Med. Univ., Sch. Med., <sup>2</sup>Dept. Mol. Biol., Sapporo Med. Univ., Sch. Med.)

Long noncoding RNA DLEU1 は HA-CD44 経路を介して口腔扁平上皮がんの発生に関与する

畠中 柚衣<sup>1,2</sup>、新沼 猛<sup>2</sup>、西山 廣陽<sup>1</sup>、北嶋 洋志<sup>2</sup>、山本 英一郎<sup>2</sup>、甲斐 正広<sup>2</sup>、荻 和弘<sup>1</sup>、宮崎 晃巨<sup>1</sup>、鈴木 拓<sup>2</sup> (<sup>1</sup>札幌医大・医・口腔外科学講座、<sup>2</sup>札幌医大・医・分子生物)

P-1169 **Transcriptional addiction to YAP1 - the major driving force of head and neck cancer evolution ?-**

Muneyuki Masuda<sup>1</sup>, Hirofumi Ohmori<sup>2,4</sup>, Kuniaki Sato<sup>1</sup>, Kenichi Taguchi<sup>2</sup>, Akira Suzuki<sup>4</sup> (<sup>1</sup>Dept. Head & Neck Surg., Natl. Kyushu Cancer Ctr., <sup>2</sup>Dept. ORL, Kyushu Univ., <sup>3</sup>Dept. Pathology., Natl. Kyushu Cancer Ctr., <sup>4</sup>Div. Mol. & Cell. Biol.)

YAP1 トランスクリプショナルアディクションは頭頸部癌進化のドライビングフォースである

益田 宗幸<sup>1</sup>、大森 裕文<sup>2,4</sup>、佐藤 晋彰<sup>1</sup>、田口 健一<sup>3</sup>、鈴木 聡<sup>4</sup> (九州がんセンター・頭頸科、<sup>2</sup>九州大・院・耳鼻咽喉科、<sup>3</sup>九州がんセンター・病理部、<sup>4</sup>神戸大・院・分子細胞生物学)

P-1170 **Ligand-independent EGFR activation by Src promotes cancer cell proliferation through phosphorylation of ErbB3**

Yuichi Ohnishi<sup>1,2</sup>, Masahiro Nakajima<sup>2</sup>, Masami Nozaki<sup>1</sup> (<sup>1</sup>Dept. Cell Biol., Res. Inst. Microbial Dis., Osaka Univ., <sup>2</sup>2nd Dept. Oral & Maxillofacial Surg., Osaka Dent. Univ.)

足場刺激性 Src によるリガンド非依存的 EGFR 活性は ErbB 3 リン酸化を介して癌細胞の増殖を促進する

大西 祐一<sup>1,2</sup>、中嶋 正博<sup>2</sup>、野崎 正美<sup>1</sup> (<sup>1</sup>大阪大・微研・細胞機能、<sup>2</sup>大歯大・口外 2)

P-1171 **Analysis of AEBP1 in the microenvironment of head and neck squamous cell carcinoma**

Akira Yorozu<sup>1,2</sup>, Eiichiro Yamao<sup>2,3</sup>, Gouta Sudo<sup>2</sup>, Yuto Numata<sup>2</sup>, Takeshi Niinuma<sup>2</sup>, Hiroshi Kitajima<sup>2</sup>, Masahiro Kai<sup>2</sup>, Takashi Kojima<sup>4</sup>, Kenichi Takano<sup>1</sup>, Hiromu Suzuki<sup>1</sup> (<sup>1</sup>Dept. Otolaryngol., Sapporo Med. Univ. Sch. Med., <sup>2</sup>Dept. Mol. Biol., Sapporo Med. Univ. Sch. Med., <sup>3</sup>Dept. Gastroenterol Hepatol., Sapporo Med. Univ. Sch. Med., <sup>4</sup>Cell Sci., Res. Inst. Frontier Med., Sapporo Med. Univ.)

頭頸部扁平上皮がんの微小環境における AEBP1 の解析

萬 頭<sup>1,2</sup>、山本 英一郎<sup>2,3</sup>、須藤 豪太<sup>2</sup>、沼田 有斗<sup>2</sup>、新沼 猛<sup>2</sup>、北嶋 洋志<sup>2</sup>、甲斐 正広<sup>2</sup>、小島 隆<sup>4</sup>、高野 賢一<sup>1</sup>、鈴木 拓<sup>1</sup> (<sup>1</sup>札幌医大・医・耳鼻咽喉科、<sup>2</sup>札幌医大・医・分子生物、<sup>3</sup>札幌医大・医・消化器内科、<sup>4</sup>札幌医大・医・フロンティア研究・細胞科学)

P-1172 **Expression of cell surface CD74 and macrophage migration inhibitory factor in malignant tumors of head and neck region**

Ryusuke Hayashi<sup>1</sup>, Toshizumi Nagato<sup>1</sup>, Takumi Kumai<sup>2</sup>, Marino Nagata<sup>1</sup>, Shohei Harabuchi<sup>1,2</sup>, Yuki Yajima<sup>1,3</sup>, Akemi Kosaka<sup>1</sup>, Takayuki Ohkuri<sup>1</sup>, Kensuke Oikawa<sup>1</sup>, Kan Kishibe<sup>2</sup>, Miki Takahara<sup>2</sup>, Yasuaki Harabuchi<sup>2</sup>, Hiroya Kobayashi<sup>1</sup> (<sup>1</sup>Dept. Pathol., Asahikawa Med. Univ., Sch. Med., <sup>2</sup>Dept. Oto., Asahikawa Med. Univ., Sch. Med., <sup>3</sup>Dept. Oral., Asahikawa Med. Univ., Sch. Med.)

頭頸部悪性腫瘍における CD74 と MIF の発現

林 隆介<sup>1</sup>、長門 利純<sup>1</sup>、熊井 琢美<sup>2</sup>、永田 真莉乃<sup>1</sup>、原淵 翔平<sup>1,2</sup>、矢島 優己<sup>1,3</sup>、小坂 朱<sup>1</sup>、大栗 敬幸<sup>1</sup>、及川 賢輔<sup>1</sup>、岸部 幹<sup>2</sup>、高原 幹<sup>2</sup>、原淵 保明<sup>2</sup>、小林 博也<sup>1</sup> (<sup>1</sup>旭川医大・医・免疫病理、<sup>2</sup>旭川医大・医・耳鼻科、<sup>3</sup>旭川医大・医・歯科)

**P-1173** **ANGPTL4 is involved in the highly-malignant potential in oral squamous cell carcinoma through the epigenetic regulation**  
 Yuka Nagao<sup>1</sup>, Akiyuki Hirosue<sup>1</sup>, Masafumi Nakamoto<sup>1,2</sup>, Sho Kawaguchi<sup>1</sup>, Shunsuke Gohara<sup>1</sup>, Keisuke Yamana<sup>1</sup>, Hisashi Takeshita<sup>1</sup>, Kenta Kawahara<sup>1</sup>, Masashi Nagata<sup>1</sup>, Ryoji Yoshida<sup>1</sup>, Hideki Nakayama<sup>1</sup> (<sup>1</sup>Dept. Oral & Maxillofacial Surg., Kumamoto Univ., Kumamoto, <sup>2</sup>Dept. Oral & Maxillofacial Surg., Tsuruta Hosp.)

口腔扁平上皮癌において、ANGPTL4 はエピジェネティック調整を介して高悪性度の獲得に関与する  
 永尾 優果<sup>1</sup>、廣末 晃之<sup>1</sup>、中元 雅史<sup>1,2</sup>、川口 翔<sup>1</sup>、郷原 俊輔<sup>1</sup>、山名 啓介<sup>1</sup>、竹下 尚志<sup>1</sup>、川原 健太<sup>1</sup>、永田 将士<sup>1</sup>、吉田 遼司<sup>1</sup>、中山 秀樹<sup>1</sup> (熊本大・院生命科学・歯科口腔外科学、<sup>2</sup>鶴田病院歯科口腔外科)

Room P(B) Sep. 26 (Thu.) 16:30-17:15 E/J  
**P14-11** **Pediatric cancer and others**  
 小児がん・その他

Chairperson: Mitsuru Miyachi (Dept. Pediatrics, Grad. Sch. of Med. Sci., Kyoto Pref. Univ. of Med.)  
 座長：宮地 充 (京都府医大・院医・小児科)

**P-1174** **Elucidation of the genetic background of thymic epithelial tumors and its application to personalized treatment**  
 Midori Shimada<sup>1,2</sup>, Hiroyuki Yamaguchi<sup>1</sup>, Hirokazu Taniguchi<sup>1</sup>, Daisuke Sasaki<sup>1</sup>, Yosuke Dotsu<sup>1</sup>, Minoru Fukuda<sup>1</sup>, Hiroshi Soda<sup>2</sup>, Takeshi Nagayasu<sup>3</sup>, Katsunori Yanagihara<sup>3</sup>, Hiroshi Mukae<sup>1</sup> (<sup>1</sup>Nagasaki Univ. Hosp., Second Dept. Internal Med., <sup>2</sup>Sasebo city General Hosp., Dept. Respiratory Med., <sup>3</sup>Nagasaki Univ. Hosp., Dept. Lab. Med., <sup>4</sup>Nagasaki Univ. Hosp., Clin. Oncology Ctr., <sup>5</sup>Nagasaki Univ. Hosp., Dept. Surg. Oncology)  
 胸腺上皮性腫瘍の遺伝学的背景の解明と個別化治療への応用  
 嶋田 緑<sup>1,2</sup>、山口 博之<sup>1</sup>、谷口 寛和<sup>1</sup>、佐々木 大介<sup>3</sup>、道津 洋介<sup>1</sup>、福田 実<sup>4</sup>、早田 宏<sup>2</sup>、永安 武<sup>5</sup>、柳原 克紀<sup>3</sup>、迎 寛<sup>1</sup> (長崎大・病院・第二内科、<sup>2</sup>佐世保市総合医療セ・呼吸器内科、<sup>3</sup>長崎大・病院・検査部、<sup>4</sup>長崎大・病院・がん診療セ、<sup>5</sup>長崎大・病院・腫瘍外科)

**P-1175** **Development of a novel therapeutic strategy targeting F1174L mutant anaplastic lymphoma kinase gene in neuroblastoma**  
 Yoko Ota<sup>1,3,4</sup>, Hiroyuki Yoda<sup>2</sup>, Takahiro Inoue<sup>1,3</sup>, Takayoshi Watanabe<sup>1</sup>, Yoshinao Shinozaki<sup>2</sup>, Atsushi Takatori<sup>1</sup>, Hiroki Nagase<sup>2,3</sup> (<sup>1</sup>Div. Innovative Cancer Therap., Chiba Cancer Ctr. Res. Inst., <sup>2</sup>Div. Cancer Genetics, Chiba Cancer Ctr. Res. Inst., <sup>3</sup>Grad. Sch. of Med. & Pharm. Sci., Chiba Univ., <sup>4</sup>Natl. Hosp. Organization, Shimoshizu Natl. Hosp.)  
 神経芽腫の ALK 遺伝子 F1174L 変異 DNA 配列を標的とした治療法開発  
 太田 陽子<sup>1,3,4</sup>、養田 裕行<sup>2</sup>、井上 貴博<sup>1,3</sup>、渡部 隆義<sup>1</sup>、篠崎 喜脩<sup>2</sup>、高取 敦志<sup>1</sup>、永瀬 浩喜<sup>2,3</sup> (千葉県がんセ・研・がん先進治療開発研、<sup>2</sup>千葉県がんセ・研・がん遺伝創薬研、<sup>3</sup>千葉大・院・医学薬学府、<sup>4</sup>独立行政法人国立病院機構・下志津病院)

**P-1176** **Genomic characterization of high-risk neuroblastoma by cancer panels**  
 Miki Ohira<sup>1</sup>, Hiroyuki Shichino<sup>2</sup>, Takashi Kubo<sup>3</sup>, Masayuki Haruta<sup>1</sup>, Tetsuya Takimoto<sup>4</sup>, Atsuko Nakazawa<sup>3</sup>, Fumito Yamazaki<sup>3</sup>, Hiroki Nagase<sup>6</sup>, Tatsuro Tajiri<sup>1</sup>, Akira Nakagawara<sup>7</sup>, Hitoshi Ichikawa<sup>3</sup>, Tomoro Hishiki<sup>4</sup>, Takehiko Kamijo<sup>1</sup> (<sup>1</sup>Res. Inst. Clin. Oncol., Saitama Cancer Ctr., <sup>2</sup>Natl. Ctr. Global Health & Med., <sup>3</sup>Natl. Cancer Ctr. Res. Inst., <sup>4</sup>Natl. Ctr. Child Health & Develop., <sup>5</sup>Saitama Childrens Med. Ctr., <sup>6</sup>Chiba Cancer Ctr. Res. Inst., <sup>7</sup>JCCG-JNBSG)  
 高リスク神経芽腫のがん遺伝子パネル解析  
 大平 美紀<sup>1</sup>、七野 浩之<sup>2</sup>、久保 崇<sup>3</sup>、春田 雅之<sup>1</sup>、瀧本 哲也<sup>4</sup>、中澤 温子<sup>5</sup>、山崎 文登<sup>3</sup>、永瀬 浩喜<sup>6</sup>、田尻 達郎<sup>7</sup>、中川原 章<sup>7</sup>、市川 仁<sup>3</sup>、菱木 知郎<sup>4</sup>、上條 岳彦<sup>1</sup> (埼玉がんセ・研、<sup>2</sup>国立国際医療研究セ、<sup>3</sup>国立がん研セ・研、<sup>4</sup>国立成育医療研究セ、<sup>5</sup>埼玉県立小児医療セ、<sup>6</sup>千葉がんセ・研、<sup>7</sup>日本小児がん研究グループ神経芽腫委員会)

**P-1177** **Unraveling the mechanisms of pancreatic neuroendocrine tumorigenesis using a new mouse model**  
 Yu Chen<sup>1</sup>, Sadahiro Iwabuchi<sup>2</sup>, Tohru Kiyono<sup>3</sup>, Shigeyuki Magi<sup>4</sup>, Yasuhito Arai<sup>5</sup>, Akihiko Yokoyama<sup>6</sup>, Mariko Okada<sup>7</sup>, Shinichi Hashimoto<sup>8</sup>, Kentaro Semba<sup>9</sup>, Rieko Ohki<sup>1</sup> (<sup>1</sup>Lab. of Fundamental Oncology, Natl. Cancer Ctr. Res. Inst., <sup>2</sup>Dept. Integrative. Med. Longevity, Kanazawa Univ., Grad. Sch. Med. Sci., <sup>3</sup>Dept. Cell Culture Tech., Natl. Cancer Ctr. Res. Inst., <sup>4</sup>Lab. of Cell Systems, Inst. for Protein Res., Osaka Univ., <sup>5</sup>Div. Cancer Genomics, Natl. Cancer Ctr. Res. Inst., <sup>6</sup>Natl. Cancer Ctr. Tsuruoka Metabolomics Lab., <sup>7</sup>Grad. Sch. of Advanced Sci. & Engineering, Waseda Univ.)  
 PHLDA3 遺伝子と MEN1 遺伝子による膵臓神経内分泌腫瘍抑制機

**構の解明**  
 陳 ヨ<sup>1</sup>、岩淵 禎弘<sup>2</sup>、清野 透<sup>3</sup>、間木 重行<sup>4</sup>、新井 康仁<sup>5</sup>、横山 明彦<sup>6</sup>、岡田 真里子<sup>4</sup>、橋本 真一<sup>2</sup>、仙波 憲太郎<sup>7</sup>、大木 理恵子<sup>1</sup> (国立がん研セ・基礎腫瘍学ユニット、<sup>2</sup>金沢大・医薬保健学・未病長寿、<sup>3</sup>国立がん研セ・発がん・予防研究分野、<sup>4</sup>大阪大・蛋白質研・細胞システム研究室、<sup>5</sup>国立がん研セ・がんゲノミクス研究分野、<sup>6</sup>国立がん研セ・がんメタボロミクス研究室、<sup>7</sup>早稲田大・先進理工・生命医科)

**P-1178** **Induction of immunogenic cell death by p53-armed telomerase-specific oncolytic adenovirus in neuroblastoma**  
 Morimichi Tani<sup>1</sup>, Hiroshi Tazawa<sup>2,3</sup>, Terutaka Tanimoto<sup>1</sup>, Hiroshi Nouse<sup>1</sup>, Yasuo Urata<sup>4</sup>, Shunsuke Kagawa<sup>2</sup>, Takuo Noda<sup>1</sup>, Toshiyoshi Fujiwara<sup>2</sup> (<sup>1</sup>Dept. Pediatric Surg., Okayama Univ., <sup>2</sup>Dept. Gastroenterological Surg., Okayama Univ. Grad. Sch. Med., <sup>3</sup>Ctr. for Innovative Clin. Med., Okayama Univ. Hosp., <sup>4</sup>Oncolys Biopharma, Inc.)  
 神経芽腫に対する p53 発現性腫瘍融解アデノウイルスによる免疫原性細胞死の誘導効果  
 谷 守通<sup>1</sup>、田澤 大<sup>2,3</sup>、谷本 光隆<sup>1</sup>、納所 洋<sup>1</sup>、浦田 泰生<sup>4</sup>、香川 俊輔<sup>2</sup>、野田 卓男<sup>1</sup>、藤原 俊義<sup>2</sup> (岡山大・小児外科、<sup>2</sup>岡山大・院医・消化器外科、<sup>3</sup>岡山大・低侵襲治療セ、<sup>4</sup>オンコリスバイオファーマ)

**15 Diagnosis**

Room P(B) Sep. 26 (Thu.) 16:30-17:15 E/J  
**P15-1** **Pathological diagnosis**  
 病理診断

Chairperson: Yoshinao Oda (Dept. Anatomic Path., Grad. Sch. of Med. Sci., Kyushu Univ.)  
 座長：小田 義直 (九州大・院医・形態機能病理)

**P-1179** **Usefulness of highly expressed EZH2 in combination with BAP1 and MTAP loss is distinguishing MPM from RMH**  
 Masayo Yoshimura, Makoto Hamasaki, Kazuki Nabeshima (Dept. Pathol., Fukuoka Univ.)  
 悪性胸膜中皮腫の診断における EZH2 高発現の応用：BAP1、MTAP 免疫との併用の有用性  
 吉村 雅代、濱崎 慎、鶴岡 一樹 (福岡大・医・病理)

**P-1180** **Re-evaluation of immunohistochemical study of thyroid tumor capsular stromal cells by an automated immunostainer**  
 Hirofumi Nakayama (Dept. Pathol. Lab. Med., JR Hiroshima Hosp.)  
 自動免疫染色装置を用いて、以前の用手免疫染色法にて得られた被胞型甲状腺腫瘍の被膜間質細胞研究の結果を再評価する  
 中山 宏文 (JR 広島病院・臨床検査科 (病理診断科))

**P-1181** **Toward an automation of fluorescence in situ hybridization scoring combined with confocal whole slide imaging**  
 Naohiro Uraoka<sup>1,2,3</sup>, Kareem Ibrahim<sup>1</sup>, Mamta Rao<sup>1</sup>, Ruth Aryeequaye<sup>1</sup>, Yanming Zhang<sup>1</sup>, Meera Hameed<sup>1</sup>, Wataru Yasui<sup>2</sup>, Yukako Yagi<sup>1</sup> (<sup>1</sup>Dept. Path., Memorial Sloan Kettering Cancer Ctr., <sup>2</sup>Dept. Mol. Path., Hiroshima Univ. Grad. Sch. Biomed. Health Sci., <sup>3</sup>Ctr. for Cause of Death Investigation Res., Hiroshima Univ.)  
 共焦点 WSI を用いた FISH スコアリングの自動化に向けて  
 浦岡 直礼<sup>1,2,3</sup>、Kareem Ibrahim<sup>1</sup>、Mamta Rao<sup>1</sup>、Ruth Aryeequaye<sup>1</sup>、Yanming Zhang<sup>1</sup>、Meera Hameed<sup>1</sup>、安井 弥<sup>2</sup>、八木 由香子<sup>1</sup> (Memorial Sloan Kettering Cancer Ctr., <sup>2</sup>広島大・医系科学研究科・分子病理学、<sup>3</sup>広島大・死因究明教育研究セ)

**P-1182** **Clinicopathologic significance and function of extracellular vesicle-miR-21 in pleural lavage of lung cancer**  
 Shiori Watabe<sup>1</sup>, Yoshinao Kikuchi<sup>1</sup>, Shigeki Morita<sup>3</sup>, Daisuke Koumura<sup>4</sup>, Satoe Numakura<sup>1</sup>, Masato Watanabe<sup>1</sup>, Noriyuki Matsutani<sup>2</sup>, Masahumi Kawamura<sup>1</sup>, Masanori Yasuda<sup>3</sup>, Hiroshi Uozaki<sup>1</sup> (<sup>1</sup>Dept. Pathol., Teikyo Univ., Sch. Med., <sup>2</sup>Dept. Surg., Teikyo Univ., Sch. Med., <sup>3</sup>Dept. Pathol., Mitsui Memorial Hosp., <sup>4</sup>Dept. Preventive Med., Tokyo Univ., Sch. Med., <sup>5</sup>Dept. Pathol., Saitama Med. Univ., International Med. Ctr.)  
 肺癌における胸腔洗浄液中の細胞外分泌小胞内 miR-21 の臨床病理学的意義と機能  
 渡部 朱織<sup>1</sup>、菊地 良直<sup>1</sup>、森田 茂樹<sup>3</sup>、河村 大輔<sup>4</sup>、沼倉 里枝<sup>1</sup>、渡邊 雅人<sup>1</sup>、松谷 哲行<sup>2</sup>、川村 雅文<sup>2</sup>、安田 政実<sup>3</sup>、宇崎 宏<sup>1</sup> (帝京大・医・病理、<sup>2</sup>帝京大・医・外科、<sup>3</sup>三井記念病院・病理、<sup>4</sup>東京大・医・分子予防医学、<sup>5</sup>埼玉医大・国際医療セ・病理)



P-1183 **ANXA10 expression correlated with lower grade/stage and better prognosis in upper urinary tract urothelial cancer**  
Tetsutaro Hayashi<sup>1</sup>, Naoya Sakamoto<sup>2</sup>, Kenichiro Ikeda<sup>1</sup>, Yohei Sekino<sup>1</sup>, Keisuke Goto<sup>1</sup>, Shogo Inoue<sup>1</sup>, Jun Teishima<sup>1</sup>, Kazuhiro Sentani<sup>2</sup>, Naohide Oue<sup>3</sup>, Wataru Yasui<sup>3</sup>, Akio Matsubara<sup>2</sup> (<sup>1</sup>Dept. Urology, Hiroshima Univ., <sup>2</sup>Dept. Mol. Path., Hiroshima Univ.)

**上部尿路上皮癌における ANXA10 発現の意義**  
林 哲太郎<sup>1</sup>、坂本 直也<sup>2</sup>、池田 健一郎<sup>1</sup>、関野 陽平<sup>1</sup>、後藤 景介<sup>1</sup>、井上 省吾<sup>1</sup>、亭島 淳<sup>1</sup>、仙谷 和弘<sup>2</sup>、大上 直秀<sup>2</sup>、安井 弥<sup>2</sup>、松原 昭郎<sup>2</sup> (<sup>1</sup>広島大・医・腎泌尿器科学、<sup>2</sup>広島大・医・分子病理学)

P-1184 **Comparison of male breast carcinoma with gynecomastia**  
Akane Toriyama<sup>1,2</sup>, Harumi Saeaki<sup>2</sup>, Hiroshi Izumi<sup>1,3</sup>, Shigeki Tomita<sup>1,2</sup>, Okio Hino<sup>2</sup> (<sup>1</sup>Dept. Path., Juntendo Univ. Urayasu Hosp., <sup>2</sup>Dept. Path. & Oncology, Juntendo Univ. Sch. of Med., <sup>3</sup>Dept. Human Path., Juntendo Univ. Sch. of Med.)

**当院における男性乳癌と女性化乳房の比較検討**  
鳥山 茜<sup>1,2</sup>、佐伯 春美<sup>2</sup>、泉 浩<sup>1,3</sup>、富田 茂樹<sup>1,2</sup>、榎野 興夫<sup>2</sup> (<sup>1</sup>順天堂大・浦安病院病理診断科、<sup>2</sup>順天堂大・医病理・腫瘍学講座、<sup>3</sup>順天堂大・医人体病理学講座)

P-1185 **Foveolar adenomas that develop in the background of normal gastric mucosa are frequently associated with KRAS mutations**  
Yoko Tateishi<sup>1</sup>, Kingo Hirasawa<sup>2</sup>, Koji Okudela<sup>1</sup>, Takehisa Suzuki<sup>1</sup>, Hideaki Mitsui<sup>1</sup>, Chihiro Koike<sup>1</sup>, Tosiaki Kataoka<sup>1</sup>, Mai Matsumura<sup>1</sup>, Yoshiaki Inayama<sup>3</sup>, Kenichi Ohashi<sup>1</sup> (<sup>1</sup>Dept. Pathol., Yokohama City Univ., Sch. Med., <sup>2</sup>Dept. Endoscopy, Yokohama City Univ. Med. Ctr., <sup>3</sup>Dept. Pathol., Yokohama City Univ. Med. Ctr.)

**正常胃粘膜を背景とする腺窩上皮型腺腫は高頻度に KRAS 変異が認められる**  
立石 陽子<sup>1</sup>、平澤 欣吾<sup>2</sup>、奥寺 康司<sup>1</sup>、鈴木 健久<sup>1</sup>、三井 秀昭<sup>1</sup>、小池 千尋<sup>1</sup>、片岡 俊朗<sup>1</sup>、松村 舞依<sup>1</sup>、稲山 嘉明<sup>3</sup>、大橋 健一<sup>1</sup> (<sup>1</sup>横浜市大・医・病理、<sup>2</sup>横浜市大・市総医セ・内視鏡、<sup>3</sup>横浜市大・市総医セ・病理)

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

**P15-2 Genetic diagnosis**  
遺伝子診断

Chairperson: Naohide Oue (Dept. Mol. Path., Hiroshima Univ. Inst. of Biomed. & Health Sci.)

座長: 大上 直秀 (広島大・医・分子病理)

P-1186 **Circulating N-cadherin in blood is a potential indicator of metastases with new regions in breast cancer**  
Takaaki Masuda, Miwa Noda, Qingjiang Hu, Kuniaki Sato, Atsushi Fujii, Naoki Hayashi, Yusuke Tsuruda, Yoshihiro Matsumoto, Hajime Ootsu, Hiroki Uchida, Koshi Mimori (Dept. Surg. Kyushu Univ. Beppu Hosp)

**末梢血中の N-cadherin 発現は乳癌における新規転移の予測マーカーである**  
増田 隆明、野田 美和、胡 慶江、佐藤 晋彰、藤井 昌志、林 直樹、鶴田 祐介、松本 佳大、大津 甫、内田 博喜、三森 功士 (九州大・別府病院・外科)

P-1187 **Development of a cell line panel for mutation standards completely covering the 114 genes in NCC Oncopanel**  
Takayoshi Suzuki<sup>1</sup>, Yoshinori Tsukumo<sup>1</sup>, Mikihiko Naito<sup>1</sup>, Arihiro Kohara<sup>2</sup> (<sup>1</sup>Mol. Target & Gene Therapy Products, Natl. Inst. Hlth. Sci., <sup>2</sup>Lab. Cell Cultr., Natl. Inst. of Biomed. Innovation., Hlth & Nutri.)

**NCC オンコパネルの 114 遺伝子を網羅する変異細胞株パネルの作製**  
鈴木 孝昌<sup>1</sup>、築茂 由則<sup>1</sup>、内藤 幹彦<sup>1</sup>、小原 有弘<sup>2</sup> (<sup>1</sup>国立衛研・遺伝子医薬、<sup>2</sup>医薬基盤・健康・栄養研・JCRB 細胞バンク)

P-1188 **Quality evaluation of FFPE tumor tissue-derived RNA for NGS testing**  
Sachiyo Mitani<sup>1</sup>, Noriko Moto<sup>2</sup>, Akihiko Yoshida<sup>2</sup>, Kazuya Tokita<sup>2</sup>, Hiroki Kakishima<sup>3</sup>, Masaya Sekimizu<sup>1</sup>, Fumito Yamazaki<sup>1</sup>, Takashi Kubo<sup>1,3</sup>, Akira Kawai<sup>1</sup>, Hitoshi Ichikawa<sup>1,5</sup> (<sup>1</sup>Dept. Clin. Genomics, Natl. Cancer Ctr. Res. Inst., <sup>2</sup>Dept. Pathol., Natl. Cancer Ctr. Hosp., <sup>3</sup>Dept. Clin. Labo., Natl. Cancer Ctr. Hosp., <sup>4</sup>Rare Cancer Ctr., Natl. Cancer Ctr. Hosp., <sup>5</sup>Div. Transl. Genomics, Natl. Cancer Ctr. EPOC)

**NGS 検査のための FFPE 腫瘍組織由来 RNA の品質評価**  
三谷 幸代<sup>1</sup>、元井 紀子<sup>2</sup>、吉田 朗彦<sup>2</sup>、時田 和也<sup>2</sup>、柿島 裕樹<sup>3</sup>、関水 壮哉<sup>1</sup>、山崎 文登<sup>1</sup>、久保 崇<sup>1,3</sup>、川井 章<sup>4</sup>、市川 仁<sup>1,5</sup> (<sup>1</sup>国立がん研セ・研・臨床ゲノム解析、<sup>2</sup>国立がん研セ・中央病院・病理、<sup>3</sup>国立がん研セ・中央病院・臨床検査、<sup>4</sup>国立がん研セ・中央病院・希少がんセ、<sup>5</sup>国立がん研セ・先端医療開発セ・ゲノム TR)

P-1189 **Cancer Risk determined by Gene Expression in Peripheral Leukocyte, Circulating Free Tumor DNA and Urine Collection**  
Toru Ouchi, Yukie Wagai, Hitomi Igarashi, Miki Tohma, Reo Hamaguchi, Hiromi Wada, Hiroko Kobayashi (GeneSci. Co., Ltd.)

**末梢血、フリー DNA、尿の解析による発がんリスク診断**  
大内 徹、和賀井 祐希江、五十嵐 仁美、當真 美紀、浜口 玲央、和田 洋巳、小林 宗子 (株) ジーンサイエンス)

P-1190 **CSPG4 is a promising marker for immunohistochemical detection of breast cancer, including triple negative breast cancer**  
Kunihiko Itoh<sup>1</sup>, Keita Hirai<sup>1</sup>, Hisashi Yoshimura<sup>2</sup>, Toshiyuki Ishiwata<sup>3</sup> (<sup>1</sup>Dept. Pharm. Sci., Univ. Shizuoka, <sup>2</sup>Nippon Veterinary & Life Sci. Univ., <sup>3</sup>Geriatric Pathol., Tokyo Metropolitan Inst. Gerontol.)

**CSPG4 はトリプルネガティブ乳がんを含めた乳がんの免疫組織化学的検出における有望なマーカーである**  
伊藤 邦彦<sup>1</sup>、平井 啓太<sup>1</sup>、吉村 久志<sup>2</sup>、石渡 俊行<sup>3</sup> (<sup>1</sup>静岡県大・薬、<sup>2</sup>日本獣医生命科学大・獣医保健看護、<sup>3</sup>東京都健康長寿医療セ・高齢者がん)

P-1191 **Detection of tyrosine kinase fusion genes in inflammatory myofibroblastic tumor/inflammatory pseudotumor by Nanostring**  
Taisei Kurihara<sup>1,2</sup>, Yoshiyuki Suehara<sup>1</sup>, Keisuke Akaike<sup>1</sup>, Nobuhiko Hasegawa<sup>1,3</sup>, Takuo Hayashi<sup>2</sup>, Shinji Kohsaka<sup>3</sup>, Tatsuya Takagi<sup>1</sup>, Takashi Yao<sup>2</sup>, Kazuo Kaneko<sup>1</sup>, Tsuyoshi Saito<sup>2</sup> (<sup>1</sup>Dept. of Orthopedic Surg., Juntendo Univ. Sch. of Med., <sup>2</sup>Dept. of Human Path., Juntendo Univ. Sch. of Med., <sup>3</sup>Div. Cell. Signaling, Natl. Cancer Ctr. Res. Inst.)

**Nanostring を用いた IMT/IPT におけるチロシンキナーゼ融合遺伝子の解析**  
栗原 大聖<sup>1,2</sup>、末原 義之<sup>1</sup>、赤池 慶祐<sup>1</sup>、長谷川 延彦<sup>1,3</sup>、林 大久生<sup>2</sup>、高阪 真路<sup>3</sup>、高木 辰哉<sup>1</sup>、八尾 隆史<sup>2</sup>、金子 和夫<sup>1</sup>、齋藤 剛<sup>2</sup> (<sup>1</sup>順天堂大・医・整形外科、<sup>2</sup>順天堂大・医・人体病理病態学、<sup>3</sup>国立がん研セ・研・細胞情報学)

P-1192 **Identification of novel TP53 mutation-associated genes through pan-cancer analysis**  
Shoichiro Tange, Masashi Idogawa, Takashi Tokino (Med. Genome Sci., Inst. Frontier Med., Sapporo Med. Univ.)

**変異 TP53 遺伝子との相関が確認された新規遺伝子群の発見**  
丹下 正一郎、井戸川 雅史、時野 隆至 (札幌医大・フロンティア研・ゲノム)

## 17 Chemotherapy and endocrine therapy

Room P(B) Sep. 26 (Thu.) 16:30-17:15

E/J

**P17-1 Natural anticancer compounds (1)**  
天然抗がん物質 (1)

Chairperson: Siro Simizu (Keio Univ.)

座長: 清水 史郎 (慶應大)

P-1193 **Cytosporolide C and its analog inhibited activities of topoisomerases and tumor cell growth**  
Ryota Kawahara, Siro Simizu (Dept. Appl. Chem., Fac. Sci. Tech., Keio Univ.)

**シトスポロリド C およびその類縁体はトポイソメラーゼを阻害しがん細胞に対し抗増殖活性を持つ**  
川原 遼太、清水 史郎 (慶應大・理工・応化)

P-1194 **Luteolin suppresses pancreatic carcinogenesis by inhibition of pSTAT3 pathway and DPYD expression**  
Hiroyuki Kato<sup>1</sup>, Aya Naiki-Ito<sup>1</sup>, Shugo Suzuki<sup>2</sup>, Yoriko Yamashita<sup>1</sup>, Satoru Takahashi<sup>1</sup> (<sup>1</sup>Dept. Exp. Pathol. Tumor Biol., Nagoya City Univ., <sup>2</sup>Dept. Mol. Pathol., Osaka City Univ.)

**Luteolin は pSTAT3 経路や DPYD 発現の抑制によって膵癌を予防する**  
加藤 寛之<sup>1</sup>、内木 綾<sup>1</sup>、鈴木 周五<sup>2</sup>、山下 依子<sup>1</sup>、高橋 智<sup>1</sup> (1名市大・院医・実験病態病理学、<sup>2</sup>大阪市大・院医・分子病理学)

P-1195 **A novel PDK4 inhibitor cryptotanshinone suppresses the tumorigenesis of KRAS-activated cancer cells via PI3K/Akt pathway**  
Yukihiko Tambe<sup>1</sup>, Tokio Terado<sup>2</sup>, Chul-Jang Kim<sup>3</sup>, Hirofumi Nakano<sup>4</sup>, Ken-ichi Mukaisho<sup>5</sup>, Hiroyuki Sugihara<sup>2</sup>, Hirokazu Inoue<sup>1</sup> (<sup>1</sup>Microbiol. Infect. Dis., Shiga Univ. Med. Sci., <sup>2</sup>Dept. Stem Cell Biol. Regen. Med., Shiga Univ. Med. Sci., <sup>3</sup>Dept. Urol., Kohka Publ. Hosp., <sup>4</sup>Kitasato Inst. Life Sci., Kitasato Univ., <sup>5</sup>Div. Mol. Diagn. Pathol., Shiga Univ. Med. Sci.)

**新規 PDK4 阻害剤 cryptotanshinone は PI3K/Akt 経路を介して KRAS 活性型癌細胞の癌化を抑制する**

目部 幸博<sup>1</sup>、寺戸 勅雄<sup>2</sup>、金 哲將<sup>3</sup>、中野 洋文<sup>4</sup>、向所 賢一<sup>5</sup>、杉原 洋行<sup>5</sup>、井上 寛一<sup>1</sup> (<sup>1</sup>滋賀医大・医・微生物感染症、<sup>2</sup>滋賀医大・医・再生修復医学、<sup>3</sup>公立甲賀病院・泌尿器科、<sup>4</sup>北里大・生命科学研、<sup>5</sup>滋賀医大・医・分子診断病理学)

**P-1196 Anti-inflammatory effect of Morus alba L. bark by suppressing NF-κB signaling pathway**

Rin Umeyama<sup>1</sup>, Satoru Yokoyama<sup>2</sup>, Yoshihiro Hayakawa<sup>1</sup> (<sup>1</sup>Div. Pathogenic Biochem., Inst. Nat. Med., Toyama Univ., <sup>2</sup>Dept. Cancer Cell Bio., Sch. Med. Pharm. Sci., Toyama Univ.)

**NF-κB シグナル伝達経路の制御を介した桑白皮の抗炎症作用**  
梅山 凜<sup>1</sup>、横山 悟<sup>2</sup>、早川 芳弘<sup>1</sup> (<sup>1</sup>富山大・和漢研・病態生化学、<sup>2</sup>富山大・薬・がん細胞生物学)

**P-1197 Caffeic acid phenethyl ester suppresses migration and invasion of prostate cancer cells via inhibition of EGFR signaling**

Jen-Chih Tseng, Chih-Pin Chuu (Inst. of Cell. & System Med., Natl. Health Res. Inst.)

**P-1198 Withdrawn**

**P-1199 Gallic Acid induces apoptosis and inhibits expression of PD-L1 through p53 signaling pathway in A549 cell line**

Kyoung-Jin Jang, Dong Young Kang, Nipin Sp, Eun Seong Jo, Young Mok Yang (Dept. Pathol.)

**1 Chemical carcinogenesis and radiation carcinogenesis**

Room **P(A)** Sep. 26 (Thu.) 17:15-18:00

E/J

**P1-2 3D cell culture experiments**  
3D 培養細胞実験

Chairperson: Hiroyuki Miyoshi (Office of Society-Academia Collaboration for Innovation, Kyoto Univ.)

座長：三好 弘之 (京都大・産官学連携本部)

**P-1200 Comparison of 2D and 3D culture system for CDDP sensitivity assay of Triple Negative Breast Cancer**

Masako Muguruma, Saeko Teraoka, Takashi Ishikawa (Dept. Breast Oncology, Tokyo Med. Univ.)

**トリプルネガティブ乳がんに対するシスプラチン感受性試験の2次元と3次元培養法の比較**

六車 雅子、寺岡 冴子、石川 孝 (東京医大・乳腺科)

**P-1201 Contractile force assay for cancer cells**

Hiroki Aosaki, Tsubasa S. Matsui, Shinji Deguchi (Div. Bioeng., Grad. Sch. Eng. Sci., Osaka Univ.)

**がん細胞が発生する力のアッセイ**

青崎 宏樹、松井 翼、出口 真次 (大阪大・基礎工・生体工学)

**P-1202 Analysis of pancreatic tumor-stromal cell interactions in 3D culture condition**

Daisuke Tatsuda<sup>1</sup>, Junjiro Yoshida<sup>1</sup>, Tomokazu Ohishi<sup>2</sup>, Manabu Kawada<sup>1,2</sup> (<sup>1</sup>Inst. Microb. Chem., Lab. Onc., <sup>2</sup>Inst. Microb. Chem., Numazu)

**3次元培養によるすい臓由来のがん細胞と間質細胞の相互作用の解析**  
立田 大輔<sup>1</sup>、吉田 潤次郎<sup>1</sup>、大石 智一<sup>2</sup>、川田 学<sup>1,2</sup> (<sup>1</sup>微化研・第1生物活性、<sup>2</sup>微化研・沼津)

**P-1203 Genetic changes that affects organoid shape differences in 3-D culture**

Yui Matsuzawa<sup>1,2</sup>, Shingo Miyamoto<sup>3</sup>, Gen Fujii<sup>4</sup>, Masami Komiya<sup>1</sup>, Takumi Narita<sup>1</sup>, Takahiro Hamoya<sup>1,2</sup>, Kouhei Miki<sup>1,2</sup>, Takahiro Teruya<sup>1,2</sup>, Michihiro Mutoh<sup>1</sup> (<sup>1</sup>Ctr. For Public Health Sci., Natl. Cancer Ctr., <sup>2</sup>Dept. Bol. Sci. & Tech., Tokyo Univ. of Sci., <sup>3</sup>Dept. Cancer Cell Res., Sasaki Inst. Sasaki Foundation, <sup>4</sup>Central Radioisotope Div., Natl. Cancer Ctr.)

**3次元培養におけるオルガノイド形状の違いに影響する遺伝的変化**  
松澤 優衣<sup>1,2</sup>、宮本 真吾<sup>3</sup>、藤井 元<sup>4</sup>、小宮 雅美<sup>1</sup>、成田 匠<sup>1</sup>、鱧屋 隆博<sup>1,2</sup>、三木 洗平<sup>1,2</sup>、照屋 貴宏<sup>1,2</sup>、武藤 倫弘<sup>1</sup> (<sup>1</sup>国立がん研セ・社会と健康研究セ、<sup>2</sup>東理大・院・基礎工、<sup>3</sup>佐々木研・附属研・腫瘍細胞、<sup>4</sup>国立がん研セ・研・RI実験施設)

**P-1204 Effects of fibroblasts on the three-dimensional morphogenesis of human prostate cancer cells on a viscous substrate**

Yasuhisa Nakagawa<sup>1</sup>, Kenichiro Ishii<sup>1</sup>, Masaya Fujiwara<sup>3</sup>, Eri Usugi<sup>1</sup>, Yoshifumi Hirokawa<sup>1</sup>, Yoshiki Sugimura<sup>2</sup>, Masatoshi Watanabe<sup>1</sup> (<sup>1</sup>Dept. Oncologic Path., Mie Univ. Grad. Sch. Med., <sup>2</sup>Dept. Nephro-Urologic Surg. & Andrology, Mie Univ. Grad. Sch. Med., <sup>3</sup>Natl. Hosp. Org. Mie Chuo Med. Ctr.)

**粘性基質上培養でのヒト前立腺癌細胞と線維芽細胞の3次元構造形成にかかわる評価**

中川 泰久<sup>1</sup>、石井 健一朗<sup>1</sup>、藤原 雅也<sup>3</sup>、臼杵 恵梨<sup>1</sup>、広川 佳史<sup>1</sup>、杉村 芳樹<sup>2</sup>、渡邊 昌俊<sup>1</sup> (<sup>1</sup>三重大・医院・腫瘍病理学、<sup>2</sup>三重大・医院・泌尿器外科学、<sup>3</sup>国立病院機構三重中央医療セ)

**P-1205 3D screening of synthetic lethal gene pairs for targeted cancer therapies**

Choa Park, Sukjoon Yoon (Dept. of Biological Sci., Sookmyung Women's Univ.)

### 3 Virus, infection, inflammation and cancer

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

#### P3-2 Virus associated gastric cancer and hepatoma ウイルス関連胃癌、肝臓がん

Chairperson: Atsushi Kaneda (Dept. Mol Oncol, Grad. Sch. Med., Chiba Univ.)  
座長: 金田 篤志 (千葉大・院医・分子腫瘍学)

- P-1206 Investigation of intrahepatic acquired immune signal involved in regulation of HBV cccDNA**  
Takuto Nosaka, Tatsushi Naito, Kazuto Takahashi, Kazuya Ofuji, Hidetaka Matsuda, Masahiro Ohtani, Katsushi Hiramatsu, Yasunari Nakamoto (2nd Dept. Int. Med., Univ. of Fukui.)  
HBV cccDNA の制御に関わる肝細胞内獲得免疫シグナルの検討  
野阪 拓人、内藤 達志、高橋 和人、大藤 和也、松田 秀岳、大谷 昌弘、平松 活志、中本 安成 (福井大・医・内科学 2)
- P-1207 Difference in the impact of entecavir treatment on the risk of HCC in HB cirrhosis in the various regions in the world**  
Kazuo Tarao (Tarao's Gastroenterologica Clinic)  
B 型肝炎変症に対するエンテカビル治療による肝発癌抑制効果の世界における地域差について  
多羅尾 和郎 (たらお内科・消化器科)
- P-1208 Clinical and pathological features of Epstein-Barr virus associated gastric cancer**  
Ayaka Yanagi<sup>1</sup>, Jun Nishikawa<sup>1</sup>, Takuya Shuto<sup>1</sup>, Tatuya Takagi<sup>1</sup>, Yutaka Suchiro<sup>2</sup>, Takahiro Yamasaki<sup>2</sup>, Hideo Yanai<sup>3</sup>, Isao Sakaida<sup>3</sup> (1)Lab. Sci. Dept., Yamaguchi Univ. Grad., Sch. Med., (2)Oncology & Lab. Dept., Yamaguchi Univ. Grad., Sch. Med., (3)Gastroenterology & Hepatology Dept., Yamaguchi Univ. Grad., Sch. Med., (4)Cli. Sci. Dept., Natl. Hosp. Organization Kanmon Med. Ctr.)  
Epstein-Barr virus 関連胃癌の臨床・病理学的特徴  
野柳 彩華<sup>1</sup>、西川 潤<sup>1</sup>、首藤 拓也<sup>1</sup>、高木 立哉<sup>1</sup>、末広 寛<sup>2</sup>、山崎 隆弘<sup>2</sup>、柳井 秀雄<sup>3</sup>、坂井田 功<sup>3</sup> (1)山口大・院医・基礎検査学、(2)山口大・院医・臨床検査腫瘍学、(3)山口大・院医・消化器内科学、(4)国立病院機構関門医療セ・臨床研究部)
- P-1209 Different effects on prognosis of EBV positivity in gastric cancer subtypes: Reanalysis of the TCGA RNA-Seq dataset**  
Daichi Sadato<sup>1</sup>, Keisuke Oboki<sup>2</sup>, Yuka Harada<sup>1</sup>, Shin-Ichiro Horiguchi<sup>3</sup>, Chizuko Hirama<sup>1</sup>, Mina Ogawa<sup>1</sup>, Tatsu Shimoyama<sup>4</sup> (1)Divisions of Clin. Res. Support, Komagome Hosp., (2)Ctr. for Med. Res. Cooperation, TMIMS, (3)Dept. Path., Komagome Hosp., (4)Dept. Med. Oncology, Komagome Hosp.)  
胃癌サブタイプにおける EBV 陽性胃癌予後への異なる影響: TCGA RNA-Seq データセットの再分析  
貞任 大地<sup>1</sup>、大保木 啓介<sup>2</sup>、原田 結花<sup>1</sup>、堀口 慎一郎<sup>3</sup>、平間 千津子<sup>1</sup>、小川 美奈<sup>1</sup>、下山 達<sup>4</sup> (1)都立駒込病院・臨床研究支援室、(2)医学部・病院等連携研究セ、(3)都立駒込病院・病理科、(4)都立駒込病院・腫瘍内科)
- P-1210 Integration of hepatitis B virus DNA into COXIII mitochondrial genomic sequences in HepG2.2.15 cell line**  
Ritsuko Oikawa<sup>1</sup>, Yoshiyuki Watanabe<sup>1,2</sup>, Hiroyuki Yamamoto<sup>3</sup>, Fumio Itoh<sup>1</sup> (1)Div. Gastroenterol. & Hepatol., St. Marianna Univ. Sch. Med., (2)Dept. Int. Med., Kawasaki Rinko General Hosp.)  
HepG2.2.15 細胞株における B 型肝炎ウイルス DNA のミトコンドリア COX3 遺伝子への組み込み  
及川 律子<sup>1</sup>、渡邊 嘉行<sup>1,2</sup>、山本 博幸<sup>1</sup>、伊東 文生<sup>1</sup> (1)聖マリアンナ医科大学・消化器・肝臓内科、(2)総合川崎臨港病院・内科)

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

#### P3-3 Inflammation and cancer (1) 炎症とがん (1)

Chairperson: Hideo Tanaka (Dept. Path. & Cell Regulation, Kyoto Pref. Univ. of Med.)  
座長: 田中 秀央 (京都府医大・院医・細胞分子病理学)

- P-1211 Development of anti-CPS antibody assay to evaluate Enterococcus faecalis infection in pancreatic cancer patients**  
Saki Itoyama<sup>1</sup>, Emika Noda<sup>1</sup>, Risako Fukaya<sup>1</sup>, Tomohiro Maekawa<sup>1</sup>, Shinji Takamatsu<sup>1</sup>, Yoshihiro Kamada<sup>1</sup>, Hidetoshi Eguchi<sup>2</sup>, Toru Tobe<sup>3</sup>, Eiji Miyoshi<sup>1</sup> (1)Dept. Mol. Biochem. & Clin. Inv., Osaka Univ., Grad Sch. Med., (2)Dept. Gastroenterol. Surg., Osaka Univ., Grad Sch. Med., (3)Dept. Microbiol., Osaka Univ., Grad Sch. Med.)  
膵臓癌患者における Enterococcus faecalis 感染を評価する抗 CPS 抗体測定系の開発

糸山 幸来<sup>1</sup>、野田 愛美香<sup>1</sup>、深谷 莉紗子<sup>1</sup>、前川 友裕<sup>1</sup>、高松 真二<sup>1</sup>、鎌田 佳宏<sup>1</sup>、江口 英利<sup>2</sup>、戸邊 亨<sup>3</sup>、三善 英知<sup>1</sup> (1)大阪大・医・保健学・機能診断科学講座、(2)大阪大・医・消化器外科、(3)大阪大・医・保健学・分子病原微生物学)

- P-1212 Analysis of cytotoxic factor contained in tumor cell line supernatants**  
Takuya Nishinakagawa, Mai Hazekawa, Tomoyo Yasukochi, Manabu Nakashima (Dept. Immuno. Mol. Pharm., Sci., Fukuoka Univ.)  
がん細胞培養上清に含まれる細胞傷害活性因子の解析  
西中川 拓也、櫛川 舞、安河内 友世、中島 学 (福岡大・薬・免疫・分子治療学)
- P-1213 Depletion of 15pgdh enhances pancreatic cancer malignancy in syngeneic mouse model**  
Luke Bu<sup>1,2</sup>, Kota Arima<sup>1</sup>, Rumi Itoyama<sup>1,2</sup>, Fumimasa Kitamura<sup>1,2</sup>, Takatsugu Ishimoto<sup>1,2</sup>, Hideo Baba<sup>1</sup> (1)Dept. Gastroenterological Surg., Grad. Sch. of Med. Sci., Kumamoto Univ., (2)International Res. Ctr. of Med. Sci. (IRCMS), Kumamoto Univ.)  
腫瘍間質における 15pgdh 発現低下を介した膵癌進展メカニズムの解明  
ブルコ<sup>1,2</sup>、有馬 浩太<sup>1</sup>、伊東山 瑠美<sup>1,2</sup>、北村 文優<sup>1,2</sup>、石本 崇胤<sup>1,2</sup>、馬場 秀夫<sup>1</sup> (1)熊本大・院消化器外科学、(2)国際先端医学研究機構)
- P-1214 Tumor mutator APOBEC3B binds to cellular non-coding RNAs to inhibit retroelements**  
Tadahiko Matsumoto, Kotaro Shirakawa, Sukenao Koyabu, Yasuhiro Kazuma, Hiroyuki Yamazaki, Hiroyuki Matsui, Akifumi Takaori-Kondo (Hematology & Oncology, Kyoto Univ.)  
がんの内性変異源 APOBEC3B の非コード RNA に結合能力はレトロエレメントを阻害に必要である  
松本 忠彦、白川 康太郎、小藪 助直、数馬 安浩、山崎 寛章、松井 宏行、高折 晃史 (京都大・院・血液・腫瘍内科学)
- P-1215 Linkage between Pro-inflammatory cytokine, TNF-alpha, and cancer through an Induction of ISG15**  
Kongthawat Chairatvit<sup>1</sup>, Wanee Lertsooksawat<sup>2</sup>, Ariyaphong Wongnoppavich<sup>3</sup> (1)Dept. Oral Biol, Faculty of Dent., Mahidol Univ., (2)Dept. Pharm, Faculty of Dent, Mahidol Univ., (3)Dept. Biochem, Faculty of Med., Chiang Mai Univ.)

### 4 Oncogenes and tumor-suppressor genes

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

#### P4-4 RB/p16 and p53 tumor suppressor pathways RB/p16 と p53 によるがん抑制経路

Chairperson: Chizu Tanikawa (The Inst. of Med. Sci., the Univ. of Tokyo)  
座長: 谷川 千津 (東京大・医科研)

- P-1216 Involvement of unique vesicles in the Micap-induced vacuoles formation during Micap-mediated cancer cell death**  
Naoki Ikari<sup>1</sup>, Yasuyuki Nakamura<sup>1</sup>, Takahiro Shibata<sup>1</sup>, Masakazu Yamamoto<sup>2</sup>, Hirofumi Arakawa<sup>1</sup> (1)Div. Cancer Biol., Natl. Cancer Ctr. Res. Inst., (2)Dept. Surg., Inst. of Gastroenterology, Tokyo Women's Med. Univ.)  
Micap 誘導性細胞死で形成される液胞の発生過程の検討  
淀直樹<sup>1</sup>、中村 康之<sup>1</sup>、柴田 貴弘<sup>1</sup>、山本 雅一<sup>2</sup>、荒川 博文<sup>1</sup> (1)国立がん研セ・研・腫瘍生物、(2)東京女子医大・消化器・一般外科)
- P-1217 RB inactivation enhances protumoral microenvironment by elevating CCL2 expression**  
Fengkai Li<sup>1</sup>, Shunsuke Kitajima<sup>1,2</sup>, Chiaki Takahashi<sup>1</sup> (1)Div. Oncology Mol. Biol., Kanazawa Univ., Cancer Res. Inst., (2)Dept. Med. Oncology, Dana-Farber cancer Inst., Boston, USA)  
RB 不活性化は CCL2 を介して腫瘍微小環境を制御する  
李 鳳凱<sup>1</sup>、北嶋 俊輔<sup>1,2</sup>、高橋 智聡<sup>1</sup> (1)金沢大・がん研・腫瘍分子、(2)米国・ダナ・ファーマー癌研・腫瘍内科)
- P-1218 p53-loss of heterozygosity with p53 gain-of-function mutation leads to cancer dormancy of intestinal tumors**  
Mizuho Nakayama<sup>1,2</sup>, Eri Sakai<sup>2</sup>, Hiroko Oshima<sup>1,2</sup>, Patrick Tan<sup>3</sup>, Masanobu Oshima<sup>1,2</sup> (1)NanoLSI, Kanazawa Univ., (2)Div. Genet., CRI, Kanazawa Univ., (3)Can. Stem Cell Biol. Prog. Duke-NUS Med. Sch.)  
変異型 p53 における野生型 p53 欠失による p53-Loss of heterogeneity は、潜在性がんとしての性質を亢進する  
中山 瑞穂<sup>1,2</sup>、坂井 絵梨<sup>2</sup>、大島 浩子<sup>1,2</sup>、タン パトリック<sup>3</sup>、大島 正伸<sup>1,2</sup> (1)金沢大・ナノ LSI、(2)金沢大・がん研・腫瘍遺伝、(3)デューク シンガポール国立大)

P-1219 **mR1 is an essential genomic element for p53-deficient osteosarcomagenesis**  
Yuki Date, Shohei Otani, Kosei Ito (Grad. Sch. Biomed. Sci., Nagasaki Univ.)

mR1 は p53 欠損骨肉腫発症に必須なゲノム上のエレメントである  
伊達 悠貴、大谷 昇平、伊藤 公成 (長崎大・院医歯薬・分子硬組織生物)

P-1220 **p53 represses c-Myc by inhibition of Runx3 to suppress osteosarcoma development**  
Shohei Otani, Yuki Date, Kosei Ito (Grad. Sch. Biomed. Sci., Nagasaki Univ.)

p53 は Runx3 の機能を阻害することにより c-Myc 発現を抑え骨肉腫発症を抑制する  
大谷 昇平、伊達 悠貴、伊藤 公成 (長崎大・院医歯薬・分子硬組織生物)

P-1221 **Establishment and characterization of human mesothelial cell lines with CRISPR/Cas9-mediated disruption of NF2 and p16**  
Karnan Sivasundaram<sup>1</sup>, Akinobu Ota<sup>1</sup>, Ichiro Hanamura<sup>2</sup>, Hideki Murakami<sup>3</sup>, Toshinori Hyodo<sup>1</sup>, Hiroyuki Konishi<sup>1</sup>, Shinobu Tsuzuki<sup>1</sup>, Yoshitaka Hosokawa<sup>1</sup> (<sup>1</sup>Dept. Biochem. Aichi Med. Univ. of Med., <sup>2</sup>Div. Hematology, Dept. Int. Med., Aichi Med., Univ. Sch. Med., <sup>3</sup>Dept. Path. Aichi Med. Univ. school)

p16/NF2 遺伝子の欠損により発現の誘導される悪性中皮腫特異的分子の同定  
シバスンドラム カルナン<sup>1</sup>、太田 明伸<sup>1</sup>、花村 一朗<sup>2</sup>、村上 秀樹<sup>3</sup>、兵頭 寿典<sup>1</sup>、小西 裕之<sup>1</sup>、都築 忍<sup>1</sup>、細川 好孝<sup>1</sup> (愛知医大・生化学講座、<sup>2</sup>愛知医大・血液内科、<sup>3</sup>愛知医大・病理学講座)

P-1222 **Analysis of RB mediated regulation of cancer and the circadian rhythm**  
Takao Miki<sup>1</sup>, Chiaki Takahashi<sup>2</sup>, Makoto Noda<sup>3</sup> (<sup>1</sup>Dept. Pharm., Kansai Med. Univ., <sup>2</sup>Cancer. Res. Inst., Kanazawa Univ., <sup>3</sup>Dept. Mol. Oncol., Kyoto Univ., Sch. Med.)

RB に着目したがんと概日リズムの連関の解析  
三木 貴雄<sup>1</sup>、高橋 智聡<sup>2</sup>、野田 亮<sup>3</sup> (関西医大・医・薬理、<sup>2</sup>金沢大・がん研、<sup>3</sup>京都大・医・分子腫瘍)

Room P(A) Sep. 26 (Thu.) 17:15-18:00 E/J  
P4-5 **Oncogenes and tumor-suppressor genes (1)**  
がん遺伝子・がん抑制遺伝子 (1)

Chairperson: Kentaro Semba (Waseda Univ.)  
座長: 仙波 憲太郎 (早稲田大・先端生命医科学セ)

P-1223 **Depletion of gamma-glutamylcyclotransferase (GGCT) inhibits cancer cell growth via AMPK-FOXO3a-p21 axis**  
Keiko Taniguchi<sup>1</sup>, Hiromi Ii<sup>1</sup>, Susumu Kageyama<sup>2</sup>, Hiroko Takagi<sup>1</sup>, Chiaki Moyama<sup>1</sup>, Shota Ando<sup>1</sup>, Eishi Ashihara<sup>3</sup>, Tokuhiro Chano<sup>4</sup>, Akihiro Kawauchi<sup>2</sup>, Susumu Nakata<sup>1</sup> (<sup>1</sup>Dept. Clin. Oncol., Kyoto Pharm. Univ., <sup>2</sup>Dept. Urol., Shiga Univ. of Med. Sci., <sup>3</sup>Dept. Clin. & Transl. Physiol., Kyoto Pharm. Univ., <sup>4</sup>Dept. Clin. Lab. Med., Shiga Univ. of Med. Sci.)

GGCT の発現低下は AMPK-FOXO3a-p21 経路を介してがん細胞の増殖を抑制する  
谷口 恵香<sup>1</sup>、飯居 宏美<sup>1</sup>、影山 進<sup>2</sup>、高木 寛子<sup>1</sup>、茂山 千愛美<sup>1</sup>、安藤 翔太<sup>1</sup>、芦原 英司<sup>3</sup>、茶野 徳宏<sup>4</sup>、河内 明宏<sup>2</sup>、中田 晋<sup>1</sup> (京都薬大・臨床腫瘍学、<sup>2</sup>滋賀医大・泌尿器科学、<sup>3</sup>京都薬大・病態生理学、<sup>4</sup>滋賀医大・臨床検査医学)

P-1224 **Mucosal Melanoma display Distinct Mutational Landscape from Cutaneous Melanoma**  
Yuuki Iida<sup>1,2</sup> (<sup>1</sup>John Wayne Cancer Inst., <sup>2</sup>Yaizu City Hosp.)  
粘膜原発悪性黒色腫は皮膚悪性黒色腫と異なる遺伝子突然変異を有する  
飯田 祐基<sup>1,2</sup> (<sup>1</sup>ジョンウェイ Cancer 研、<sup>2</sup>焼津市立総合病院)

P-1225 **Cell-based functional analysis of a HER2 VUS detected in a colorectal cancer patient**  
Yosuke Mitani, Shinya Ohashi, Tomoki Saito, Manabu Muto (Therapeutic Oncology, Kyoto. Univ. Sch. Med.)  
大腸癌患者から検出された HER2 VUS の cell-based assay を用いた機能解析  
三谷 洋介、大橋 真也、齋藤 伴樹、武藤 学 (京都大・医・腫瘍薬物治療学講座)

P-1226 **Hippo-YAP1 signaling drives head-and-neck squamous cell carcinoma onset and progression**  
Yosuke Miyachi<sup>1</sup>, Hirofumi Omori<sup>1,2</sup>, Miki Nishio<sup>1</sup>, Muneyuki Masuda<sup>3</sup>, Akira Suzuki<sup>1,4</sup> (<sup>1</sup>Div. Mol. Cell. Biol., Grad. Sch. Med., Kobe Univ., <sup>2</sup>Dept. Otorhinolaryngol., Grad. Sch. Med., Kyushu Univ., <sup>3</sup>Dept. Head Neck Surg., Natl. Hosp. Org. Kyushu Cancer Ctr., <sup>4</sup>Med. Inst. Bioreg., Kyushu Univ.)

Hippo-YAP1 シグナルによる頭頸部扁平上皮がんの発症および進展の制御

宮地 洋佑<sup>1</sup>、大森 裕文<sup>1,2</sup>、西尾 美希<sup>1</sup>、益田 宗幸<sup>3</sup>、鈴木 聡<sup>1,4</sup> (神戸大・院医・分子細胞生物学、<sup>2</sup>九州大・院医・耳鼻科、<sup>3</sup>九州がんセンター頭頸科、<sup>4</sup>九州大・生医研)

P-1227 **Autocrine TGF-beta 1 potentiates ECM anchorage in the invasive leader cell**  
Jei Ming Peng (ITRBM, Kaohsiung CGMH)

P-1228 **Clinical significance of FOXM1 isoform in cholangiocarcinoma**  
Nathakan Klinhom-on<sup>1</sup>, Sopot Wongkham<sup>1,3</sup>, Wunchana Seubwai<sup>2,3</sup> (<sup>1</sup>Dept. Biochem., Med., Khon Kaen Univ., <sup>2</sup>Dept. Forensic Med., Med., Khon Kaen Univ., <sup>3</sup>Cholangiocarcinoma research Inst, Khon Kaen Univ.)

P-1229 **GPR161 regulates cell proliferation and migration in skin cancer**  
Jinhyeon Choi, Eunsun Jung, Tae-Su Han, Hyun Seung Ban, Jang-Seong Kim (Korea Res. Inst. of Biosci. & Biotechnology)

## 5 Signal transduction and gene expression

Room P(A) Sep. 26 (Thu.) 17:15-18:00 E/J

P5-2 **Cell proliferation**  
細胞増殖

Chairperson: Yoshiki Murakumo (Dept. Path., Kitasato Univ. Sch. of Med.)  
座長: 村雲 芳樹 (北里大・医・病理学)

P-1230 **CD271 is an essential regulator for cell proliferation in squamous cell carcinoma**  
Mai Mochizuki<sup>1</sup>, Shinkichi Morita<sup>2,3</sup>, Kazunori Yamaguchi<sup>3</sup>, Kazuo Sugamura<sup>3</sup>, Keiichi Tamai<sup>1</sup> (<sup>1</sup>Miyagi Cancer Ctr. Res. Inst. Div. Cancer Stem Cell, <sup>2</sup>Miyagi Cancer Ctr. Dept. Head & Neck Surg., <sup>3</sup>Miyagi Cancer Ctr. Res. Inst. Div. Mol. & Cell. Ono.)

CD271 は扁平上皮癌の増殖を制御する有望な治療標的である  
望月 麻衣<sup>1</sup>、森田 真吉<sup>2,3</sup>、山口 豊範<sup>3</sup>、菅村 和夫<sup>3</sup>、玉井 恵一<sup>1</sup> (宮城県がんセンター・研・がん幹細胞、<sup>2</sup>宮城県がんセンター頭頸部外科、<sup>3</sup>宮城県がんセンター・研・発がん制御)

P-1231 **PRAS40 hyperexpression promotes hepatocarcinogenesis**  
Lin Huang (Dept. Pathophys., Dalian Med. Univ.)

肝臓がんにおける PRAS40 高発現について  
黄 琳 (大連医大・病理生理)

P-1232 **The role of Ano9 in esophageal squamous cell carcinoma**  
Shunji Kato, Atsushi Shiozaki, Keita Katsurahara, Toshiyuki Kosuga, Michihiro Kudou, Katsutoshi Shoda, Tomohiro Arita, Hirotaka Konishi, Yasutoshi Murayama, Takeshi Kubota, Masayoshi Nakanishi, Hitoshi Fujiwara, Eigo Otsuji (Div. Digestive Surg. Kyoto Pref. Univ. of Med.)

食道扁平上皮癌における Ano9 の役割について  
加藤 俊治、塩崎 敦、葛原 啓太、小菅 敏幸、工藤 道弘、庄田 勝俊、有田 智洋、小西 博真、村山 康利、窪田 健、中西 正芳、藤原 育、大辻 英吾 (京都府医大・外科学教室・消化器外科学)

P-1233 **Role of Tsc2-mTORC1 signaling in regulation of colonic epithelial homeostasis**

Takenori Kotani, Setiawan Jajar, Noriko Ihara, Saki Okamoto, Yoji Murata, Yasuyuki Saito, Takashi Matozaki (Div. Mol. & Cell. Signal., Kobe Univ. Grad. Sch. Med.)

大腸上皮の恒常性制御における Tsc2-mTORC1 シグナルの役割  
小谷 武徳、Setiawan Jajar、井原 紀子、岡本 沙樹、村田 陽二、齋藤 泰之、崎崎 尚 (神戸大・院医・シグナル統合学)

P-1234 **S100A10 regulates proliferation and migration of HNSCC cells through cytoskeleton control**  
Naoko Ogama<sup>1</sup>, Katsuhiko Kojima<sup>2</sup>, Takayuki Imai<sup>3</sup>, Maki Kobayashi<sup>1</sup>, Kazuto Matsuura<sup>3</sup>, Nobuyuki Tanaka<sup>1</sup> (<sup>1</sup>Cancer Biol. & Therap., Miyagi Cancer Ctr. Res. Inst., <sup>2</sup>Microbiology & Immunol. Shinshu Univ. Sch. of Med., <sup>3</sup>Head & Neck Surg., Miyagi Cancer Ctr.)

S100A10は細胞骨格を介して頭頸部がんの増殖と浸潤を制御する  
小鎌 直子<sup>1</sup>、小嶋 克彦<sup>2</sup>、今井 隆之<sup>3</sup>、小林 真紀<sup>1</sup>、松浦 一登<sup>3</sup>、田  
中 伸幸<sup>1</sup> (宮城県がんセ・研・がん先進治療開発、<sup>2</sup>信州大・医・免  
疫微生物、<sup>3</sup>宮城県がんセ・頭頸部外科)

P-1235 **Role of CAMSAP3 on lung cancer cell proliferation**

Onsurang Wattanathamsan<sup>1</sup>, Varisa Pongrakhananon<sup>2</sup> (Dept. Pharm.,  
Grad. Sch. Chulalongkorn Univ., <sup>2</sup>Dept. Pharmacol. & Physiol. Facult.  
of Pharm. Sci. Chulalongkorn Univ.)

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

P5-3 **MicroRNAs (1)**  
マイクロRNA (1)

Chairperson: Hidetoshi Tahara (Dept. Cell. & Mol. Biol., Sch. of Pharm. Sci., Grad.  
Sch. Biomed. & Health Sci., Hiroshima Univ.)

座長: 田原 栄俊 (広島大・院医・細胞分子生物)

P-1236 **Role of 5-fluorouracil (5-FU) resistance-related microRNA-31 in colorectal tumors**

Yoshihito Nakagawa<sup>1</sup>, Yuki Kuranaga<sup>2</sup>, Yukihiko Akao<sup>2</sup> (Dept.  
Gastroenterology, Fujita Health Univ., Sch. Med., <sup>2</sup>United Graduated  
Sch. Drug Discovery Med. Information Sci., Gifu Univ.)

5-FU 耐性に関する micro-RNA-31 の耐性機序

中川 義仁<sup>1</sup>、倉永 祐希<sup>2</sup>、赤尾 幸博<sup>2</sup> (藤田医大・医・消化器内科、  
<sup>2</sup>岐阜大・院・連合創薬・医療情報研究科)

P-1237 **Identification of novel therapeutic target for EV-mediated cancer progression by microRNA-based screening**

Nobuyoshi Kosaka<sup>1</sup>, Fumihiko Urabe<sup>1</sup>, Tomofumi Yamamoto<sup>1</sup>, Yusuke  
Yamamoto<sup>2</sup>, Takahiro Ochiya<sup>1</sup> (Dept. Mol. Cell. Med., Inst. Med. Sci.  
Tokyo Med. Univ., <sup>2</sup>Div. Cell. Sig., Natl. Cancer Ctr. Res. Inst.)

がん由来エクソソームによるがんの悪性化を標的とした新規のがん治  
療標的の同定

小坂 展慶<sup>1</sup>、占部 文彦<sup>1</sup>、山元 智史<sup>1</sup>、山本 雄介<sup>2</sup>、落谷 孝広<sup>1</sup> (東京  
医大・医総研・分子細胞治療、<sup>2</sup>国立がん研セ・研・細胞情報)

P-1238 **Function-based microRNA library screening identified novel tumor suppressive microRNAs targeting BRD4**

Yuki Takagawa<sup>1,2</sup>, Yasuyuki Gen<sup>1</sup>, Tomoki Muramatsu<sup>1</sup>, Hiroyuki  
Harada<sup>2</sup>, Johji Inazawa<sup>1,3</sup> (Dept. Mol. Cytogenet., Med. Res. Inst.,  
Tokyo Med. & Dent. Univ., <sup>2</sup>Dept. Oral Maxillofacial Surg., Tokyo Med.  
& Dent. Univ., <sup>3</sup>Bioresource Res. Ctr., Tokyo Med. & Dent. Univ.)

機能的 miRNA ライブラリースクリーニングによる、BRD4 を標的  
とする新規癌抑制型 miRNA の同定

高川 祐希<sup>1,2</sup>、玄 泰行<sup>1</sup>、村松 智輝<sup>1</sup>、原田 浩之<sup>2</sup>、稲澤 謙治<sup>1,3</sup> (東京  
医歯大・難研・分子細胞遺伝、<sup>2</sup>東京医歯大・顎口腔外科、<sup>3</sup>東京医歯  
大・疾患バイオリソースセ)

P-1239 **Circulating pre-miR-488 in blood is a potential prognostic biomarker for gastric cancer**

Yusuke Tsuruda<sup>1,2</sup>, Takaaki Msauda<sup>1</sup>, Takeo Fukagawa<sup>3,4</sup>, Miwa Noda<sup>1</sup>,  
Dai Shimizu<sup>1</sup>, Yukihiko Yoshikawa<sup>1</sup>, Shuhei Ito<sup>1</sup>, Qingjiang Hu<sup>1</sup>,  
Yoshihiro Matsumoto<sup>1</sup>, Hajime Otsu<sup>1</sup>, Hiroki Uchida<sup>1</sup>, Shoji Natsugoe<sup>2</sup>,  
Koshi Mimori<sup>1</sup> (Dept. Surg., Kyushu Univ. Beppu Hosp., <sup>2</sup>Dept.  
Digestive Surg., Breast & Thyroid Surg., Kagoshima Univ., <sup>3</sup>Dept.  
Gastric Surg., Natl. Cancer Ctr. Hosp., <sup>4</sup>Dept. Surg., Teikyo Univ.)

胃癌の予後予測因子としての血中 pre-miR-488 の同定

鶴田 祐介<sup>1,2</sup>、増田 隆明<sup>1</sup>、深川 剛生<sup>3,4</sup>、野田 美和<sup>1</sup>、清水 大<sup>1</sup>、吉  
川 幸宏<sup>1</sup>、伊藤 修平<sup>1</sup>、胡 慶江<sup>1</sup>、松本 佳大<sup>1</sup>、大津 甫<sup>1</sup>、内田 博  
喜<sup>1</sup>、夏越 祥次<sup>2</sup>、三森 功士<sup>1</sup> (九州大・病院・別府病院・外科、<sup>2</sup>鹿  
児島大・消化器・乳腺甲状腺外科、<sup>3</sup>国立がん研セ・胃外科、<sup>4</sup>帝京  
大・外科)

P-1240 **Eribulin suppresses the epithelial mesenchymal transition through the regulation of microRNA expression in breast cancer**

Yosuke Inomata<sup>1</sup>, Kohei Taniguchi<sup>1,2</sup>, Takahumi Shima<sup>1</sup>, Kentaro  
Matsuo<sup>1</sup>, Kazuhisa Uchiyama<sup>1</sup> (Dept. Gastroint. Surg., Osaka Med.  
College, <sup>2</sup>Translational Res. Program, Osaka Med. College)

Eribulin の乳癌細胞における microRNA 発現調節を介した上皮間  
葉転換抑制効果の検証

猪俣 陽介<sup>1</sup>、谷口 高平<sup>1,2</sup>、島 卓史<sup>1</sup>、松尾 謙太郎<sup>1</sup>、内山 和久<sup>1</sup> (大  
阪医大・医・一般消化器外科、<sup>2</sup>大阪医大・医・TR 部門)

P-1241 **A novel chemically-modified miR-143 impairs KRAS network**

Nobuhiko Sugito, Kazuki Heishima, Yukihiko Akao (Uni. Grad. Sch.,  
Drug, Med. Info. Sci., Gifu Univ.)

新規化学修飾 miR-143 による KRAS ネットワークの破壊

杉戸 信彦、平島 一輝、赤尾 幸博 (岐阜大・院・連合創薬医療情報研  
究科)

P-1242 **Anti-tumor effect of MIRTIX in refractory tumor cells**

Midori Goto<sup>1</sup>, Yuhki Yokoyama<sup>1</sup>, Yuma Irie<sup>1</sup>, Haruka Hirose<sup>1</sup>, Takashi  
Kijima<sup>2</sup>, Yasuo Miyoshi<sup>3</sup>, Satoshi Shibata<sup>1</sup>, Hirofumi Yamamoto<sup>1</sup> (Dept.  
Mol. Pathol., Health&Sci., Grad. Sch. Med., Osaka Univ., <sup>2</sup>Div. Resp.  
Med., Dept. Int Med., Hyogo College Med., <sup>3</sup>Dept. Surg., Hyogo College  
Med.)

難治性癌に対する核酸医薬 MIRTIX の抗腫瘍効果の検討

五島 碧<sup>1</sup>、横山 雄起<sup>1</sup>、入江 侑馬<sup>1</sup>、廣瀬 遥香<sup>1</sup>、木島 貴志<sup>2</sup>、三好 康  
雄<sup>3</sup>、柴田 理志<sup>1</sup>、山本 浩文<sup>1</sup> (大阪大・院・保・分子病理、<sup>2</sup>兵庫医  
大・医・呼内、<sup>3</sup>兵庫医大・医・乳腺・内分泌外科)

7 Cancer genome/genetics

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

P7-2 **Hereditary cancer**  
遺伝性腫瘍

Chairperson: Yoichi Furukawa (The Inst. of Med. Sci., the Univ. of Tokyo)

座長: 古川 洋一 (東京大・医科研)

P-1243 **Aurora A-dependent ubiquitination of OLA1 in the regulation of centrosome number**

Zhenzhou Fang<sup>1</sup>, Huicheng Qi<sup>1</sup>, Takahiro Mori<sup>2</sup>, Yuki Yoshino<sup>1</sup>, Moe  
Suzuki<sup>1</sup>, Chikashi Ishioka<sup>1</sup>, Natsuko Chiba<sup>1</sup> (Dept. Cancer Biol., IDAC,  
Tohoku Univ., <sup>2</sup>NHO Sagami Hosp. Clinic. Oncol. & Gastroent.  
Surg., <sup>3</sup>Dept. Clin. Oncol., IDAC, Tohoku Univ.)

Aurora A による OLA1 のユビキチン化は中心体複製制御に重要で  
ある

方 震宙<sup>1</sup>、齊 匯成<sup>1</sup>、森 隆弘<sup>2</sup>、吉野 優樹<sup>1</sup>、鈴木 萌<sup>1</sup>、石岡 千加  
史<sup>3</sup>、千葉 奈津子<sup>1</sup> (東北大・加齢研・腫瘍生物学、<sup>2</sup>国立相模原・腫  
内・消外、<sup>3</sup>東北大・加齢研・臨床腫瘍学)

P-1244 **Isolated juvenile polyps or juvenile polyposis syndrome?-genetic counseling for an infant found with intussusception**

Tomoko Tamaoki (Hashimoto)<sup>1,2</sup> (Dept. Mol. & Clin. Genetics,  
Takatsuki General Hosp., <sup>2</sup>Clin. Genetics Unit, Kyoto Univ. Hosp.)

腸重積を契機に若年性ポリポース症候群が疑われた幼児例への遺伝  
カウンセリング

玉置 (橋本) 知子<sup>1,2</sup> (愛仁会高槻病院・遺伝医療部門、<sup>2</sup>京都大・病  
院・遺伝子診療部)

P-1245 **Quantitative balance of splice variants of the MUTYH gene is involved in colorectal cancer**

Kazuo Tamura<sup>1,2</sup>, Naohiro Tomita<sup>2</sup> (Dept. Life Sci., Sci. & Engineer.,  
Kindai Univ., <sup>2</sup>Div. Lower Gastroenterol. Surg., Dept. Surg., Hyogo  
Col. Med.)

MUTYH 遺伝子のスプライスバリエーションの量的バランスと大腸がん  
との関連

田村 和朗<sup>1,2</sup>、富田 尚裕<sup>2</sup> (近畿大・理工・生命科学、<sup>2</sup>兵庫医大・外  
科・下部消化管外科)

P-1246 **Study on homologous recombination activities of VUSs in hereditary breast and ovarian cancer susceptibility genes**

Zeyu Xu<sup>1</sup>, Qianqian Guo<sup>1</sup>, Hiroko Saito<sup>2</sup>, Shigeaki Sunada<sup>1</sup>, Yoshio  
Miki<sup>1,2</sup> (Mol. Genetics, Med. Research Inst., TMDU, <sup>2</sup>Genetic  
Dingaosis, The Cancer Research Inst. of JFCR)

遺伝性乳がん卵巣がんの原因遺伝子の VUS に対する相同組み換え活  
性に関する研究

ZEYU XU<sup>1</sup>, QIANQIAN GUO<sup>1</sup>、齊藤 広子<sup>2</sup>、砂田 成章<sup>1</sup>、三木 義  
男<sup>1,2</sup> (東京医歯大・難研・分子遺伝、<sup>2</sup>公財) がん研・遺診)

P-1247 **Germline CDH1 variants Predispose Asian Populations to Gastric Cancer**

Akihiro Suzuki<sup>1,4</sup>, Miwako Kakiuchi<sup>1</sup>, Amane Tagashira<sup>1,5</sup>, Daisuke  
Komura<sup>2</sup>, Hiroto Katoh<sup>2</sup>, Shogo Yamamoto<sup>1</sup>, Kenji Tatsuno<sup>1</sup>, Takashi  
Ohshima<sup>3</sup>, Masashi Fukayama<sup>3</sup>, Yasushi Rino<sup>3</sup>, Atsushi Nakajima<sup>4</sup>,  
Shumpei Ishikawa<sup>2</sup>, Hiroyuki Aburatani<sup>1</sup> (Genome Sci. Div. Reast,  
Tokyo Univ., <sup>2</sup>Mol. Preventive Med. Dept. Tokyo Univ., Sch. Med.,  
<sup>3</sup>Surg. Dept. Yokohama City Univ., Sch. Med., <sup>4</sup>Gastroenterology &  
Hepatology Dept. Yokohama City Univ., Sch. Med., <sup>5</sup>Path. Dept. Tokyo  
Univ., Sch. Med.)

CDH1 の生殖細胞変異はアジア人の胃癌の遺伝学的素因となる

鈴木 章浩<sup>1,4</sup>、垣内 美和子<sup>1</sup>、田頭 周<sup>1,5</sup>、河村 大輔<sup>2</sup>、加藤 洋人<sup>2</sup>、山  
本 尚吾<sup>1</sup>、辰野 健二<sup>1</sup>、大島 貴<sup>3</sup>、深山 正久<sup>5</sup>、利野 靖<sup>3</sup>、中島 淳<sup>4</sup>、  
石川 俊平<sup>2</sup>、油谷 浩幸<sup>1</sup> (東京大・先端研・ゲノムサイエンス、<sup>2</sup>東京  
大・医・分子予防医学、<sup>3</sup>横浜市大・医・外科治療学、<sup>4</sup>横浜市大・  
医・肝胆膵消化器病学、<sup>5</sup>東京大・医・病理学)

**P-1248 Identification and analysis of germline CNV of FAF1 gene in familial and early onset gastric cancer patients**

De Hu<sup>1</sup>, Hiderata Yamada<sup>1</sup>, Tsutomu Ohta<sup>1,2</sup>, Hong Tao<sup>1</sup>, Naomi Sato<sup>3</sup>, Fumihiko Tanioka<sup>4</sup>, Tomoaki Kahyo<sup>5</sup>, Haruhiko Sugimura<sup>1</sup> (<sup>1</sup>Dept. Tumor Pathol., Hamamatsu Univ. Sch. of Med., <sup>2</sup>Dept. Physical Therapy, Faculty of Health Sci., Tokoha Univ., <sup>3</sup>Dept. Clin. Nursing, Hamamatsu Univ. Sch. of Med., <sup>4</sup>Div. Pathol., Iwata City Hosp., <sup>5</sup>Dept. Cell. & Mol. Anatomy, Hamamatsu Univ. Sch. of Med.)

家族性および若年性胃癌患者における FAF1 遺伝子の生殖細胞コピー数変化の同定と解析

胡 徳<sup>1</sup>, 山田 英孝<sup>1</sup>, 太田 力<sup>1,2</sup>, 陶 弘<sup>1</sup>, 佐藤 直美<sup>3</sup>, 谷岡 書彦<sup>4</sup>, 華表 友暁<sup>5</sup>, 相村 春彦<sup>1</sup> (<sup>1</sup>浜松医大・腫瘍病理学, <sup>2</sup>常葉大・保健医療・理学療法学科, <sup>3</sup>浜松医大・臨床看護学, <sup>4</sup>磐田市立総合病院・病理診断科, <sup>5</sup>浜松医大・細胞分子解剖学)

**P-1249 Elucidation of the regulation mechanism of BRCA2 protein levels in the cell cycle**

Enkhat Gerelmaa<sup>1,2</sup>, Hiroyuki Uetake<sup>2</sup>, Akira Nakanishi<sup>1</sup>, Yoshio Miki<sup>1,3</sup> (<sup>1</sup>Dept. Mol. Genet., Tokyo Med&Dent. Univ. (TMDU), <sup>2</sup>Dept. Specialized Surgeries, Tokyo Med&Dent. Univ. (TMDU), <sup>3</sup>Dept. Mol. Diagnosis, JFCR, The Cancer Inst.)

## 9 Epigenetics

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

P9-2

**Diagnostic and therapeutic application of aberrant DNA methylation**

DNA メチル化異常の診断・治療応用

Chairperson: Keiko Shinjo (Div. Cancer Biol., Nagoya Univ. Grad. Sch. Med.)  
座長: 新城 恵子 (名古屋大・院医・腫瘍生物学)

**P-1250 Aberrant methylation of IRX1 is a frequent event that may confer growth advantage to prostate cancer cells**

Masahiro Takahashi<sup>1,2</sup>, Koji Mitsuzuka<sup>2</sup>, Akihiro Ito<sup>2</sup>, Akira Horii<sup>1</sup>, Shinichi Fukushima<sup>1</sup> (<sup>1</sup>Dept. Mol. Path., Tohoku Univ. Sch. Med., <sup>2</sup>Dept. Urology, Tohoku Univ. Sch. Med.)

IRX1 の異常メチル化は前立腺癌に高頻度で発生し増殖を活性化させる高橋 正博<sup>1,2</sup>, 三塚 浩二<sup>2</sup>, 伊藤 明宏<sup>2</sup>, 堀井 明<sup>1</sup>, 福重 真一<sup>1</sup> (<sup>1</sup>東北大・院医・分子病理, <sup>2</sup>東北大・院医・泌尿器科)

**P-1251 Epigenomic alterations during developmental stages of non-inflammatory hepatocellular carcinoma of unknown etiology**

Satomi Makiuchi<sup>1</sup>, Eri Arai<sup>1</sup>, Ying Tian<sup>1</sup>, Noboru Tsuda<sup>1</sup>, Junko Kuramoto<sup>3</sup>, Hidenori Ojima<sup>1</sup>, Yoriko Takahashi<sup>2</sup>, Nobuyoshi Hiraoka<sup>3</sup>, Teruhiko Yoshida<sup>4</sup>, Yae Kanai<sup>1</sup> (<sup>1</sup>Dept. Path., Keio Univ. Sch. of Med., <sup>2</sup>Biomed. Dept., Solution Ctr., Mitsui Knowledge Industry Co., Ltd., <sup>3</sup>Dept. Path. & Clin. Lab., Natl. Cancer Ctr. Hosp., <sup>4</sup>FIOC, Natl. Cancer Ctr. Res. Inst.)

非炎症性病原因不明肝細胞がんの発生過程におけるエピゲノム異常  
牧内 里美<sup>1</sup>, 新井 恵史<sup>1</sup>, 田 迎<sup>1</sup>, 津田 昇<sup>1</sup>, 藏本 純子<sup>1</sup>, 尾島 英知<sup>1</sup>, 高橋 順子<sup>2</sup>, 平岡 伸介<sup>3</sup>, 吉田 輝彦<sup>4</sup>, 金井 弥栄<sup>1</sup> (<sup>1</sup>慶應大・院医・病理, <sup>2</sup>三井情報(株)バイオメディカル室, <sup>3</sup>国立がん研セ・病理, <sup>4</sup>国立がん研セ・FIOC)

**P-1252 Epigenome alterations and histological heterogeneity of non-alcoholic steatohepatitis-related hepatocellular carcinomas**

Noboru Tsuda<sup>1</sup>, Eri Arai<sup>1</sup>, Satomi Makiuchi<sup>1</sup>, Ying Tian<sup>1</sup>, Junko Kuramoto<sup>3</sup>, Yoriko Takahashi<sup>2</sup>, Shinsuke Hiraoka<sup>3</sup>, Teruhiko Yoshida<sup>4</sup>, Yae Kanai<sup>1</sup> (<sup>1</sup>Dept. Path., Keio Univ. Sch. of Med., <sup>2</sup>Biomed. Dept., Solution Ctr., Mitsui Knowledge Industry Co., Ltd., <sup>3</sup>Dept. Path. & Clin. Lab., Natl. Cancer Ctr. Hosp., <sup>4</sup>Fundamental Innovative Oncology Core Ctr., Natl. Cancer Ctr. Res. Inst.)

非アルコール性脂肪性肝炎由来肝細胞がんの組織学的多様性に関する DNA メチル化異常

津田 昇<sup>1</sup>, 新井 恵史<sup>1</sup>, 牧内 里美<sup>1</sup>, 田 迎<sup>1</sup>, 藏本 純子<sup>1</sup>, 高橋 順子<sup>2</sup>, 平岡 伸介<sup>3</sup>, 吉田 輝彦<sup>4</sup>, 金井 弥栄<sup>1</sup> (<sup>1</sup>慶應大・院医・病理, <sup>2</sup>三井情報・ソリューションセ, <sup>3</sup>国立がん研セ・中央病院・病理, <sup>4</sup>国立がん研セ・FIOC)

**P-1253 Dual role of PCDHB15 promoter methylation in gastric cancer**  
Po-Yen Hsu<sup>1</sup>, Yu-Ting Lee<sup>1,2</sup>, Yu-Ming Chuang<sup>1</sup>, Hongchuan Jin<sup>3</sup>, Alfred S.L. Cheng<sup>4</sup>, Enders K.W. Ng<sup>5</sup>, Yin-Chen Chen<sup>1</sup>, Frank Cheng<sup>1</sup>, Michael W. Y. Chan<sup>1</sup> (<sup>1</sup>Dept. Biomed Sci. & CIRAS, Natl. Chung-Cheng Univ., Taiwan, <sup>2</sup>Div. Hematology & Oncology, Chiayi Christian Hosp., Taiwan, <sup>3</sup>Lab of Cancer Biol., Med. Sch. of Zhejiang Univ., China, <sup>4</sup>Sch. of Biomed Sci, Chinese Univ. of Hong Kong, China, <sup>5</sup>Dept. of Surg., Chinese Univ. of Hong Kong, China)

**P-1254 Establishment of DNA methylation diagnostics criteria for urothelial carcinoma of the upper urinary tract**

Mao Fujimoto<sup>1</sup>, Eri Arai<sup>1</sup>, Koji Tsumura<sup>2</sup>, Akiko Maeshima<sup>3</sup>, Hiroyuki Fujimoto<sup>3</sup>, Teruhiko Yoshida<sup>3</sup>, Yae Kanai<sup>1</sup> (<sup>1</sup>Dept. Path., Keio Univ. Sch. Med., <sup>2</sup>Dept. Urol., Grad. Sch. Med., Univ. Tokyo, <sup>3</sup>Dept. Pathol. & Clin. Lab., Natl. Cancer Ctr. Hosp., <sup>4</sup>Dept. Urol., Natl. Cancer Ctr. Hosp., <sup>5</sup>Fund. Innov. Oncol. Core, Natl. Cancer Ctr. Res. Inst.)

DNA メチル化プロファイルに基づく上部尿路がん診断基準の確立  
藤本 真央<sup>1</sup>, 新井 恵史<sup>1</sup>, 津村 功志<sup>2</sup>, 前島 亜希子<sup>3</sup>, 藤元 博行<sup>4</sup>, 吉田 輝彦<sup>5</sup>, 金井 弥栄<sup>1</sup> (<sup>1</sup>慶應大・院医・病理学教室, <sup>2</sup>東京大・院医・泌尿器科学教室, <sup>3</sup>国立がん研セ・中央病院・病理科, <sup>4</sup>国立がん研セ・中央病院・泌尿器科, <sup>5</sup>国立がん研セ・研・FIOC)

**P-1255 Downregulation of HOXD9 is an unfavorable prognostic marker in cholangiocarcinoma**

Wiphawan Wasenang<sup>1,2</sup>, Anucha Puapairoj<sup>3</sup>, Chatri Settasatian<sup>3</sup>, Siriporn Prongvitayita<sup>1,4</sup>, Temduang Limpaboon<sup>1,4</sup> (<sup>1</sup>Ctr. for Res. & Dept. Med. Diagnostic Lab., Thailand, <sup>2</sup>Biomed. Sci., Grad. Sch., Khon Kaen Univ., Thailand, <sup>3</sup>Dept. Path., Faculty of Med., Khon Kaen Univ., Thailand, <sup>4</sup>Cholangiocarcinoma Res. Inst., Faculty of Med., Khon Kaen Univ., Thailand)

## 10 Invasion and metastasis

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

P10-3

**Molecular pathology of cancer behavior (2)**  
がんの浸潤と転移のメカニズム (2)

Chairperson: Kazuo Okamoto (Dept. Osteoimmunol., Grad. Sch. of Med. & Faculty of Med., The Univ. of Tokyo)

座長: 岡本 一男 (東京大・院医・骨免疫学寄付講座)

**P-1256 Interaction of PODXL1 with chemokine receptors impacts on metastasis of PDAC**

Eisaku Kondo, Hidekazu Iioka, Ken Saito (Div. Mol. Cell. Pathol., Niigata Univ. Grad. Sch. Med. Dent. Sci.)

膵がんの転移を制御するポドカリキシンとケモカイン受容体の相互応

近藤 英作, 飯岡 英和, 斎藤 憲 (新潟大・院医・分子細胞病理)

**P-1257 Functional analysis of the prognostic biomarkers actinin-4 and its splice variant**

Nami Miura<sup>1</sup>, Hideki Yamaguchi<sup>2</sup>, Kazufumi Honda<sup>1,3</sup> (<sup>1</sup>Dept. Biomar. Early Det. Cancer, Natl. Cancer Ctr. Res. Inst., <sup>2</sup>Dept. Cancer Cell Res., Sasaki Inst., <sup>3</sup>CREST (AMED, CREST))

予後予測バイオマーカーであるアクチニン-4 とそのスプライスバリアントの機能解析  
三浦 奈美<sup>1</sup>, 山口 英樹<sup>2</sup>, 本田 一文<sup>1,3</sup> (<sup>1</sup>国立がん研セ・研・早期診断, <sup>2</sup>佐々木研・付属研・腫瘍細胞, <sup>3</sup>日本医研開発機構)

**P-1258 Cancer-associated fibroblasts promote the migration and invasion of oral cancer cells via enhancing SOX9 expression**

Kenta Haga<sup>1,2</sup>, Manabu Yamazaki<sup>3</sup>, Satoshi Maruyama<sup>4</sup>, Tadaharu Kobayashi<sup>2</sup>, Jun-ichi Tanuma<sup>3</sup> (<sup>1</sup>Div. Biomimetics, Niigata Univ. Grad. Sch. Med. Dent. Sci., <sup>2</sup>Div. OMS, Niigata Univ. Grad. Sch. Med. Dent. Sci., <sup>3</sup>Div. Oral Pathol., Niigata Univ. Grad. Sch. Med. Dent. Sci., <sup>4</sup>Oral Path. Sec., Dept. Surg. Path., Niigata Univ. Hosp.)

癌関連線維芽細胞は SOX9 を高発現させ口腔癌細胞の遊走および浸潤を促進する

羽賀 健太<sup>1,2</sup>, 山崎 学<sup>3</sup>, 丸山 智<sup>4</sup>, 小林 正治<sup>2</sup>, 田沼 順一<sup>3</sup> (<sup>1</sup>新潟大・院医歯学総合・再生工学, <sup>2</sup>新潟大・院医歯学総合・口腔再建, <sup>3</sup>新潟大・院医歯学総合・口腔病理, <sup>4</sup>新潟大・院医歯学総合病院・歯科病理検査室)

**P-1259 Actin cytoskeleton reorganization mediated by a cellular target of gefitinib**

Masaki Hiramoto<sup>1</sup>, Naoharu Takano<sup>1</sup>, Hiromi Kazama<sup>1</sup>, Hirotsugu Hino<sup>1,2</sup>, Keisuke Miyazawa<sup>1</sup> (<sup>1</sup>Dept. Biochem., Tokyo Med. Univ., <sup>2</sup>Div. Anat. Sci., Dept. Funct. Morphol., Nihon Univ. Sch. Med.)

ゲフィチニブの分子標的によるアクチン細胞骨格の再構成  
平本 正樹<sup>1</sup>、高野 直治<sup>1</sup>、風間 宏美<sup>1</sup>、日野 浩嗣<sup>1,2</sup>、宮澤 啓介<sup>1</sup> (東  
京医大・生化学、<sup>2</sup>日本大・医・機能形態学系・生体構造医学)

P-1260 **A new co-culture model of intrahepatic cholangiocarcinoma organoids and hepatic stellate cells in a microfluidic device**  
Yuta Suda, Yoshimasa Saito, Hidetsugu Saito (Div. Pharmacotherap., Keio Univ. Faculty of Pharm.)

マイクロ流体デバイスを用いた肝内胆管がんオルガノイドと肝星細胞の新しい共培養モデル  
須田 雄大、齋藤 義正、齋藤 英樹 (慶應大・薬・薬治)

P-1261 **CCDC85A is regulated by miR-224 and alters migration and proliferation of pancreatic cancer cells**  
So Takahashi<sup>1,2</sup>, Kurara Takagane<sup>3</sup>, Akiteru Goto<sup>3</sup>, Masamitsu Tanaka<sup>2</sup> (<sup>1</sup>Gastroenterol. & Neurol., Akita Univ., Sch. Med., <sup>2</sup>Mol. Med. & Biochem., Akita Univ., Sch. Med., <sup>3</sup>Cell. & Organ Path., Akita Univ., Sch. Med.)

DIPA family タンパク質 CCDC85A は miR-224 により調節され、癌細胞の移動能及び増殖能を変化させる  
高橋 壮<sup>1,2</sup>、高金 くらら<sup>2</sup>、後藤 明輝<sup>3</sup>、田中 正光<sup>2</sup> (秋田大・医・消化器内科・神経内科、<sup>2</sup>秋田大・医・分子生化学、<sup>3</sup>秋田大・医・器官病態学)

P-1262 **The Rab11-dependent non-canonical EphA2 activation induces cell motility**  
Yue Zhou, Iori Yamahata, Tomohiro Yamamura, Satoru Yokoyama, Hiroaki Sakurai (Dept. Cancer Cell Biol., Univ. Toyama)

非定型的活性型 EphA2 による細胞遊走促進は小胞遊走関連タンパク Rab11 に依存する  
周 越、山畑 伊織、山村 朋弘、横山 悟、櫻井 宏明 (富山大・院薬・がん細胞生物学)

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

**P10-4 Angiogenesis**  
血管新生

Chairperson: Mitsuhiro Osaki (Div. Pathol. Biochem., Faculty of Med., Tottori Univ.)

座長: 尾崎 充彦 (鳥取大・医・病態生化学)

P-1263 **MTA1 is involved in tumor angiogenesis via interaction with S100A4 in endothelial cells**  
Mizuho Ishikawa<sup>1</sup>, Mitsuhiro Osaki<sup>1,2</sup>, Makoto Yamagishi<sup>3</sup>, Kunishige Onuma<sup>1</sup>, Futoshi Okada<sup>1,2</sup>, Hideya Endo<sup>4</sup> (<sup>1</sup>Div. Pathol. Biochem., Fac. Med., Tottori Univ., <sup>2</sup>Chr. Chromo. Engineering, Tottori Univ., <sup>3</sup>DCBMS, Grad. Sch. Front. Sci., The Univ. of Tokyo, <sup>4</sup>Dept. Cancer Biol., Inst. Med. Sci., The Univ. of Tokyo)

血管内皮細胞における MTA1 と S100A4 の相互作用は腫瘍内血管新生に関与する  
石川 瑞穂<sup>1</sup>、尾崎 充彦<sup>1,2</sup>、山岸 誠<sup>3</sup>、小沼 邦重<sup>1</sup>、岡田 太<sup>1,2</sup>、遠藤 英也<sup>4</sup> (鳥取大・医・病態生化学、<sup>2</sup>鳥取大・染色体工学研究セ、<sup>3</sup>東京大・院・新領域・メディカル情報生命、<sup>4</sup>東京大・医科研・分子発癌分野)

P-1264 **Withdrawn**

P-1265 **Macrolide antibiotics affect gene expression on angiogenesis and histamine receptors in oral cancer cell lines**  
Masahito Ogasawara<sup>1</sup>, Masahiro Yamashita<sup>2</sup>, Makoto Maemondo<sup>2</sup> (<sup>1</sup>Div. Bioreg., Dept. Pharm. Iwate Med. Univ., <sup>2</sup>Div. Pulmonary Med. Dept. Int. Med. Iwate Med. Univ.)

マクロライド系抗生薬の口腔癌に対する効果  
小笠原 正人<sup>1</sup>、山下 雅大<sup>2</sup>、前門戸 任<sup>2</sup> (岩手医大・薬理・病態制御、<sup>2</sup>岩手医大・医・呼吸器)

P-1266 **NDRG1 is indispensable for VEGF-A-induced tumor angiogenesis by PLCγ/ERK signal activation in vascular endothelial cells**  
Kosuke Watari<sup>1</sup>, Tomohiro Shibata<sup>1</sup>, Hiroshi Nabeshima<sup>1</sup>, Akihiko Kawahara<sup>2</sup>, Yuichi Murakami<sup>1,3</sup>, Michihiko Kuwano<sup>3</sup>, Mayumi Ono<sup>1</sup> (<sup>1</sup>Dept. Pharm. Oncology, Grad. Sch. Pharm. Sci., Kyushu Univ., <sup>2</sup>Dept. Diagnostic Pathol., Kurume Univ. Hosp., <sup>3</sup>Cancer Translational Res. Ctr., St. Mary's Inst. Health Sci.)

血管内皮細胞における NDRG1 は VEGF-A 誘導の PLCγ/ERK シグナルを活性化し、がん血管新生を促進する  
渡 公佑<sup>1</sup>、柴田 智博<sup>1</sup>、鍋島 弘嗣<sup>1</sup>、河原 明彦<sup>2</sup>、村上 雄一<sup>1,3</sup>、桑野 信彦<sup>3</sup>、小野 真弓<sup>1</sup> (九州大・院薬・創薬腫瘍科学講座、<sup>2</sup>久留米大・病院・病理、<sup>3</sup>聖マリア健康科学研)

P-1267 **Increased ABCB1 expression in tumor blood vessels of urothelial carcinoma after chemotherapy**  
Hiroshi Kikuchi<sup>1</sup>, Nako Maishi<sup>1</sup>, Masahiro Morimoto<sup>1</sup>, Hirofumi Morimoto<sup>1</sup>, Kunihiko Tsuchiya<sup>2</sup>, Takashige Abe<sup>3</sup>, Yasuhiro Hida<sup>3</sup>, Toru Harabayashi<sup>3</sup>, Yoshihiro Matsuno<sup>4</sup>, Nobuo Shinohara<sup>3</sup>, Kyoko Hida<sup>1</sup> (<sup>1</sup>Dept. Oral Pathol. Biol., Hokkaido Univ. Grad. Sch. Dent. Med., <sup>2</sup>Dept. Urol., Hokkaido Univ. Grad. Sch. Med., <sup>3</sup>Dept. CV & Thoracic Surg., Hokkaido Univ. Grad. Sch. Med., <sup>4</sup>Dept. Surg Pathol., Hokkaido Univ. Hosp., <sup>5</sup>Dept. Urol., Hokkaido Canc. Ctr.)

尿路上皮癌における抗癌剤治療後の腫瘍血管 ABCB1 発現亢進  
菊地 央<sup>1</sup>、間石 奈湖<sup>1</sup>、森本 真弘<sup>1</sup>、森本 浩史<sup>1</sup>、土屋 邦彦<sup>2</sup>、安部 崇重<sup>2</sup>、樋田 泰浩<sup>3</sup>、原林 透<sup>5</sup>、松野 吉宏<sup>4</sup>、篠原 信雄<sup>2</sup>、樋田 京子<sup>1</sup> (北海道大・歯・口腔病理、<sup>2</sup>北海道大・医・腎臓、<sup>3</sup>北海道大・医・循・呼外、<sup>4</sup>北海道大・病理、<sup>5</sup>北海道がんセンター・腎臓)

P-1268 **A novel endothelial cell specific-gene, DESM, regulated pathological angiogenesis**  
Yuri Miyamura, Masashi Muramatsu, Takashi Minami (Div. Mol. Vas. Bio., Pharm. /IRDA, Kumamoto Univ.)

内皮特異的に発現する新規遺伝子 DESM は病的血管新生を制御する  
宮村 優里、村松 昌、南 敬 (熊本大・院薬/生命資源セ・分子血管)

P-1269 **Effect of cancer-associated fibroblasts on proliferation of lymphatic vessels in malignant melanoma**  
Shusaku Maeda<sup>1</sup>, Masakazu Yashiro<sup>2</sup>, Hisashi Motomura<sup>1</sup>, Takaharu Hatano<sup>1</sup>, Heishiro Fujikawa<sup>1</sup> (<sup>1</sup>Dept. Plast. Surg., Osaka City Univ. Grad. Sch. Med., <sup>2</sup>Dept. Oncol. Surg., Osaka City Univ. Grad. Sch. Med.)

悪性黒色腫における癌関連線維芽細胞のリンパ管内皮細胞に対する影響の検討  
前田 周作<sup>1</sup>、八代 正和<sup>2</sup>、元村 尚嗣<sup>1</sup>、羽多野 隆治<sup>1</sup>、藤川 平四朗<sup>1</sup> (大阪大・医・形成外科、<sup>2</sup>大阪大・医・腫瘍外科)

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

**P10-5 New methods for studying invasion and metastasis**  
新たな浸潤・転移実験法

Chairperson: Hidetoshi Eguchi (Dept. Gastroenterological Surg., Grad. Sch. of Med., Osaka Univ.)

座長: 江口 英利 (大阪大・院・消化器外科学)

P-1270 **Multicolor fluorescent imaging analysis of peritoneally disseminated tumors of scirrhous gastric carcinoma**

Makoto Miyazaki<sup>1</sup>, Shingo Miyamoto<sup>1</sup>, Kazuyoshi Yanagihara<sup>2</sup>, Kiyoko Fukami<sup>3</sup>, Hideki Yamaguchi<sup>1</sup> (<sup>1</sup>Dept. Cancer Cell Res., Sasaki Inst., Sasaki Foundation, <sup>2</sup>Div. Biomarker Discovery, EPOC, Natl. Cancer Ctr., <sup>3</sup>Lab. of Genome & Biosignals, Tokyo Univ. Pharm. Life Sci.)  
マルチカラー蛍光イメージングを用いたスキルス胃癌腹膜播種機構の解析  
宮崎 允<sup>1</sup>、宮本 真吾<sup>1</sup>、柳原 五吉<sup>2</sup>、深見 希代子<sup>3</sup>、山口 英樹<sup>1</sup> (佐々木研・附属研・腫瘍細胞、<sup>2</sup>国立がん研セ・先端医療開発セ、<sup>3</sup>東薬大・生命科学・ゲノム病態医学)

P-1271 **Preparation of human T cell-derived exosomes with high purity and quality for clinical use against advanced tumor**

Naohiro Seo<sup>1,2</sup>, Junko Nakamura<sup>1</sup>, Fumiyasu Momose<sup>1</sup>, Asako Shimoda<sup>3</sup>, Kazunari Akiyoshi<sup>2,3</sup>, Tsuguhiko Kaneda<sup>1</sup>, Hiroshi Shiku<sup>1</sup> (<sup>1</sup>Dept. Immunogen. Ther., Mie Univ. Grad. Sch. Med., <sup>2</sup>JST CREST, <sup>3</sup>Dept. Polymer Chem., Grad. Sch. Engineering, Kyoto Univ.)  
進行癌治療に応用可能な高い精製度と質を備えたヒトT細胞エクソソームの調製法  
瀬尾 尚宏<sup>1,2</sup>、中村 純子<sup>1</sup>、百瀬 文康<sup>1</sup>、下田 麻子<sup>3</sup>、秋吉 一成<sup>2,3</sup>、金田 次弘<sup>1</sup>、珠玖 洋<sup>1</sup> (三重大・医・遺伝子・免疫細胞治療学、<sup>2</sup>JST・CREST、<sup>3</sup>京都大・工・高分子化学)

P-1272 **Mechanism for intestinal tumor metastasis by polyclonal origins**  
SauYee Kok<sup>1</sup>, Hiroko Oshima<sup>1,2</sup>, Eri Sakai<sup>1</sup>, Mizuho Nakayama<sup>1,2</sup>, Masanobu Oshima<sup>1,2</sup> (<sup>1</sup>Div. Genetics, Cancer Res. Inst., Kanazawa Univ., <sup>2</sup>WPI NanoLSI, Kanazawa Univ.)

がん転移における遺伝的多様性の役割  
SauYee Kok<sup>1</sup>、大島 浩子<sup>1,2</sup>、坂井 絵梨<sup>1</sup>、中山 瑞穂<sup>1,2</sup>、大島 正伸<sup>1,2</sup> (金沢大・がん研・腫瘍遺伝、<sup>2</sup>金沢大・WPI-NanoLSI)

P-1273 **Separation and analysis of CTC in mouse metastasis model using oral cancer cells**

Yoshiaki Matsumura<sup>1</sup>, Koji Takata<sup>2</sup>, Kenichi Kume<sup>1</sup>, Mahiro Beppu<sup>1</sup>, Mayumi Yamashita<sup>1</sup>, Toyoshi Sugiura<sup>1</sup> (<sup>1</sup>Dept. Oral. Surg., Kagoshima Univ. Hosp., <sup>2</sup>Toyama Indus. Technol. R&D Ctr.)  
口腔癌細胞を用いたマウス転移モデルにおける CTC の分離と解析  
松村 吉晃<sup>1</sup>、高田 耕児<sup>2</sup>、久米 健一<sup>1</sup>、別府 真広<sup>1</sup>、山下 麻由美<sup>1</sup>、杉

浦 剛<sup>1</sup> (1鹿児島大・病院・口腔外科, 2富山県産技研)

**P-1274 Establishment and Characterization of Luminal Osteolytic Breast Cancer Cell Using Intra-Caudal Arterial Injection**

Yuxuan Han<sup>1</sup>, Jun Nakayama<sup>1,2</sup>, Mitsuru Futakuchi<sup>3</sup>, Emi Ito<sup>4</sup>, Shinya Watanabe<sup>5</sup>, Kentaro Semba<sup>1,4</sup> (1Dept. Life Sci. & Med. Biosci., Waseda Univ., 2CBBD-OIL, AIST, 3Dept. Path., Nagasaki Univ., 4TR Ctr., Fukushima Med. Univ.)

**尾動脈注射手法を用いた溶骨性 luminal 乳がん細胞株の樹立と性状解析**

韓 宇軒<sup>1</sup>、中山 淳<sup>1,2</sup>、二口 充<sup>3</sup>、伊藤 恵美<sup>4</sup>、渡辺 慎哉<sup>4</sup>、仙波 憲太郎<sup>1,4</sup> (1早稲田大・先進理工・生命医科, 2産総研・CBBD-OIL, 3長崎大・病理学, 4福島医大・TR セ)

**P-1275 NIR Luciferin Analogues for *in vivo* Optical Imaging**

Nobuo Kitada<sup>1</sup>, Ryohei Saito<sup>1</sup>, Takahiro Kuchimaru<sup>4</sup>, Shinac Kizaka-Kondoh<sup>5</sup>, Jun Nakayama<sup>2</sup>, Kentaro Semba<sup>3</sup>, Shojiro Maki<sup>1,2</sup> (1Dept. Sci. Eng., UEC, 2CNBE, UEC, 3Dept. Life Sci. & Med. Biosci., Waseda Univ., 4Ctr. for Mol. Med., Jichi Med. Univ., 5Sch. of Life Sci. & Tech., Tokyo Tech)

***in vivo* 光イメージングを志向した NIR ルシフェリンアナログ**

北田 昇雄<sup>1</sup>、齋藤 亮平<sup>1</sup>、二口 高弘<sup>4</sup>、近藤 科江<sup>5</sup>、中山 淳<sup>3</sup>、仙波 憲太郎<sup>3</sup>、牧 昌次郎<sup>1,2</sup> (1電通大・情報理工, 2電通大・脳医工学, 3早稲田大・先進理工・生命医科, 4自治医大・分子病態研, 5東工大・生命理工)

**P-1276 Generation of cancer vascular invasion model with 3D culture method**

Kiminori Yanagisawa<sup>1,2</sup>, Masamitsu Konno<sup>2,3</sup>, Tsunekazu Mizushima<sup>1</sup>, Taroh Satoh<sup>3</sup>, Michiya Matsuzaki<sup>4</sup>, Masaki Mori<sup>5</sup>, Yuichiro Doki<sup>1,2,3</sup>, Hideshi Ishii<sup>2,3</sup> (1Dept. Gastroenterologicalsurg., Osaka Univ., Sch. Med., 2Dept. Med. Data Sci., Osaka Univ., Sch. Med., 3Dept. Cancer & Chemother., Osaka Univ., Sch. Med., 4Dept. Applied Chem., Osaka Univ., Sch. Engineering, 5Dept. Surg. & Sci., Kyushu Univ., Sch. Med.)

**3D 培養を利用した癌血管浸潤モデルの作成**

柳澤 公紀<sup>1,2</sup>、今野 雅允<sup>2,3</sup>、水島 恒和<sup>1</sup>、佐藤 太郎<sup>3</sup>、松崎 典弥<sup>4</sup>、森 正樹<sup>5</sup>、土岐 祐一郎<sup>1,2,3</sup>、石井 秀始<sup>2,3</sup> (1大阪大・医・消化器外科, 2大阪大・医・疾患データサイエンス, 3大阪大・医・先進癌薬物療法開発, 4大阪大・工・応用化学有機工業化学, 5九州大・医・消化器・総合外科)

## 11 Characteristics of cancer cells

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

**P11-5 Cancer stem cell (3)**  
がん幹細胞 (3)

Chairperson: Masaharu Seno (Grad. Sch. of Interdisciplinary Sci. & Engineering in Health Systems, Okayama Univ.)

座長: 妹尾 昌治 (岡山大・院ヘルスシステム統合科学研究科)

**P-1277 The role of CD44 variants and xCT in therapy resistance of canine tumors**

Atsushi Tanabe, Juri Ichige, Akihiro Kawanami, Hitoshi Yamaga, Hiroeki Sahara (Lab. Biol., Azabu Univ. Sch. Vet. Med.)

**イヌ癌の治療抵抗性における CD44 バリエントと xCT の役割**

田辺 敦、市毛 樹梨、河南 輝大、山我 仁志、佐原 弘益 (麻布大・獣医・生物学)

**P-1278 Linoleic acid-related signal pathway associated with dormant stemness**

Ruiko Ogata, Shiori Mori, Rina Tani, Shingo Kishi, Yi Luo, Takamitsu Sasaki, Hiroki Kuniyasu (Dept. Molpatho., Nara Med. Univ.)

**リノール酸による休止性幹細胞関連シグナル経路の検討**

緒方 瑠衣子、森 汐莉、谷 里奈、岸 真五、羅 奕、佐々木 隆光、國安 弘基 (奈良医大・分子病理)

**P-1279 The role of Lgr5 as cancer stem cell in gastric cancer and regulatory mechanism**

Yumi Terakado<sup>1</sup>, Kazuhiro Murakami<sup>1</sup>, Hiroko Oshima<sup>2</sup>, Masanobu Oshima<sup>2</sup>, Nick Barker<sup>1,3</sup> (1Div. Epithelial Stem Cell Biol., CRI, Kanazawa Univ., 2Div. Genet., CRI, Kanazawa Univ., 3Inst. of Med. Biology., Singapore)

**胃がんにおける Lgr5 のがん幹細胞としての役割とその制御機構**

寺門 侑美、村上 和弘<sup>1</sup>、大島 浩子<sup>2</sup>、大島 正伸<sup>2</sup>、Nick Barker<sup>1,3</sup> (1金沢大・がん研・上皮幹細胞, 2金沢大・がん研・腫瘍遺伝, 3Inst. of Med. Biology., Singapore)

**P-1280 Analysis of molecular mechanism by HIF-1a in gefitinib-resistance acquisition in lung cancer**

Chisato Iwabuchi, Nobuyuki Tanaka (Dept. Mol. Onc., Int. Adv. Med., Nippon Med. Sch.)

**肺癌における転写制御因子 HIF-1a の薬剤耐性獲得機構と癌幹細胞維持機構の解析**

岩淵 千里、田中 信之 (日本医大・先端研・遺伝子)

**P-1281 Identification of BCAAs metabolism pathway as a common machinery for maintaining the stemness of human colorectal cancer**

Fumiyasu Hanamura<sup>1</sup>, Yoshikane Kikushige<sup>1</sup>, Eishi Baba<sup>2</sup>, Koichi Akashi<sup>1</sup> (1Dept. Med. & Bio Sci., Kyushu Univ., Grad Sch., 21 Dept. Social & Enviro Med., Kyushu Univ., Grad Sch.)

**ヒト大腸癌における分岐鎖アミノ酸代謝経路の役割の解明**

花村 文康<sup>1</sup>、菊繁 吉謙、馬場 英司<sup>2</sup>、赤司 浩一<sup>1</sup> (1九州大・医・病態修復内科 (第一内科), 2九州大・医・社会環境医学)

**P-1282 Plasminogen activator inhibitor is a novel indicator of cancer stem cell tumorigenicity in multiple cancer types**

In-Sun Hong<sup>1</sup> (1Dept. Health Sci. & Tech., GAIHST, Gachon Univ., 2Dept. Mol. Med., Sch. of Med., Gachon Univ.)

Room P(A) Sep. 26 (Thu.) 17:15-18:00

E/J

**P11-6 Cell-cell communication in cancer development**  
がん発生における細胞間コミュニケーション

Chairperson: Tatsushi Igaki (Lab. of Genetics, Kyoto Univ. Grad. Sch. of Biostudies)

座長: 井垣 達史 (京都大・院生命)

**P-1283 Bone metastasis model in prostate cancer by side contentous connecting co-culture with three types of cells**

Kagenori Ito<sup>1,2</sup>, Yusuke Yamamoto<sup>1</sup>, Fumihiko Urabe<sup>2</sup>, Takahiro Kimura<sup>2</sup>, Shin Egawa<sup>2</sup>, Takahiro Ochiya<sup>3</sup> (1Div. Cell. Sig., Natl. Cancer Ctr. Res. Inst., 2Dept. Urology, Jikei Univ., Sch. Med., 3Dept. Mol. Cell. Med., Inst. Med. Sci, Tokyo Med.)

**三種の細胞を用いた共培養による骨転移モデル作成**

伊藤 景紀<sup>1,2</sup>、山本 雄介<sup>1</sup>、占部 文彦<sup>2</sup>、木村 高弘<sup>2</sup>、颯川 晋<sup>2</sup>、落谷 孝広<sup>3</sup> (1国立がん研セ・研・細胞情報, 2慈恵医大・泌尿器科, 3東京医大・医総研・分子細胞治療)

**P-1284 Co-culture Assay of Breast Cancer and Stromal Cells using Spheroid Microplates and HTS Transwell Permeable Supports**

Akiko Taguchi (CORNING)

**スフェロイドマイクロプレートと HTS Transwell を用いた乳癌と間質細胞の共培養アッセイ**

田口 亜紀子 (コーニングインターナショナル (株))

**P-1285 A novel technology for optically labeling stromal cells interacting with cancer cells in the metastatic microenvironment**

Misa Minegishi<sup>1,2</sup>, Shinac Kizaka-Kondoh<sup>1</sup>, Takahiro Kuchimaru<sup>2</sup> (1Tokyo Tech., Sch. of Life Sci. & Tech., 2Jichi Med. Univ., Ctr. for Mol. Med.)

**転移微小環境においてがん細胞と相互作用する間質細胞を光標識する新規技術**

峯岸 美紗<sup>1,2</sup>、近藤 科江<sup>1</sup>、二口 高弘<sup>2</sup> (1東工大・生命理工, 2自治医大・分子病態治療研究セ)

**P-1286 Overexpression of CADM1 enhances the malignant features of small cell lung cancer**

Toko Funaki, Takeshi Ito, Yoshinori Murakami (Div. Mol. Path., Inst. of Med. Sci., Tokyo Univ.)

**小細胞肺がんの悪性化における細胞接着分子 CADM1 の機能解析**

船城 桐子、伊東 剛、村上 善則 (東京大・医科研・人癌)

**P-1287 The biological features of exosomes secreted from highly metastatic mouse mammary carcinomas**

Yuko Ito<sup>1</sup>, Masa-aki Shibata<sup>2</sup>, Kohei Taniguchi<sup>1</sup>, Yukihiko Akao<sup>3</sup>, Kazuhisa Uciyama<sup>1</sup> (1Dept. Dept. Gastro Surg., Osaka Med. College, 2Dept. Anatomy & Cell Biol., Div. Life Sci., Osaka Med. College, 3Uni. Grad. Sch., Drug. Med. Info. Sci., Gifu Univ.)

**高転移性マウス乳癌細胞が分泌するエクソソームの生物学的特徴について**

伊藤 裕子<sup>1</sup>、柴田 雅朗<sup>2</sup>、谷口 高平<sup>1</sup>、赤尾 幸博<sup>3</sup>、内山 和久<sup>1</sup> (1大阪医大・医・消化器外科, 2大阪医大・医・解剖学, 3岐阜大・連創・医療情報研究科)



P-1288 **Influence of gemcitabine on secretion from and surface marker expression of exosomes in pancreatic cancer cells**  
 Satoko Yamamoto<sup>1</sup>, Yoichi Matsuo<sup>2</sup>, Yuichi Hayashi<sup>2</sup>, Toshinari Minamoto<sup>3</sup>, Takeo Shimasaki<sup>1</sup> (<sup>1</sup>Med. Res. Inst., Kanazawa Med. Univ., <sup>2</sup>Gastro. Sur. Nagoya City Univ., <sup>3</sup>Div. Transl. Clin. Oncol., Cancer Res. Inst., Kanazawa Univ.)  
 抗がん剤ゲムシタピンによる膵がん細胞のエクソソーム分泌及びエクソソーム表面マーカーへの影響  
 山本 聡子<sup>1</sup>、松尾 洋一<sup>2</sup>、林 祐一<sup>2</sup>、源 利成<sup>3</sup>、島崎 猛夫<sup>1</sup> (<sup>1</sup>金沢医大・総医研、<sup>2</sup>名古屋市大・消外、<sup>3</sup>金沢大・がん研・腫瘍制御)

P-1289 **Extracellular vesicles derived from cancer-associated fibroblasts inhibit NK cell anti-tumor activity**  
 Tomohiro Umezumi<sup>1</sup>, Kazuma Ohyashiki<sup>2</sup>, Masahiko Kuroda<sup>1</sup> (<sup>1</sup>Dept. Mol. Pathol., Tokyo Med. Univ., <sup>2</sup>Tokyo Med. Univ.)  
 がん間質由来細胞外小胞がNK細胞の抗腫瘍効果を抑制する  
 梅津 知宏<sup>1</sup>、大屋敷 一馬<sup>2</sup>、黒田 雅彦<sup>1</sup> (<sup>1</sup>東京医大・医・分子病理、<sup>2</sup>東京医大・医)

Room P(A) Sep. 26 (Thu.) 17:15-18:00 E/J  
**P11-7 PDX and organoid**  
 PDXとオルガノイド

Chairperson: Tadashi Kondo (Div. of Rare Cancer Res., Natl. Cancer Ctr. Res. Inst.)  
 座長: 近藤 格 (国立がん研セ・研・希少がん研究分野)

P-1290 **Novel drug development platform: constructing a data base of PDXs and cell lines from the same gastric primary tumors**  
 Yuki Iino<sup>1</sup>, Takeshi Kuwata<sup>2,3</sup>, Teruo Komatsu<sup>1</sup>, Kazuyoshi Yanagihara<sup>1</sup>, Atsushi Ochiai<sup>1</sup> (<sup>1</sup>Div. Biomarker Discovery, EPOC, Natl. Cancer Ctr., <sup>2</sup>Dept. Path. Clin. Lab., EPOC, Natl. Cancer Ctr., <sup>3</sup>Dept. Path. Clin. Lab., Natl. Cancer Ctr. Hosp. East.)  
 胃癌治療のための新しい薬物開発プラットフォーム: 同一原発腫瘍からのPDX及びそれに由来する細胞株のデータベース構築  
 飯野 由貴<sup>1</sup>、桑田 健<sup>2,3</sup>、小松 輝夫<sup>1</sup>、柳原 五吉<sup>1</sup>、落合 淳志<sup>1</sup> (<sup>1</sup>国立がん研セ・先端医療開発セ、<sup>2</sup>国立がん研セ・先端医療開発セ、<sup>3</sup>国立がん研セ・東病院)

P-1291 **Characterization of floating round cells in the human pancreatic cancer cell line, MIA PaCa-2**  
 Fujiya Gomi<sup>1</sup>, Norihiko Sasaki<sup>1</sup>, Kaiyo Takubo<sup>1</sup>, Junko Aida<sup>1</sup>, Tomio Arai<sup>2</sup>, Toshiyuki Ishiwata<sup>1</sup> (<sup>1</sup>Res. Team for Geriatric Pathol. Tokyo Met. Inst. Gerontol., <sup>2</sup>Res. Team for Geriatric Med. Tokyo Met. Inst. Gerontol., <sup>3</sup>Dept. Pathol. Tokyo Met. Geriat. Hosp.)  
 膵癌細胞 MIA PaCa-2 浮遊細胞の特徴  
 五味 不二也<sup>1</sup>、佐々木 紀彦<sup>2</sup>、田久保 海誉<sup>1</sup>、相田 順子<sup>1</sup>、新井 富生<sup>3</sup>、石渡 俊行<sup>1</sup> (<sup>1</sup>都健康長寿医療セ・研・高齢者がん、<sup>2</sup>都健康長寿医療セ・研・血管医学、<sup>3</sup>東京都健康長寿医療セ・病理診断科)

P-1292 **Establishment of PDX-derived salivary gland adenoid cystic carcinoma cell lines using organoid culture method**  
 Kentaro Takada<sup>1</sup>, Yoshihiro Aizawa<sup>1</sup>, Daisuke Sano<sup>1</sup>, Ryo Okuda<sup>2</sup>, Keisuke Sekine<sup>2</sup>, Yasuhiro Ueno<sup>2</sup>, Jun Aoyama<sup>1</sup>, Hideki Taniguchi<sup>2</sup>, Nobuhiko Oridate<sup>1</sup> (<sup>1</sup>Dept. Head & Neck Surg., Yokohama City Univ., Sch. Med., <sup>2</sup>Dept. Regenerative Med., Yokohama City Univ., Sch. Med.)  
 オルガノイド培養法を用いたPDX由来唾液腺腺様嚢胞癌の癌細胞株作製  
 高田 顕太郎<sup>1</sup>、相澤 圭洋<sup>1</sup>、佐野 大佑<sup>1</sup>、奥田 諒<sup>2</sup>、関根 圭輔<sup>2</sup>、上野 康晴<sup>2</sup>、青山 準<sup>1</sup>、谷口 英樹<sup>2</sup>、折館 伸彦<sup>1</sup> (<sup>1</sup>横浜市大・医・耳鼻咽喉科、<sup>2</sup>横浜市大・医・臓器再生)

P-1293 **Characterization of a newly established cell line (UROC-2) originating from a human metastatic renal cell carcinoma**  
 Takashi Yamada (Dept. Pathol., Osaka Med. college)  
 新たに樹立したヒト転移腎細胞癌由来培養細胞株(UROC-2)の樹立とその性状  
 山田 隆司 (大阪医大・医・病理)

P-1294 **Organoid culture of pancreatic acinar cell carcinoma**  
 Daisuke Hoshi<sup>1</sup>, Emiri Kita<sup>1,2</sup>, Yoshiaki Maru<sup>1</sup>, Yoshitaka Hippo<sup>1</sup> (<sup>1</sup>Div. Mol. Carcin., Chiba Can. Ctr. Res. Inst., <sup>2</sup>Dept. Gastroenterol., Chiba Can. Ctr.)  
 膵腺房細胞癌のオルガノイド培養  
 星 大輔<sup>1</sup>、喜多 絵美里<sup>1,2</sup>、丸 喜明<sup>1</sup>、筆宝 義隆<sup>1</sup> (<sup>1</sup>千葉県がんセ・研・発がん制御、<sup>2</sup>千葉県がんセ・消化器内科)

## 12 Cancer immunity

Room P(A) Sep. 26 (Thu.) 17:15-18:00 E/J  
**P12-2 Tumor antigen / effector**  
 標的抗原・エフェクター

Chairperson: Keiko Udaka (Dept. Immunol., Sch. of Med., Kochi Univ.)  
 座長: 宇高 恵子 (高知大・医・免疫学)

P-1295 **Trial of Locoregional TCR analysis in Esophageal Squamous Cell Carcinoma**  
 Tomoya Sudo<sup>1,2</sup>, Jun Akiba<sup>1,2</sup>, Hiroyuki Nakane<sup>1</sup>, Haruhiro Hino<sup>1</sup>, Yuya Tanaka<sup>1</sup>, Hideaki Kaku<sup>1</sup>, Suguru Ogata<sup>1</sup>, Taizan Minami<sup>1</sup>, Kouhei Saisho<sup>1</sup>, Satoru Matono<sup>1</sup>, Naoki Mori<sup>1</sup>, Akira Yamada<sup>3</sup>, Yoshito Akagi<sup>1</sup> (<sup>1</sup>Dept. Surg. Kurume Univ. Sch. of Med., <sup>2</sup>Res. Ctr. for Innovative Cancer Therapy, Kurume Univ., <sup>3</sup>Dept. Pathol. Kurume Univ. Sch. of Med.)  
 食道扁平上皮癌局所における腫瘍局所のTCR解析の試み  
 主藤 朝也<sup>1,2</sup>、秋葉 純<sup>1,2</sup>、中根 浩幸<sup>1</sup>、日野 東洋<sup>1</sup>、田中 侑哉<sup>1</sup>、加来 秀彰<sup>1</sup>、緒方 傑<sup>1</sup>、南 泰山<sup>1</sup>、最所 公平<sup>1</sup>、の野 吾<sup>1</sup>、森 直樹<sup>1</sup>、山田 亮<sup>3</sup>、赤木 由人<sup>1</sup> (<sup>1</sup>久留米大・外科学講座、<sup>2</sup>久留米大・先端癌治療研究セ、<sup>3</sup>久留米大・病院病理部)

P-1296 **Tumor-infiltrating CD8+ T cell recognizes an intra-tumor neoantigen of clear cell renal cell carcinoma**  
 Masahiro Matsuki<sup>1,2,3</sup>, Yoshihiko Hirohashi<sup>1</sup>, Terufumi Kubo<sup>1</sup>, Munehide Nakatsugawa<sup>1,4</sup>, Takayuki Kanaseki<sup>1</sup>, Tomohide Tsukahara<sup>1</sup>, Toshiaki Tanaka<sup>2</sup>, Naoya Masumori<sup>2</sup>, Toshihiko Torigoe<sup>1</sup> (<sup>1</sup>Dept. Path., Sapporo Med. Univ. Sch. of Med., <sup>2</sup>Dept. Urology, Sapporo Med. Univ. Sch. of Med., <sup>3</sup>Dept. Urology, NTT-East Corporation Sapporo Med. Ctr., <sup>4</sup>Dept. Path., Tokyo Med. Univ. Hachioji Med. Ctr.)  
 腎細胞癌における腫瘍浸潤リンパ球は腫瘍内不均一抗原を認識する  
 松本 雅裕<sup>1,2,3</sup>、廣橋 良彦<sup>1</sup>、久保 輝文<sup>1</sup>、中津川 宗秀<sup>1,4</sup>、金関 貴幸<sup>1</sup>、塚原 智英<sup>1</sup>、田中 俊明<sup>2</sup>、舛森 直哉<sup>2</sup>、鳥越 俊彦<sup>1</sup> (<sup>1</sup>札幌医大・病理学第一講座、<sup>2</sup>札幌医大・泌尿器科学講座、<sup>3</sup>NTT 東日本札幌病院・泌尿器科、<sup>4</sup>東京医大・八王子医療セ・病理診断科)

P-1297 **The analysis of human innate lymphoid cells in colorectal cancer**  
 Atsuyo Ikeda<sup>1</sup>, Takayuki Ogino<sup>1</sup>, Yoshifumi Watanabe<sup>1</sup>, Shiki Fujino<sup>1</sup>, Hidekazu Takahashi<sup>1</sup>, Norikatsu Miyoshi<sup>1</sup>, Mamoru Uemura<sup>1</sup>, Chu Matsuda<sup>1</sup>, Hirofumi Yamamoto<sup>1</sup>, Tsunekazu Mizushima<sup>1</sup>, Masaki Mori<sup>2</sup>, Yuichiro Doki<sup>1</sup> (<sup>1</sup>Dept. Gastroenterol. Surg. Osaka Univ., <sup>2</sup>Dept. Surg. Science. Kyusyu. Univ.)  
 ヒト大腸癌における自然リンパ球の解析  
 池田 敦世<sup>1</sup>、荻野 崇之<sup>1</sup>、渡部 嘉文<sup>1</sup>、藤野 志季<sup>1</sup>、高橋 秀和<sup>1</sup>、三吉 範克<sup>1</sup>、植村 守<sup>1</sup>、松田 宙<sup>1</sup>、山本 浩文<sup>1</sup>、水島 恒和<sup>1</sup>、森 正樹<sup>2</sup>、土岐 祐一郎<sup>1</sup> (<sup>1</sup>大阪大・消化器外科、<sup>2</sup>九州大・消化器・総合外科)

P-1298 **HLA ligand repertoire of primary colorectal cancer**  
 Satoru Matsumoto<sup>1,2</sup>, Takayuki Kanaseki<sup>1</sup>, Toshihiko Torigoe<sup>1</sup> (<sup>1</sup>Sapporo Med. Univ. Sch. of Med. Dept. Path., <sup>2</sup>IMS Sapporo Digestive Disease Ctr. General Hosp.)  
 大腸癌組織におけるHLAリガンドレパートリー  
 松本 哲<sup>1,2</sup>、金関 貴幸<sup>1</sup>、鳥越 俊彦<sup>1</sup> (<sup>1</sup>札幌医大・第一病理学講座、<sup>2</sup>イムス札幌消化器中央総合病院)

P-1299 **An open-label trial of cancer vaccination by fusion cells from patient-derived ovarian cancer cells and dendritic cells**  
 Kyoso Ishida<sup>1,2</sup>, Tomoyuki Nishikawa<sup>1</sup>, Aasa Shimizu<sup>2</sup>, Kenjiro Sawada<sup>2</sup>, Tadashi Kimura<sup>2</sup>, Yasufumi Kaneda<sup>1</sup> (<sup>1</sup>Div. Gene Therapy Sci., Osaka Univ. Grad. Sch. Med., <sup>2</sup>Dept. Obstet. Gynecol., Osaka Univ. Grad. Sch. Med.)  
 卵巣癌患者を対象とした患者由来不活化卵巣癌細胞と樹状細胞の融合細胞を用いたがんワクチン療法オープンラベル試験  
 石田 享相<sup>1,2</sup>、西川 智之<sup>1</sup>、清水 亜麻<sup>2</sup>、澤田 健二郎<sup>2</sup>、木村 正<sup>2</sup>、金田 安史<sup>1</sup> (<sup>1</sup>大阪大・医・遺伝子治療、<sup>2</sup>大阪大・医・産婦人科)

Room P(A) Sep. 26 (Thu.) 17:15-18:00 E/J  
**P12-3 Novel approaches in cancer immunotherapy**  
 がん免疫療法の新戦略

Chairperson: Kazuhiko Kakimi (Dept. Immunotherapeutics, The Univ. of Tokyo Hosp.)  
 座長: 垣見 和宏 (東京大・医・附属病院)

P-1300 **Analysis of exsomes with tetraspanin-knocked out cells**  
 Kouki Okita<sup>1,2</sup>, Kazuki Imai<sup>1</sup>, Akitaka Yamasaki<sup>1</sup>, Takashi Masuko<sup>1</sup> (<sup>1</sup>Cell Biol Lab, Sch. Phar, Kindai Univ., <sup>2</sup>Carna Biosci., Inc.)  
 テトラスパニン遺伝子破壊細胞を用いたエクソソームの性状解析  
 沖田 鋼季<sup>1,2</sup>、今井 一貴<sup>1</sup>、山崎 晶貴<sup>1</sup>、益子 高<sup>1</sup> (<sup>1</sup>近畿大・薬・細胞

生物、<sup>2</sup>カルナバイオサイエンス(株)

- P-1301 Targeting GD2 on cancer cells by an anti-GD2 antibody is promising in a variety of cancers: Challenge by CAR T**  
Koichi Furukawa<sup>1</sup>, Yasushi Akahori<sup>2</sup>, Yuhsuke Ohmi<sup>1</sup>, Yesmin Farhana<sup>1</sup>, Takeshi Urano<sup>3</sup>, Keiko Furukawa<sup>1</sup>, Hiroshi Shiku<sup>2</sup> (<sup>1</sup>Dept. Biomed. Sci., Chubu Univ., Coll. Life Health Sci., <sup>2</sup>Dept. Immuno-Gene Therapy, Mie Univ., Grad. Sch. Med., <sup>3</sup>Dept. Biochem., Shimare Univ., Sch. Med.)

**抗GD2抗体を用いた抗癌治療の種々の癌に対する有効性：CAR Tによる挑戦**  
古川 鋼一<sup>1</sup>、赤堀 泰<sup>2</sup>、大海 雄介<sup>1</sup>、ファーハナ イエスミン<sup>1</sup>、浦野 健<sup>3</sup>、古川 圭子<sup>1</sup>、珠玖 洋<sup>2</sup> (<sup>1</sup>中部大・生命健康・生命医科、<sup>2</sup>三重大・院医・免疫遺伝子治療、<sup>3</sup>島根大・医・生化学)

- P-1302 A novel CAR-T therapy targeting MAGE-A4p230-239/HLA-A\*02:01 complex for solid tumors**  
Linan Wang<sup>1</sup>, Yoshihiro Miyahara<sup>2,3</sup>, Yasushi Akahori<sup>2</sup>, Kazuko Shirakura<sup>1</sup>, Chisaki Amaike<sup>1</sup>, Takuma Kato<sup>3</sup>, Shinichi Kageyama<sup>1</sup>, Hiroshi Shiku<sup>1,2,3</sup> (<sup>1</sup>Dept. Immuno-Gene Therapy, Mie Univ., <sup>2</sup>Cent. Comprehensive Cancer Immunotherapy, Mie Univ., <sup>3</sup>Cent. Comprehensive Cancer Immunotherapy, Mie Univ.)

**固形腫瘍に対するMAGE-A4p230-239 / HLA-A \* 02 : 01 複合体を標的とする新規CAR-T療法開発**  
王立楠<sup>1</sup>、宮原慶裕<sup>2,3</sup>、赤堀泰<sup>2</sup>、白倉和子<sup>1</sup>、天池千咲<sup>1</sup>、加藤琢磨<sup>3</sup>、影山慎一<sup>1</sup>、珠玖洋<sup>1,2,3</sup> (<sup>1</sup>三重大・医・遺伝子・免疫細胞治療学、<sup>2</sup>三重大・医・個別化癌免疫治療学、<sup>3</sup>三重大・複合的がん免疫療法研究セ)

- P-1303 Treatment with a column adsorbing immunosuppressive cells in spontaneous canine melanoma as a model for human melanoma**  
Mami Murakami, Takashi Mori (Joint Vet Med., Gifu Univ.)  
**ヒトメラノーマモデルとして自然発生メラノーマ罹患犬を用いた免疫抑制細胞吸着カラムによる治療**  
村上麻美、森崇 (岐阜大・共同獣医)

- P-1304 Expression of CD146 in human colon adenocarcinoma contributes antitumor immunity**  
Yui Shimizu, Takumi Yamazaki, Kazunori Kato (Dept. Biomed. Eng., Grad. Sch. Sci. Eng., Toyo Univ.)

**CD146の発現はヒト大腸がん細胞における免疫抑制に関与する**  
清水 唯、山崎 拓実、加藤 和則 (東洋大・理工・生体医工)

- P-1305 Second study to investigate effects of laughter on comprehensive immune profile in cancer patients -WAROTEMAE2018-**  
Norimitsu Inoue<sup>1,2</sup>, Takashi Akazawa<sup>2,3</sup>, Isao Miyashiro<sup>4</sup>, Nariaki Matsuura<sup>5</sup> (<sup>1</sup>Dept. Mol. Genetics, Wakayama Med. Univ., <sup>2</sup>Dept. Tumor Immunol., Res. Ctr., Osaka International Cancer Inst., <sup>3</sup>Dept. Cancer Drug Discovery & Development, Osaka International Cancer Inst., <sup>4</sup>Cancer Control Ctr., Osaka International Cancer Inst., <sup>5</sup>Osaka International Cancer Inst.)

**「お笑い」が免疫に及ぼす影響の網羅的な解析第2報ーわろてまえ劇場2018ー**  
井上 徳光<sup>1,2</sup>、赤澤 隆<sup>2,3</sup>、宮代 勲<sup>4</sup>、松浦 成昭<sup>5</sup> (<sup>1</sup>和歌山医大・分子遺伝、<sup>2</sup>大阪国際がんセ・研・腫瘍免疫、<sup>3</sup>大阪国際がんセ・研・がん創薬、<sup>4</sup>大阪国際がんセ・がん対策セ、<sup>5</sup>大阪国際がんセ)

## 14 Cancer basic, diagnosis and treatment

Room **P(B)** Sep. 26 (Thu.) 17:15-18:00

E/J

### P14-12 Gastric cancer: carcinogenesis

胃がん：発がん機構

Chairperson: Shin Maeda (Dept. Gastroenterology, Yokohama City Univ.)  
座長：前田 慎 (横浜市大・医・消化器内科)

- P-1306 Genomic abnormality in single crypts of chronic inflamed gastric mucosa with intestinal metaplasia**  
Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Soichi Arasawa, Eriko Iguchi, Haruhiko Takeda, Yuji Eso, Ken Takahashi, Shin'ichi Miyamoto, Yoshihide Ueda, Hiroshi Seno (Dept. Gastroent., Kyoto Univ.)

**腸上皮化生を伴う慢性胃炎粘膜を構成する一腺管あたりの遺伝子異常の解析**  
熊谷 健、清水 孝洋、高井 淳、荒澤 壮一、井口 恵里子、竹田 治彦、恵荘 裕嗣、高橋 健、宮本 心一、上田 佳秀、妹尾 浩 (京都大・消化器)

- P-1307 Distinctive cancer-associated fibroblasts are involved in scirrhous gastric cancer progression**  
Suguru Kasai<sup>1</sup>, Kazuo Yasumoto<sup>1</sup>, Atsuhiko Kawashima<sup>2</sup>, Kunio Matsumoto<sup>3</sup>, Seiji Yano<sup>4</sup>, Yoshiharu Motoo<sup>1</sup> (<sup>1</sup>Dept. Med. Oncol., Kanazawa Med. Uni., Sch. Med., <sup>2</sup>Dept. Clin. Lab., Kanazawa Med. Ctr., <sup>3</sup>Div. Tumor Dynam. & Reg., <sup>4</sup>Div. Med. Oncol., Cancer Res. Inst., Kanazawa Uni.)

**スキルス胃癌発育進展に特有のCAFが関与する**  
葛西 傑<sup>1</sup>、安本 和生<sup>1</sup>、川島 篤弘<sup>2</sup>、松本 邦夫<sup>3</sup>、矢野 聖二<sup>4</sup>、元雄 良治<sup>1</sup> (<sup>1</sup>金沢医大・腫瘍内科、<sup>2</sup>金沢医療セ・臨床検査科、<sup>3</sup>金沢大・がん研・腫瘍制御、<sup>4</sup>金沢大・がん研・腫瘍内科)

- P-1308 MSC-derived CXCL16 promotes proliferation and migration of gastric cancer cells by inducing expression of Ror1**  
Taro Ikeda<sup>1,2</sup>, Michiru Nishita<sup>1</sup>, Yoshihiro Kakeji<sup>2</sup>, Yasuhiro Minami<sup>1</sup> (<sup>1</sup>Dept. Physiol & Cell Biol., Kobe Univ. Grad. Sch. Med., <sup>2</sup>Div. Gastrointestinal Surg., Dept. Surg., Kobe Univ. Grad. Sch. Med.)

**間葉系間質細胞由来のCXCL16は胃癌細胞においてRor1の発現を誘導し増殖と遊走を促進する**  
池田 太郎<sup>1,2</sup>、西田 満<sup>1</sup>、掛地 吉弘<sup>2</sup>、南 康博<sup>1</sup> (<sup>1</sup>神戸大・院医・細胞生理学、<sup>2</sup>神戸大・院医・食道胃腸外科)

- P-1309 Identification and functional analysis of a long non-coding RNA associated with chronic gastritis and gastric cancer**  
Hiroshi Kitajima<sup>1</sup>, Reo Maruyama<sup>2</sup>, Akira Takasawa<sup>3</sup>, Eiichiro Yamamoto<sup>1,4</sup>, Takeshi Niinuma<sup>1</sup>, Masahiro Kai<sup>1</sup>, Takashi Tokino<sup>5</sup>, Hiroshi Nakase<sup>4</sup>, Hiromu Suzuki<sup>1</sup> (<sup>1</sup>Dept. Mol. Biol., Sapporo. Med. Univ., <sup>2</sup>Project Cancer Epigenome, The Cancer Inst., JFCR, <sup>3</sup>Dept., Pathol. Sapporo Med. Univ., <sup>4</sup>Dept. Gastroentrol. Hepatol. Sapporo. Med., <sup>5</sup>Med. Genome. Sci., Dept. Frontier Med., Sapporo. Med. Univ.)

**慢性胃炎および胃がんに関連する長鎖 non-coding RNA の同定と機能解析**  
北嶋 洋志<sup>1</sup>、丸山 玲緒<sup>2</sup>、高澤 啓<sup>3</sup>、山本 英一郎<sup>1,4</sup>、新沼 猛<sup>1</sup>、甲斐 正広<sup>1</sup>、時野 隆至<sup>5</sup>、仲瀬 裕志<sup>4</sup>、鈴木 拓<sup>1</sup> (<sup>1</sup>札幌医大・医・分子生物、<sup>2</sup>(公財)がん研・研・がん工ピゲノム、<sup>3</sup>札幌医大・医・病理2、<sup>4</sup>札幌医大・医・消化器内科、<sup>5</sup>札幌医大・フコ研・ゲノム医科)

- P-1310 Investigation of platelet-derived microparticles in patients with gastric cancer**  
Suguru Maruyama, Ryo Saito, Naoki Ashizawa, Yuko Nakayama, Hiroki Shimizu, Daisuke Ichikawa (1st Dept. Faculty of Med., Univ. of Yamanashi)

**胃癌患者での血小板由来 microparticle の検討**  
丸山 傑、齊藤 亮、芦沢 直樹、中山 裕子、清水 浩紀、市川 大輔 (山梨医大・医・第1外科)

- P-1311 Withdrawn**

- P-1312 Next-generation disease modelling: Patient-derived organoids as in vitro models for gastric cancer therapeutics**  
Yivien Koh<sup>1</sup>, Shing Leng Chan<sup>2</sup>, Yoshiaki Ito<sup>3</sup>, Jimmy So<sup>1,3</sup>, Yana Zavros<sup>4</sup>, Wei Peng Yong<sup>1,2</sup> (<sup>1</sup>Natl. Univ. Cancer Inst. Singapore, Natl. Univ. Health System, <sup>2</sup>Cancer Sci. Inst. of Singapore, Natl. Univ. of Singapore, <sup>3</sup>Dept. Surg., Natl. Univ. of Singapore, <sup>4</sup>Univ. of Cincinnati, Ohio, United States of America)

Room **P(B)** Sep. 26 (Thu.) 17:15-18:00

E/J

### P14-13 Esophageal cancer therapy and tumor-associated macrophages

食道がん治療と腫瘍関連マクロファージ

Chairperson: Shunsuke Kagawa (Minimally Invasive Therapy Ctr., Okayama Univ. Hosp.)

座長：香川 俊輔 (岡山大・病院・低侵襲治療セ)

- P-1313 The combination effect of PRIMA-1MET and chemotherapy via p73-NOXA axis in esophageal cancer**  
Teruyuki Kobayashi<sup>1</sup>, Tomoki Makino<sup>1</sup>, Makoto Yamasaki<sup>1</sup>, Kotaro Yamashita<sup>1</sup>, Koji Tanaka<sup>1</sup>, Takuro Saito<sup>1</sup>, Tsuyoshi Takahashi<sup>1</sup>, Yukinori Kurokawa<sup>1</sup>, Kiyokazu Nakajima<sup>1</sup>, Masaki Mori<sup>2</sup>, Yuichiro Doki<sup>1</sup> (<sup>1</sup>Dept. Gastroenterological Surg., Grad. Sch. of Med., Osaka Univ., <sup>2</sup>Dept. Surg. & Sci., Kyushu Univ.)

**食道癌におけるPRIMA-1METと化学療法のp73-NOXA軸を介した併用効果**  
小林 照之<sup>1</sup>、牧野 知紀<sup>1</sup>、山崎 誠<sup>1</sup>、山下 公太郎<sup>1</sup>、田中 晃司<sup>1</sup>、西塔 拓郎<sup>1</sup>、高橋 剛<sup>1</sup>、黒川 幸典<sup>1</sup>、中島 清一<sup>1</sup>、森 正樹<sup>2</sup>、土岐 祐一郎<sup>1</sup> (<sup>1</sup>大阪大・医・消化器外科、<sup>2</sup>九州大・医・消化器・総合外科)

**P-1314 Analysis of miR-132-5p downregulated in esophageal squamous cell carcinoma after co-culture with TAMs**

Masataka Fujikawa<sup>1</sup>, Tomoki Fujita<sup>1</sup>, Kohei Tanigawa<sup>1,2</sup>, Masaki Shimizu<sup>1,2</sup>, Takayuki Kodama<sup>1</sup>, Hiroki Sakamoto<sup>1,2</sup>, Yumi Ichihara<sup>1</sup>, Himiko Kodaira<sup>1</sup>, Mari Nishio<sup>1</sup>, Manabu Shigeoka<sup>1</sup>, Yuichiro Koma<sup>1</sup>, Hiroshi Yokozaki<sup>1</sup> (<sup>1</sup>Div. Pathol., Dept. Pathol., Kobe Univ., Grad. Sch. Med., <sup>2</sup>Div. Gastro-intestinal Surg., Dept. Surg., Kobe Univ., Grad. Sch. Med.)

腫瘍関連マクロファージとの共培養により食道扁平上皮癌細胞で発現低下する miR-132-5p の解析

藤川 正隆<sup>1,2</sup>、藤田 知樹<sup>1</sup>、谷川 航平<sup>1,2</sup>、清水 将来<sup>1,2</sup>、児玉 貴之<sup>1</sup>、坂本 浩輝<sup>1,2</sup>、市原 有美<sup>1</sup>、小平 日美子<sup>1</sup>、西尾 真理<sup>1</sup>、重岡 學<sup>1</sup>、狛 雄一郎<sup>1</sup>、横崎 宏<sup>1</sup> (<sup>1</sup>神戸大・院医・病理学、<sup>2</sup>神戸大・院医・食堂胃腸外科学)

**P-1315 Tumor-associated macrophages promote migration and invasion of esophageal squamous cell carcinoma via CCL3-CCR5 axis**

Takayuki Kodama<sup>1</sup>, Tomoki Fujita<sup>1</sup>, Kohei Tanigawa<sup>1,2</sup>, Masaki Shimizu<sup>1,2</sup>, Hiroki Sakamoto<sup>1,2</sup>, Masataka Fujikawa<sup>1,2</sup>, Himiko Kodaira<sup>1</sup>, Mari Nishio<sup>1</sup>, Manabu Shigeoka<sup>1</sup>, Yuichiro Koma<sup>1</sup>, Hiroshi Yokozaki<sup>1</sup> (<sup>1</sup>Div. Pathol., Dept. Pathol., Kobe Univ., Grad. Sch. Med., <sup>2</sup>Div. Gastro-intestinal Surg., Dept. Surg., Kobe Univ., Grad. Sch. Med.)

腫瘍関連マクロファージは CCL3-CCR5 系を介して食道扁平上皮癌の遊走能と浸潤能を亢進する

児玉 貴之<sup>1</sup>、藤田 知樹<sup>1</sup>、谷川 航平<sup>1,2</sup>、清水 将来<sup>1,2</sup>、坂本 浩輝<sup>1,2</sup>、藤川 正隆<sup>1,2</sup>、小平 日美子<sup>1</sup>、西尾 真理<sup>1</sup>、重岡 學<sup>1</sup>、狛 雄一郎<sup>1</sup>、横崎 宏<sup>1</sup> (<sup>1</sup>神戸大・院医・病理学、<sup>2</sup>神戸大・院医・食道胃腸外科学)

**P-1316 Sulfasalazine synergizes with radiotherapy to induce ROS in CD44 positive esophageal squamous cell carcinoma cells**

Seiichiro Takao<sup>1</sup>, Takaaki Masuda<sup>2</sup>, Yushi Motomura<sup>1</sup>, Hiroaki Wakiyama<sup>1</sup>, Yusuke Tsuruda<sup>2</sup>, Hajime Otsu<sup>2</sup>, Hiroki Uchida<sup>2</sup>, Yoshihiro Matsumoto<sup>2</sup>, Koshi Mimori<sup>2</sup> (<sup>1</sup>Dept. Radiol., Beppu Hosp., Kyushu Univ., <sup>2</sup>Dept. Surg., Beppu Hosp., Kyushu Univ.)

CD44 陽性食道扁平上皮癌に対する活性酸素誘導によるスルファサラジンの放射線治療との相乗効果

高尾 誠一郎<sup>1</sup>、増田 隆明<sup>2</sup>、本村 有史<sup>1</sup>、脇山 浩明<sup>1</sup>、鶴田 祐介<sup>2</sup>、大津 甫<sup>2</sup>、内田 博喜<sup>2</sup>、松本 佳大<sup>2</sup>、三森 功士<sup>2</sup> (<sup>1</sup>九州大・別府病院・放射線科、<sup>2</sup>九州大・別府病院・外科)

**P-1317 Interaction between esophageal squamous cell carcinoma and macrophage promotes cancer progression**

Yuichiro Koma<sup>1</sup>, Tomoki Fujita<sup>1</sup>, Takayuki Kodama<sup>1</sup>, Kohei Tanigawa<sup>1,2</sup>, Masaki Shimizu<sup>1,2</sup>, Hiroki Sakamoto<sup>1,2</sup>, Masataka Fujikawa<sup>1,2</sup>, Himiko Kodaira<sup>1</sup>, Yumi Ichihara<sup>1</sup>, Mari Nishio<sup>1</sup>, Manabu Shigeoka<sup>1</sup>, Hiroshi Yokozaki<sup>1</sup> (<sup>1</sup>Div. Pathol., Dept. Pathol., Kobe Univ., Grad. Sch. Med., <sup>2</sup>Div. Gastro-intestinal Surg., Dept. Surg., Kobe Univ., Grad. Sch. Med.)

食道扁平上皮癌と腫瘍関連マクロファージとの相互作用は癌進展に関与する

狛 雄一郎<sup>1</sup>、藤田 知樹<sup>1</sup>、児玉 貴之<sup>1</sup>、谷川 航平<sup>1,2</sup>、清水 将来<sup>1,2</sup>、坂本 浩輝<sup>1,2</sup>、藤川 正隆<sup>1,2</sup>、小平 日美子<sup>1</sup>、市原 有美<sup>1</sup>、西尾 真理<sup>1</sup>、重岡 學<sup>1</sup>、横崎 宏<sup>1</sup> (<sup>1</sup>神戸大・院医・病理学、<sup>2</sup>神戸大・院医・食道胃腸外科学)

**P-1318 The role of direct cell-cell interactions between ESCC cells and TAMs in cancer progression**

Kohei Tanigawa<sup>1,2</sup>, Tomoki Fujita<sup>1</sup>, Takayuki Kodama<sup>1</sup>, Masaki Shimizu<sup>1,2</sup>, Hiroki Sakamoto<sup>1,2</sup>, Masataka Fujikawa<sup>1,2</sup>, Himiko Kodaira<sup>1</sup>, Yumi Ichihara<sup>1</sup>, Mari Nishio<sup>1</sup>, Manabu Shigeoka<sup>1</sup>, Yuichiro Koma<sup>1</sup>, Hiroshi Yokozaki<sup>1</sup> (<sup>1</sup>Div. Pathol., Dept. Pathol., Kobe Univ., Grad. Sch. Med., <sup>2</sup>Div. Gastro-intestinal Surg., Dept. Surg., Kobe Univ., Grad. Sch. Med.)

食道扁平上皮癌の進展における癌細胞と腫瘍関連マクロファージの直接接触による細胞間相互作用の解析

谷川 航平<sup>1,2</sup>、藤田 知樹<sup>1</sup>、児玉 貴之<sup>1</sup>、清水 将来<sup>1,2</sup>、坂本 浩輝<sup>1,2</sup>、藤川 正隆<sup>1,2</sup>、小平 日美子<sup>1</sup>、市原 有美<sup>1</sup>、西尾 真理<sup>1</sup>、重岡 學<sup>1</sup>、狛 雄一郎<sup>1</sup>、横崎 宏<sup>1</sup> (<sup>1</sup>神戸大・院医・病理学、<sup>2</sup>神戸大・院医・食道胃腸外科学)

**P14-14 Colorectal cancer: diagnosis, prognosis factor (1)**

大腸がん：診断・予後因子 (1)

Chairperson: Etsuko Kiyokawa (Kanazawa Med. Univ., Sch. Med., Dept. Oncol Pathol.)

座長：清川 悦子 (金沢医大・医・病理学 I)

**P-1319 Prediction of downsizing in rectal cancer patients treated by preoperative chemoradiotherapy according to cancer size**

Eiji Shinto<sup>1</sup>, Yoshiki Kajiwara<sup>1</sup>, Koichi Okamoto<sup>1</sup>, Satsuki Mochizuki<sup>1</sup>, Masato Yamadera<sup>1</sup>, Tadakazu Ao<sup>1</sup>, Takehiro Shiraishi<sup>1</sup>, Yojiro Hashiguchi<sup>2</sup>, Hitoshi Tsuda<sup>3</sup>, Kazuo Hase<sup>1</sup>, Hideki Ueno<sup>1</sup> (<sup>1</sup>Dept. Surg., Natl. Defense Med. College, <sup>2</sup>Dept. Surg., Teikyo Univ., <sup>3</sup>Dept. Path., Natl. Defense Med. College)

治療前生検組織による直腸癌術前化学放射線療法の効果予測—腫瘍径に着目した検討—

神藤 英二<sup>1</sup>、梶原 由規<sup>1</sup>、岡本 耕一<sup>1</sup>、望月 早月<sup>1</sup>、山寺 勝人<sup>1</sup>、阿尾 理一<sup>1</sup>、白石 壮宏<sup>1</sup>、橋口 陽二郎<sup>2</sup>、津田 均<sup>3</sup>、長谷 和生<sup>1</sup>、上野 秀樹<sup>1</sup> (<sup>1</sup>防衛医大・外科、<sup>2</sup>帝京大・外科、<sup>3</sup>防衛医大・病態病理)

**P-1320 Clinicopathological characteristics of surgical cases for ulcerative colitis related colitic cancer**

Takayuki Ogino<sup>1</sup>, Tsunekazu Mizushima<sup>1</sup>, Shiki Fujino<sup>1</sup>, Norikatsu Miyoshi<sup>1</sup>, Hidekazu Takahashi<sup>1</sup>, Mamoru Uemura<sup>1</sup>, Chu Matsuda<sup>1</sup>, Hirofumi Yamamoto<sup>1</sup>, Masaki Mori<sup>2</sup>, Yuichiro Doki<sup>1</sup> (<sup>1</sup>Dept. Gastroenterol Surg., Osaka Univ., Sch. Med., <sup>2</sup>Dept. Surg & Sci., Kyushu Univ., Sch. Med.)

潰瘍性大腸炎関連癌手術症例の臨床病理学的検討

荻野 崇之<sup>1</sup>、水島 恒和<sup>1</sup>、藤野 志季<sup>1</sup>、三吉 範克<sup>1</sup>、高橋 秀和<sup>1</sup>、植村 守<sup>1</sup>、松田 宙<sup>1</sup>、山本 浩文<sup>1</sup>、森 正樹<sup>2</sup>、土岐 祐一郎<sup>1</sup> (<sup>1</sup>大阪大・医・消外、<sup>2</sup>九州大・医・消外)

**P-1321 The clinicopathological significance of heterogeneic Ezrin expression in PDCs of colorectal cancer**

Akane Aikawa, Etsuko Kiyokawa (Dept. Oncologic Pathol., Kanazawa Med. Univ., Sch. Med.)

大腸癌低分化胞巣における Ezrin の不均一な発現の臨床病理学的意義

相川 あかね、清川 悦子 (金沢医大・医・病理学 I)

**P-1322 The clinicopathological significance of intelectin-1 in colorectal tumor**

Narutaka Katsuya<sup>1</sup>, Kazuhiro Sentani<sup>1</sup>, Naohide Oue<sup>1</sup>, Amatya Vishwajeet<sup>2</sup>, Yukio Takeshima<sup>2</sup>, Takuya Hattori<sup>1</sup>, Naoya Sakamoto<sup>1</sup>, Wataru Yasui<sup>1</sup> (<sup>1</sup>Dept. Mol. Path., Hiroshima Univ. Med., <sup>2</sup>Dept. Path., Hiroshima Univ. M)

Intelectin-1 の大腸腫瘍における臨床病理学的意義

勝矢 脩嵩<sup>1</sup>、仙谷 和弘<sup>1</sup>、大上 直秀<sup>1</sup>、Amatya Vishwajeet<sup>2</sup>、武島 幸男<sup>2</sup>、服部 拓也<sup>1</sup>、坂本 直也<sup>1</sup>、安井 弥<sup>1</sup> (<sup>1</sup>広島大・医・分子病理、<sup>2</sup>広島大・医・病理)

**P-1323 Clinical usefulness of SMOC1 as a diagnostic marker of colorectal precancerous lesions**

Hironori Aoki<sup>1,2</sup>, Eiichiro Yamamoto<sup>1</sup>, Akira Takasawa<sup>3</sup>, Takeshi Niinuma<sup>1</sup>, Hiro-o Yamano<sup>4</sup>, Akira Yorozu<sup>1</sup>, Hiroshi Kitajima<sup>1</sup>, Masahiro Kai<sup>1</sup>, Makoto Osanai<sup>3</sup>, Hiroshi Nakase<sup>1</sup>, Tamotsu Sugai<sup>3</sup>, Hiromu Suzuki<sup>1</sup> (<sup>1</sup>Dept. Mol. Biol., Sapporo Med. Univ., Sch. Med., <sup>2</sup>Ctr. for Gastroenterol., Teine-Keijinkai Hosp., <sup>3</sup>2nd Dept. Path., Sapporo Med. Univ., Sch. Med., <sup>4</sup>Dept. Gastroenterol., Sapporo Med. Univ., Sch. Med., <sup>5</sup>Dept. Mol. Diagn. Path., Iwate Med. Univ., Sch. Med.)

SMOC1 の大腸腫瘍診断マーカーとしての臨床的有用性の検討

青木 敬則<sup>1,2</sup>、山本 英一郎<sup>1</sup>、高澤 啓<sup>3</sup>、新沼 猛<sup>1</sup>、山野 泰穂<sup>4</sup>、萬 頭<sup>1</sup>、北嶋 洋志<sup>1</sup>、甲斐 正広<sup>1</sup>、小山内 誠<sup>3</sup>、仲瀬 裕志<sup>4</sup>、菅井 有<sup>5</sup>、鈴木 拓<sup>1</sup> (<sup>1</sup>札幌医大・医・分子生物、<sup>2</sup>手稲溪仁会病院・消化器病科、<sup>3</sup>札幌医大・医・第 2 病理、<sup>4</sup>札幌医大・医・消化器内科、<sup>5</sup>岩手医大・医・病理診断)

**P-1324 Prognostic Significance of NOX5 expression in colon cancer patients**

Ashizawa Naoki, Hiroki Shimizu, Ryo Saito, Suguru Maruyama, Yuko Nakayama, Daisuke Ichikawa (SurgI. Yamanashi Univ.)

ヒト大腸癌における NOX5 の予後因子としての意義

芦沢 直樹、清水 浩紀、齋藤 亮、丸山 傑、中山 裕子、市川 大輔 (山梨医大・第 1 外科)

## P14-15 Pancreatic cancer (2)

膵がん (2)

Chairperson: Yoshiki Murakami (Tokyo Med. Univ.)

座長：村上 善基 (東京医科大・先端核酸医療講座)

P-1325 **Is the site of metastasis after surgery for pancreatic cancer predicted by the preoperative sample?**

Go Shinke<sup>1,2</sup>, Daisaku Yamada<sup>1,3</sup>, Hidetoshi Eguchi<sup>1</sup>, Masaki Mori<sup>1,4</sup>,

Yuichiro Doki<sup>1</sup> (<sup>1</sup>Dept. Gastroenterol Surg., Grad Sch. Med., Osaka Univ., <sup>2</sup>Dept. Surg. Kawasaki Hosp., <sup>3</sup>Dept. Gastroenterol Surg., Osaka Int. Cancer Inst., <sup>4</sup>Dept. Surg. & Sci., Grad Sch. Med. Sci., Kyushu Univ.)

膵癌の転移形式は術前血清で予想できるか?

新毛 豪<sup>1,2</sup>、山田 大作<sup>1,3</sup>、江口 英利<sup>1</sup>、森 正樹<sup>1,4</sup>、土岐 祐一郎<sup>1</sup> (大阪大・院・消化器外科、<sup>2</sup>川崎病院・外科、<sup>3</sup>大阪国際がんセンター・消化器外科、<sup>4</sup>九州大・院・消化器・総合外科)

P-1326 **Identification of aberrant proteins involved in peritoneal dissemination of pancreatic cancer**

Fumimasa Kitamura<sup>1,2</sup>, Takatsugu Ishimoto<sup>1,2</sup>, Takahiko Akiyama<sup>1,2</sup>,

Norio Uemura<sup>1</sup>, Tadahito Yasuda<sup>1,2</sup>, Astuko Yonemura<sup>1,2</sup>, Rumi Itouyama<sup>1,2</sup>, Tomoyuki Uchihara<sup>1,2</sup>, Takaaki Higashi<sup>1</sup>, Katsunori Imai<sup>1</sup>, Hiromitsu Hayashi<sup>1</sup>, Yoichi Yamashita<sup>1</sup>, Hideo Baba<sup>1</sup> (<sup>1</sup>Dept. Gastroenterol. Surg., Kumamoto Univ., <sup>2</sup>The Int. Res. Ctr. for Med. Sci., Kumamoto Univ.)

膵癌腹膜播種に関与する異常タンパクの同定

北村 文優<sup>1,2</sup>、石本 崇胤<sup>1,2</sup>、秋山 貴彦<sup>1,2</sup>、上村 紀雄<sup>1</sup>、安田 忠仁<sup>1,2</sup>、米村 敦子<sup>1,2</sup>、伊東山 瑠美<sup>1,2</sup>、内原 智幸<sup>1,2</sup>、東 孝暁<sup>1</sup>、今井 克憲<sup>1</sup>、林 洋光<sup>1</sup>、山下 洋市<sup>1</sup>、馬場 秀夫<sup>1</sup> (熊本大・医・消化器外科、<sup>2</sup>熊本大・医・国際先端医学研究機構)

P-1327 **Development of a gene expression database of pancreatic ductal adenocarcinoma cases to identify tumor markers**

Mikiya Takao<sup>1,2</sup>, Hirotaaka Matsuo<sup>2</sup>, Seiko Shimizu<sup>2</sup>, Makoto Kawaguchi<sup>2,3</sup>, Akiyoshi Nakayama<sup>2</sup>, Yusuke Kawamura<sup>2</sup>, Keiichi Ito<sup>3</sup>, Yoji Kishi<sup>1</sup>, Nariyoshi Shinomiya<sup>2</sup> (<sup>1</sup>Dept. Surg., Natl. Defense Med. Col., <sup>2</sup>Dept. Integrative Physiol., Natl. Defense Med. Col., <sup>3</sup>Dept. Urol., Natl. Defense Med. Col.)

HiCEP 法と次世代シーケンサーを併用した新規発現解析法による膵癌の遺伝子発現データベースの構築と膵癌マーカーの同定

高尾 幹也<sup>1,2</sup>、松尾 洋孝<sup>2</sup>、清水 聖子<sup>2</sup>、川口 真<sup>2,3</sup>、中山 昌喜<sup>2</sup>、河村 優輔<sup>2</sup>、伊藤 敬一<sup>3</sup>、岸 庸二<sup>1</sup>、四ノ宮 成祥<sup>2</sup> (<sup>1</sup>防衛医大・外科、<sup>2</sup>防衛医大・分子生体制御学、<sup>3</sup>防衛医大・泌尿器科)

P-1328 **Clinical Significance of eIF5-mimic protein 1 expression in pancreatic cancer**

Yushi Motomura<sup>1</sup>, Takaaki Masuda<sup>2</sup>, Kuniaki Sato<sup>2</sup>, Atsushi Fujii<sup>2</sup>, Akihiro Kitagawa<sup>2</sup>, Miwa Noda<sup>2</sup>, Seiichiro Takao<sup>1</sup>, Hiroaki Wakiyama<sup>1</sup>, Yusuke Tsuruda<sup>2</sup>, Yoshihiro Matsumoto<sup>2</sup>, Hajime Otsu<sup>2</sup>, Hiroki Uchida<sup>2</sup>, Koshi Mimori<sup>2</sup> (<sup>1</sup>Dept. Radiology, Beppu Hosp., Kyushu Univ., <sup>2</sup>Dept. Surg., Beppu Hosp., Kyushu Univ.)

膵癌における eIF5-mimic protein 1 (5MP1) 発現の臨床的意義

本村 有史<sup>1</sup>、増田 隆明<sup>2</sup>、佐藤 晋彰<sup>2</sup>、藤井 昌志<sup>2</sup>、北川 彰洋<sup>2</sup>、野田 美和<sup>2</sup>、高尾 誠一郎<sup>1</sup>、脇山 浩明<sup>1</sup>、鶴田 祐介<sup>2</sup>、松本 佳大<sup>2</sup>、大津 甫<sup>2</sup>、内田 博喜<sup>2</sup>、三森 功士<sup>2</sup> (九州大・病院・別府病院・放射線科、<sup>2</sup>九州大・病院・別府病院・外科)

P-1329 **High expression of ARHGEF2 is associated with poor prognosis in Patients with Pancreatic Cancer**

Yosuke Nakao, Shigeki Nakagawa, Yo-ichi Yamashita, Rumi Itoyama, Toshihiko Yusa, Naoki Umezaki, Tatsunori Miyata, Hirohisa Okabe, Katsunori Imai, Hideo Baba (Dept. of Gastroenterological Surg., Kumamoto Univ.)

Rho ファミリー関連蛋白 ARHGEF2 高発現は予後不良に関与する中尾 陽佑、中川 茂樹、山下 洋市、伊東山 瑠美、遊佐 俊彦、梅崎 直紀、宮田 辰徳、岡部 弘尚、今井 克憲、馬場 秀夫 (熊本大・院・消化器外科学)

P-1330 **Cancer progression by an enzyme expression under serum starvation and hypoxia**

Katsuya Takenaka, Yukako Komori, Yoshiyasu Nakamura, Shiro Koizume, Yohei Miyagi (Mol. Path. Genetics Div., Kanagawa Cancer Ctr. Res. Inst.)

血清飢餓低酸素環境で発現誘導される酵素とその産物による腫瘍悪性化機序

竹中 克也、小森 由香子、中村 圭靖、小井 詔 史朗、宮城 洋平 (神奈川県がんセンター・臨床研・がん分子病態)

## P14-16 Predictive and prognostic marker in lung cancer (1)

肺がんの効果および予後予測因子 (1)

Chairperson: Tetsuya Oguri (Dept. of Education & Res. Ctr. for Community Med., Nagoya City Univ. Grad. Sch. of Med. Sci.)

座長：小栗 鉄也 (名古屋市大・院医・地域医療教育研究セ)

P-1331 **Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702)**

Yuka Fujita<sup>1,2</sup>, Megumi Furuta<sup>2,3</sup>, Jun Sakakibara-Konishi<sup>2,3</sup>, Hajime Kikuchi<sup>2</sup>, Hiroshi Yokouchi<sup>2</sup>, Hiroyuki Minemura<sup>4</sup>, Masao Harada<sup>2</sup>, Shigeo Yamazaki<sup>2</sup>, Kenji Akie<sup>2</sup>, Satoshi Oizumi<sup>2</sup>, Hirotohi Dosaka-Akita<sup>2</sup>, Hiroshi Isobe<sup>2</sup> (<sup>1</sup>Dept. Respiratory Med., NHO Asahikawa Med. Ctr., <sup>2</sup>Hokkaido Lung Cancer Clin. Study Group, <sup>3</sup>Dept. Respiratory Med., Hokkaido Univ., <sup>4</sup>Fukushima Investigative Group for Healing Thoracic Malignancy)

小細胞肺癌切除検体における DLL3、ASCL1 に関する検討 (HOT1702)

藤田 結花<sup>1,2</sup>、古田 恵<sup>2,3</sup>、榎原 純<sup>2,3</sup>、菊池 創<sup>2</sup>、横内 浩<sup>2</sup>、峯村 浩之<sup>4</sup>、原田 眞雄<sup>2</sup>、山崎 成夫<sup>2</sup>、秋江 研志<sup>2</sup>、大泉 聡史<sup>2</sup>、秋田 弘俊<sup>2</sup>、磯部 宏<sup>2</sup> (旭川医療セ・呼吸器内科、<sup>2</sup>北海道肺癌臨床研究会、<sup>3</sup>北海道大・院医・呼吸器内科、<sup>4</sup>福島県肺癌研究会)

P-1332 **Significance of REV7 expression in biological characteristics of small cell lung carcinoma**

Itaru Sanoyama, Yoshiki Murakumo, Masaaki Ichinoe, Yasutaka Sakurai (Dept. Pathol., Kitasato Univ., Sch. Med.)

小細胞肺癌の生物学的特性における REV7 発現の意義

眞山 到、村雲 芳樹、戸 昌明、櫻井 靖高 (北里大・医・病理学)

P-1333 **A measurement of KRAS mutant allele frequency in honeycomb lesions of interstitial pneumonia**

Toshiaki Kataoka<sup>1</sup>, Koji Okudela<sup>1</sup>, Hiromasa Arai<sup>3</sup>, Tomohisa Baba<sup>4</sup>, Hideaki Mitsui<sup>1</sup>, Ryouta Ushio<sup>2</sup>, Chihiro Koike<sup>1</sup>, Mai Matsumura<sup>1</sup>, Yoko Tateishi<sup>1</sup>, Kenichi Ohashi<sup>1</sup> (<sup>1</sup>Dept. Pathol., Yokohama City Univ., Sch. Med., <sup>2</sup>Dept. Resp., Yokohama City Univ. Med. Ctr., <sup>3</sup>Dept. Surg. Resp., Kanagawa. Cardio. Resp. Ctr., <sup>4</sup>Dept. Resp., Kanagawa. Cardio. Resp. Ctr.)

間質性肺炎の蜂巢肺における KRAS 遺伝子変異頻度の測定

片岡 俊朗<sup>1</sup>、奥寺 康司<sup>1</sup>、荒井 宏雅<sup>3</sup>、馬場 智久<sup>4</sup>、三井 秀昭<sup>1</sup>、牛尾 良太<sup>2</sup>、小池 千尋<sup>1</sup>、松村 舞依<sup>1</sup>、立石 陽子<sup>1</sup>、大橋 健一<sup>1</sup> (横浜市大・医・病態病理学、<sup>2</sup>横浜市民総合医療セ・呼吸器内科、<sup>3</sup>神奈川循環セ・胸部一般外科、<sup>4</sup>神奈川循環セ・呼吸器内科)

P-1334 **Kallikrein-related peptidase 13: a predictive marker of lymphatic vessel invasion of lung squamous cell carcinoma**

Ryusuke Sumiya<sup>1</sup>, Kazuhiko Yamada<sup>1</sup>, Norihiro Kokudo<sup>1</sup>, Yuki Kawamura<sup>2</sup> (<sup>1</sup>Dept. Surg., Nat. Ctr. Global Health Med., <sup>2</sup>Dept. Gastroenterol., Res. Inst., Nat. Ctr. Global Health Med.)

KLK13 の肺がん新規予後マーカーとしての期待

住谷 隆輔<sup>1</sup>、山田 和彦<sup>1</sup>、國土 典宏<sup>1</sup>、河村 由紀<sup>2</sup> (<sup>1</sup>国立国際医療研究セ・外科、<sup>2</sup>国立国際医療研究セ・研・肝炎・免疫研セ・消)

P-1335 **MicroRNA profiling and validation analysis with serum-derived exosomes in squamous cell carcinomas arising in the lung**

Yoshihisa Shimada<sup>1</sup>, Yujin Kudo<sup>1</sup>, Tatsuo Ohira<sup>1</sup>, Masahiko Kuroda<sup>2</sup>, Norihiko Ikeda<sup>1</sup> (<sup>1</sup>Dept. Surg., Tokyo Med. Univ., <sup>2</sup>Dept. Mol Pathol., Tokyo Med. Univ.)

肺扁平上皮癌の網羅的 miRNA プロファイルと血清由来エキソソームによる検証解析

嶋田 善久<sup>1</sup>、工藤 勇人<sup>1</sup>、大平 達夫<sup>1</sup>、黒田 雅彦<sup>2</sup>、池田 徳彦<sup>1</sup> (東京医大・医・呼吸器外科、<sup>2</sup>東京医大・医・分子病理)

P-1336 **CD271 expression in metastatic mediastinal lymph nodes serves as a prognostic marker in pN2 non-small cell lung cancer**

Yoko Kataoka<sup>1,2</sup>, Takuya Fujita<sup>2</sup>, Jun Hanaoka<sup>1</sup> (<sup>1</sup>Dept. Surg., Shiga Univ. Med. Sci., <sup>2</sup>Gen. Thorac. Surg., Kohka Pub. Hosp.)

pN2 非小細胞肺癌における予後予測因子としての CD271 発現の意義

片岡 瑛子<sup>1,2</sup>、藤田 琢也<sup>2</sup>、花岡 淳<sup>1</sup> (滋賀医大・医・呼吸器外科、<sup>2</sup>甲賀病院・呼吸器外科)

## P14-17 Breast cancer (1) luminal disease

乳がん (1) luminal disease

Chairperson: Hiroko Yamashita (Dept. Breast Surg., Hokkaido Univ. Hosp.)  
座長: 山下 啓子 (北海道大・病院・乳腺外科)

## P-1337 Estradiol regulates half life time of HER3 protein in ER-positive breast cancer

Junko Suga<sup>1,2</sup>, Nobuyuki Tanaka<sup>3</sup>, Shigehira Saji<sup>1</sup> (1)Dept. Med. Oncol., Fukushima Med. Univ., (2)Dept. Med. Oncol., Kyoto Univ. Hosp., (3)Cancer Bio. Therap., Miyagi Cancer Ctr. Res. Inst.)

ER 陽性乳癌におけるエストロゲン刺激は HER3 の分解を促進する  
須賀 淳子<sup>1,2</sup>、田中 伸幸<sup>3</sup>、佐佐 重衡<sup>1</sup> (1)福島県医大・腫瘍内科学、<sup>2</sup>京都大・病院・腫瘍内科、<sup>3</sup>宮城県がんセンター・がん先進)

P-1338 Multiple mechanisms of aromatase inhibitor resistance in resistant model breast cancer cell lines established *in vivo*

Yuri Yamaguchi<sup>1</sup>, Miki Ohira<sup>1</sup>, Takehiko Kamijo<sup>1</sup>, Shin-ichi Hayashi<sup>2</sup> (1)Res. Inst. Clin. Oncol., Saitama Cancer Ctr., (2)Dept. Mol. Functional Dynamics, Tohoku Univ., Grad. Sch. Med.)

*In vivo* で樹立したアロマトラーゼ阻害剤耐性乳癌モデル細胞における耐性機序の多様性  
山口 ゆり<sup>1</sup>、大平 美紀<sup>1</sup>、上條 岳彦<sup>1</sup>、林 慎一<sup>2</sup> (1)埼玉がんセンター・臨床腫瘍研、<sup>2</sup>東北大・院医・分子機能解析学)

## P-1339 The expression of heterogeneous nuclear ribonucleoprotein K in breast cancer

Erina Iwabuchi<sup>1,2</sup>, Yasuhiro Miki<sup>3</sup>, Takanori Ishida<sup>4</sup>, Hironobu Sasano<sup>1</sup> (1)Dept. Pathol. Tohoku Univ., Grad. Sch. Med., (2)JSPS, (3)Dept. Disaster Ob/Gyn. Tohoku Univ., Int. Res. Inst. Disaster Sci., (4)Dept. Breast & Endocrine Surg. Oncology. Tohoku Univ., Grad. Sch. Med.)

乳癌における heterogeneous nuclear ribonucleoprotein K の発現意義の検討  
岩淵 英里奈<sup>1,2</sup>、三木 康宏<sup>3</sup>、石田 孝宣<sup>4</sup>、笹野 公伸<sup>1</sup> (1)東北大・院医・病理診断、<sup>2</sup>日本学術振興会、<sup>3</sup>東北大・災害研・災害産婦人科学、<sup>4</sup>東北大・院医・乳腺・内分泌外科学)

## P-1340 Androgen-induced C-C motif chemokine ligand 5 secretion of macrophages regulate breast cancer progression

Mio Yamaguchi<sup>1</sup>, Kiyoshi Takagi<sup>1</sup>, Yasuhiro Miki<sup>2</sup>, Yoshiaki Onodera<sup>3</sup>, Takanori Ishida<sup>4</sup>, Hironobu Sasano<sup>5</sup>, Takashi Suzuki<sup>1</sup> (1)Dept., Pathol & Histotech., Tohoku Univ., Grad., Sch., Med., (2)Disaster Obstetrics & Gynecol., IRIDEs., Tohoku Univ., (3)Dept., Anatomic Pathol., Tohoku Univ., Grad., Sch., Med., (4)Dept., Breast & Endo. Surg. Oncology., Tohoku Univ., Grad., Sch., Med., (5)Dept., Pathol., Tohoku Univ., Hosp.)

腫瘍随伴マクロファージにおけるアンドロゲン誘導性性因子 CCL5 は乳癌の進展に寄与する  
山口 美桜<sup>1</sup>、高木 清司<sup>1</sup>、三木 康宏<sup>2</sup>、小野寺 好明<sup>3</sup>、石田 孝宣<sup>4</sup>、笹野 公伸<sup>5</sup>、鈴木 貴<sup>1</sup> (1)東北大・院医・病理検査学、<sup>2</sup>東北大・災害科学国際研、<sup>3</sup>東北大・院医・病理診断学、<sup>4</sup>東北大・院医・乳腺・内分泌外科学、<sup>5</sup>東北大・病院・病理部)

## P-1341 Significance of CLEC2D expression in breast cancer

Yui Kurihara<sup>1</sup>, Kiyoshi Takagi<sup>1</sup>, Yasuhiro Miki<sup>2</sup>, Takanori Ishida<sup>3</sup>, Hironobu Sasano<sup>4,5</sup>, Takashi Suzuki<sup>1</sup> (1)Dept., Pathol & Histotech., Tohoku Univ., Grad., Sch., Med., (2)Disaster Obstetrics & Gynecol., IRIDEs., Tohoku Univ., (3)Dept., Breast & Endo. Surg. Oncology., Tohoku Univ., Grad., Sch., Med., (4)Dept., Anatomic Pathol., Tohoku Univ., Grad., Sch., Med., (5)Dept., Pathol., Tohoku Univ. Hosp.)

CLEC2D の乳癌における発現意義

栗原 唯<sup>1</sup>、高木 清司<sup>1</sup>、三木 康宏<sup>2</sup>、石田 孝宣<sup>3</sup>、笹野 公伸<sup>4,5</sup>、鈴木 貴<sup>1</sup> (1)東北大・院医・病理検査学、<sup>2</sup>東北大・災害科学国際研、<sup>3</sup>東北大・院医・乳腺内分泌外科学、<sup>4</sup>東北大・院医・病理診断学、<sup>5</sup>東北大・病院・病理部)

## P-1342 Cytochrome c1 in estrogen receptor-positive breast carcinoma

Ai Sato<sup>1</sup>, Kiyoshi Takagi<sup>1</sup>, Yasuhiro Miki<sup>2,3</sup>, Takanori Ishida<sup>4</sup>, Hironobu Sasano<sup>5</sup>, Takashi Suzuki<sup>1</sup> (1)Dept. Pathol & Histotech., Tohoku Univ., Grad. Sch. Med., (2)Dept. Anatomic Pathol., Tohoku Univ., Grad. Sch. Med., (3)Disaster Ob/Gyn, Int. Res. Inst. of Disaster Sci., Tohoku Univ., (4)Dept. Breast & Endo. Surg. Oncology., Tohoku Univ., Grad. Sch. Med., (5)Dept. Pathol., Tohoku Univ., Hosp.)

エストロゲン受容体陽性浸潤性乳癌における CYC1 の発現意義

佐藤 和<sup>1</sup>、高木 清司<sup>1</sup>、三木 康宏<sup>2,3</sup>、石田 孝宣<sup>4</sup>、笹野 公伸<sup>2,5</sup>、鈴木 貴<sup>1</sup> (1)東北大・院医・病理検査学、<sup>2</sup>東北大・院医・病理診断学、<sup>3</sup>東北大・災害研・災害産婦人科学、<sup>4</sup>東北大・院医・乳腺内分泌外科学、<sup>5</sup>東北大・病院・病理部)

## P-1343 Molecular characterization of Palbociclib resistance using the aromatase inhibitor-resistant breast cancer cells

Takanori Hayashi, Takashi Watanabe, Yohei Shimono (Dept. Biochem., Fujita Helth Univ., Sch. Med.)

アロマトラーゼ阻害剤耐性乳がん細胞を用いたバルボシクリブ耐性機構の解析  
林 孝典、渡辺 崇、下野 洋平 (藤田医大・医・生化)

## P14-18 Breast cancer (2) triple negative disease

乳がん (2) triple negative disease

Chairperson: Hitoshi Tsuda (Dept. Basic Path., Natl. Def. Med. Col.)

座長: 津田 均 (防衛医科大学校・病態病理学講座)

## P-1344 Characterization of URST1 as a novel prognostic biomarker and therapeutic target for triple negative breast cancer

Masako Nakamura<sup>1</sup>, Atsushi Takano<sup>1,2</sup>, Thang PhungManh<sup>1,2</sup>, Yohei Miyagi<sup>3</sup>, Yataro Daigo<sup>1,2</sup> (1)Med. Oncol. & Vaccine Ctr, Shiga Univ. of Med. Sci., (2)Antibody & Vaccine Therapy, Inst. Med. Sci., Univ. of Tokyo, (3)Dept. Mol. Pathol. Kanagawa Cancer Ctr.)

トリプルネガティブ乳癌に対する新規予後バイオマーカーおよび治療標的としての URST1 の特性

中村 正子<sup>1</sup>、高野 淳<sup>1,2</sup>、フン マンタン<sup>1,2</sup>、宮城 洋平<sup>3</sup>、醍醐 弥太郎<sup>1,2</sup> (1)滋賀医大臨床腫瘍学講座、<sup>2</sup>東京大・医科研・抗体ワクチンセ、<sup>3</sup>神奈川県がんセンター)

## P-1345 Trial of quantitative and qualitative evaluation of tumor infiltrating lymphocytes in triple negative breast cancer

Toshihiko Mikami<sup>1</sup>, Hideji Masuoka<sup>1</sup>, Yoshihiko Hirohashi<sup>2</sup>, Hiroaki Shima<sup>3</sup>, Goro Kutomi<sup>3</sup>, Kiyoshi Furumura<sup>1</sup>, Kazuhiko Matuo<sup>4</sup>, Toshihiko Torigoe<sup>2</sup>, Kazuaki Asaishi<sup>1</sup> (1)Sapporo Kotoni breast clinic, (2)Dept. Path. 1, Sapporo Med. Univ., (3)Dept. Surg., surgical Oncology & Sci., Sapporo Med. Univ., (4)Sapporo Clin. Lab. Inc)

トリプルネガティブ乳癌における腫瘍浸潤リンパ球の量的評価と質的評価の試み

三神 俊彦<sup>1</sup>、増岡 秀次<sup>1</sup>、廣橋 良彦<sup>2</sup>、島 宏彰<sup>3</sup>、九富 五郎<sup>3</sup>、古村 喜好<sup>4</sup>、松尾 和彦<sup>4</sup>、鳥越 俊彦<sup>2</sup>、浅石 和昭<sup>1</sup> (1)札幌ことに乳腺クリニック、<sup>2</sup>札幌医大・医・第一病理、<sup>3</sup>札幌医大・医・第一外科、<sup>4</sup>札幌臨床検査セ)

## P-1346 High microsatellite instability tumours might be absent among TIL-high triple negative breast cancers

Yoshiya Horimoto<sup>1,2</sup>, Harumi Sacki<sup>2</sup>, Aiko Arakawa<sup>3</sup>, Shuji Matsuoka<sup>4</sup>, Shigehisa Kitano<sup>5</sup>, Mitsue Saito<sup>1</sup> (1)Dept. Breast Oncol., Juntendo Univ. Sch. Med., (2)Dept. Pathol. Oncol., Juntendo Univ. Sch. Med., (3)Dept. Human Pathol., Juntendo Univ. Sch. Med., (4)Dept. Immunol. Diag., Juntendo Univ. Grad. Sch. Med., (5)Dept. Exp. Therap., Nat. Cancer Ctr.)

腫瘍浸潤リンパ球の高度なトリプルネガティブ乳癌に MSI-high 腫瘍は含まれない

堀本 義哉<sup>1,2</sup>、佐伯 春美<sup>2</sup>、荒川 愛子<sup>3</sup>、松岡 周二<sup>4</sup>、北野 滋久<sup>5</sup>、齊藤 光江<sup>1</sup> (1)順天堂大・医・乳腺腫瘍学、<sup>2</sup>順天堂大・医・病理・腫瘍学、<sup>3</sup>順天堂大・医・人体病理病態学、<sup>4</sup>順天堂大・医学研究科・免疫診断学、<sup>5</sup>国立がん研セ・先端医療科)

## P-1347 Isoform specific antibody against periostin exon17 inhibits the directly binding with wnt3a in SPR binding analysis

Yuka Ikeda-Iwababu, Yoshiaki Taniyama, Ryuichi Morishita (Osaka Univ., Sch. of Med., Dept. Clin. Gene Therapy)

アイソフォーム特異的なペリオスチン エクソン 17 抗体は SPR 分析において wnt3a との結合を阻害する  
池田(岩部) 裕香、谷山 義明、森下 竜一 (大阪大・院医・臨床遺伝子治療学)

## P-1348 BRCAness As a Prognostic Factor in Breast Cancer Patients With or Without Neoadjuvant Chemotherapy

Matsunaga Yuki<sup>1</sup>, Lei Liu<sup>1,2</sup>, Sadako Akashi-Tanaka<sup>1</sup>, Mayuko Inuzuka<sup>1</sup>, Hiroko Masuda<sup>1</sup>, Arisa Ata<sup>1</sup>, Toshimitsu Yamaoka<sup>3</sup>, Motoi Oba<sup>3</sup>, Seigo Nakamura<sup>1</sup>, Junji Turutani<sup>2</sup> (1)Div. Breast Surg. Oncology, Showa Univ. Sch. of Med., (2)Advanced Cancer Translational Res. Inst., Showa Univ.)

術前化学療法あり、なし乳がん患者における予後因子としての BRCAness 検討

松永 有紀<sup>1</sup>、リウ レイ<sup>1,2</sup>、明石 定子<sup>1</sup>、犬塚 真由子<sup>1</sup>、増田 紘子<sup>1</sup>、阿多 亜里沙<sup>1</sup>、山岡 利光<sup>2</sup>、大場 基<sup>2</sup>、中村 清吾<sup>1</sup>、鶴谷 純司<sup>2</sup> (1)昭和 大・乳腺外科、<sup>2</sup>昭和 大・先端がん治療研)

**P14-20 Hematological malignancies (1)**  
 造血器腫瘍 (1)

Chairperson: Kazuya Shimoda (Div. Gastroenterology &amp; Hematology, Dept. Internal Med., Faculty of Med., Univ. of Miyazaki)

座長: 下田 和哉 (宮崎大・血液内科)

**P-1356 Establishment of diagnostic biomarkers for relapsed refractory multiple myeloma**

 Masayuki Kobayashi<sup>1,7</sup>, Hiroshi Yasui<sup>2</sup>, Kota Sato<sup>3</sup>, Tadao Ishida<sup>3</sup>, Hideto Tamura<sup>4</sup>, Hiroshi Handa<sup>5</sup>, Makoto Sasaki<sup>6</sup>, Toyotaka Kawamata<sup>2</sup>, Junya Makiyama<sup>2</sup>, Kazuaki Yokoyama<sup>2</sup>, Arinobu Tojo<sup>1,2</sup>, Yoichi Imai<sup>2</sup> (1Mol. Therapy, Inst. of Med. Sci., Tokyo Univ., 2Dept. Hematol/Oncol, Inst. of Med. Sci., Tokyo Univ., 3Dept. Hematol, Japanese Red Cross Med. Ctr., 4Dept. Hematol, Nippon Med. Sch., 5Dept. Hematol, Gunma Univ., Grad. Sch. of Med., 6Dept. Hematol, Juntendo Univ., Sch. of Med., 7Dept. Hematol, Tokyo Metropolitan Bokutoh Hosp.)

**多発性骨髄腫における治療抵抗性バイオマーカーの探索**

 小林 真之<sup>1,7</sup>、安井 寛<sup>2</sup>、佐藤 広太<sup>3</sup>、石田 禎夫<sup>3</sup>、田村 秀人<sup>4</sup>、半田 寛<sup>5</sup>、佐々木 純<sup>6</sup>、川俣 豊隆<sup>2</sup>、牧山 純也<sup>2</sup>、横山 和明<sup>2</sup>、東條 有伸<sup>1,2</sup>、今井 陽一<sup>2</sup> (1東京大・医科研・分子療法分野、2東京大・医科研・附属病院血液腫瘍内科、3日本赤十字社医療セ・血液内科、4日本医大・血液内科、5群馬大・院・血液内科、6順天堂大・血液内科、7東京都立墨堤病院・血液内科)

**P-1357 Resistance of pyrimidine analogs in primary lymphoma cells is induced by exosomes from cancer associated fibroblasts**

 Shunsuke Kunou<sup>1</sup>, Kazuyuki Shimada<sup>1</sup>, Tomoya Hikita<sup>2</sup>, Akihiko Sakamoto<sup>3</sup>, Chitose Onayama<sup>3</sup>, Hitoshi Kiyoi<sup>1</sup> (1Dept. Hematology & Oncology, Nagoya Univ. Grad. Sch. of Med., 2Div. Cancer Cell Regulation, Aichi Cancer Ctr. Res. Inst., 3Dept. Mechanism of Aging, Natl. Ctr. for Geriatrics Gerontology)

**癌関連線維芽細胞由来のエクソソームはリンパ腫細胞の薬剤耐性を誘導する**

 久納 俊祐<sup>1</sup>、島田 和之<sup>1</sup>、疋田 智也<sup>2</sup>、坂本 明彦<sup>3</sup>、小根山 千歳<sup>2</sup>、清井 仁<sup>1</sup> (1名古屋大・院・血液・腫瘍内科学、2愛知県がんセ・腫瘍制御学分野、3国立長寿医療研究セ)

**P-1358 Identification and functional analysis of interacting proteins for DNA cytosine deaminase APOBEC3B**

 Yasuhiro Kazuma<sup>1</sup>, Kotaro Shirakawa<sup>1</sup>, Hiroyuki Matsui<sup>1</sup>, Hiroyuki Yamazaki<sup>1</sup>, Tadahiko Matsumoto<sup>1</sup>, Shinji Ito<sup>2</sup>, Akifumi Takaori<sup>1</sup> (1Dept. Hematol. Oncol., Kyoto Univ., Sch. Med., 2Med. Res. Support Ctr., Kyoto Univ., Sch. Med.)

**シトシン脱アミノ化酵素 APOBEC3B の相互作用蛋白の同定と機能的解析**

 数馬 安浩<sup>1</sup>、白川 康太郎<sup>1</sup>、松井 宏行<sup>1</sup>、山崎 寛章<sup>1</sup>、松本 忠彦<sup>1</sup>、伊藤 慎二<sup>2</sup>、高折 晃史<sup>1</sup> (1京都大・医・血液腫瘍内科学、2京都大・医・医学研究支援セ)

**P-1359 IgVH clonality analysis of *in situ* follicular neoplasia (ISFN)**

Fumiko Arakawa, Satoko Ogata, Hiroaki Miyoshi, Koichi Ohshima (Dept., Path., Kurume Univ., Sch. Med.)

***in situ* follicular neoplasia (ISFN) の IgVH クローン解析**  
 荒川 文子、尾形 智子、三好 寛明、大島 孝一 (久留米大・医・2病理)

**P-1360 Analysis of the downstream signals of BCR-&#x2012;ABL in CML cells**

Kenta Moriyama, Toshiyuki Hori (Biomed. Sci., Grad. Sch. Life. Sci., Ritsumeikan Univ.)

**CML 細胞における BCR&#x2012;ABL の下流シグナルの解析**  
 森山 健太、堀 利行 (立命館大・生命研・生命医科学)

**P-1403 Involvement of altered translation machinery in leukemogenesis**

 Satoru Shinriki<sup>1</sup>, Akinori Kanai<sup>2</sup>, Akiko Nagamachi<sup>2</sup>, Toshiya Inaba<sup>2</sup>, Hirotaka Matsui<sup>1</sup> (1Dept. Mol. Lab. Med., Kumamoto Univ., 2Dept. Mol. Oncol., Res. Inst. Rad. Biol. Med., Hiroshima Univ.)

**白血病発症における翻訳異常の関与**

 神力 悟<sup>1</sup>、金井 昭教<sup>2</sup>、長町 安希子<sup>2</sup>、稲葉 俊哉<sup>2</sup>、松井 啓隆<sup>1</sup> (1熊本大・医・臨床病態解析学、2広島大・原医研・がん分子病態研究分野)

**P-1349 Correlation between PTEN reduction and metaplastic breast carcinoma**

 Takahiro Suzuki<sup>1,2</sup>, Yoko Nakanishi<sup>1</sup>, Tomoaki Inoue<sup>1</sup>, Yukari Hirofumi<sup>1</sup>, Haruna Nishimaki<sup>1</sup>, Hiroko Kobayashi<sup>1</sup>, Sumie Ohni<sup>1</sup>, Yoshiaki Kusumi<sup>1</sup>, Xiaoyan Tang<sup>1</sup>, Kenichi Hakamada<sup>2</sup>, Shinobu Masuda<sup>1</sup> (1Dept. Path., Nihon Univ., Sch. Med., 2Dept. Gastroenterol. Surg., Hirosaki Univ., Grad. Sch. Med.)

**PTEN 発現低下と乳腺化生癌との相互関係**

 鈴木 貴弘<sup>1,2</sup>、中西 陽子<sup>1</sup>、井上 智章<sup>1</sup>、廣谷 ゆかり<sup>1</sup>、西巻 はるな<sup>1</sup>、小林 博子<sup>1</sup>、大荷 澄江<sup>1</sup>、楠美 嘉晃<sup>1</sup>、唐 小燕<sup>1</sup>、袴田 健一<sup>2</sup>、増田 しのぶ<sup>1</sup> (1日本大・医・病理、2弘前大・院医・消化器外科)

Room P(B) Sep. 26 (Thu.) 17:15-18:00

E/J

**P14-19 Ovarian cancer**  
 卵巣がん

Chairperson: Nozomu Yanaihara (Dept. Obstetrics &amp; Gynecol., The Jikei Univ. Sch. of Med.)

座長: 矢内原 臨 (東京慈恵会医大・産婦人科学講座)

**P-1350 Identification of unique miRNA profiling in squamous cell carcinoma arising from mature teratoma of ovary**

Kosuke Yoshida, Akira Yokoi, Satoshi Tamauchi, Masato Yoshihara, Nobuhisa Yoshikawa, Kimihiro Nishino, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa (Dept. Obstet. &amp; Gynecol., Nagoya Univ., Sch. Med.)

**卵巣成熟奇形腫の悪性転化における特徴的な miRNA 発現プロファイルの同定**

吉田 康将、横井 暁、玉内 学志、吉原 雅人、芳川 修久、西野 公博、新美 薫、鈴木 史朗、梶山 広明、吉川 史隆 (名古屋大・産婦人科)

**P-1351 *In vivo* pooled shRNA library screening identifies USP32 as a new drug target of epithelial ovarian cancer**

Aya Nakae, Tadashi Kimura, Kenjiro Sawada, Michiko Kodama, Kae Hashimoto, Erika Nakatsuka (ob &amp; gyne., Med., Osaka Univ.)

**生体内プール型 shRNA ライブラリースクリーニングにより同定された上皮性卵巣癌の新規治療標的候補 USP32 の検証**

中江 彩、木村 正、澤田 健二郎、小玉 美智子、橋本 香映、中塚 えりか (大阪大・医・産婦人科)

**P-1352 Immunological changes of BRCA1-KO ovarian cancer after Olaparib treatment**

 Rin Mizuno<sup>1</sup>, Kaoru Abiko<sup>2</sup>, Sachiko Kitamura<sup>1</sup>, Naoki Horikawa<sup>1</sup>, Ken Yamaguchi<sup>1</sup>, Junzo Hamanishi<sup>1</sup>, Masaki Mandai<sup>1</sup> (1Kyoto Univ. Graduate school of Med., 2Natl. Hosp. Organization Kyoto Med. Ctr.)

**BRCA1 変異を伴う卵巣癌マウスモデルにおけるオラパリブ治療によるの宿主免疫の変化**

 水野 林<sup>1</sup>、安彦 郁<sup>2</sup>、北村 幸子<sup>1</sup>、堀川 直城<sup>1</sup>、山口 建<sup>1</sup>、濱西 潤三<sup>1</sup>、万代 昌紀<sup>1</sup> (1京都大・産婦人科、2国立病院機構京都医療セ)

**P-1353 Tumor suppressive roles of MARK3 in high-grade serous ovarian carcinomas**

 Hidenori Machino<sup>1,2,3</sup>, Syuzo Kaneko<sup>1</sup>, Masaaki Komatsu<sup>1,3</sup>, Ai Dozen<sup>1</sup>, Kanto Shozu<sup>1</sup>, Ryuji Hamamoto<sup>1,3</sup> (1Div. Mol. Mod. Cancer Biol., Natl. Cancer Ctr. Res. Inst., 2Reproductive, Developmental & Aging Sci., The Univ. of Tokyo, 3Cancer Transl. Res. Team, RIKEN Ctr. for AIP project)

**高異型度卵巣漿液性がんにおける MARK3 のがん抑制遺伝子としての役割**

 町野 英徳<sup>1,2,3</sup>、金子 修三<sup>1</sup>、小松 正明<sup>1,3</sup>、同前 愛<sup>1</sup>、生水 貴人<sup>1</sup>、浜本 隆二<sup>1,3</sup> (1国立がん研セ・研・がん分子修飾制御学、2東京大・院・生殖発達加齢医学、3理研・革新知能統合研究セ・がん探索医療)

**P-1354 Ferroptosis resistance may be correlated with epithelial-mesenchymal transition**

Yoko Furutake, Ken Yamaguchi, Sachiko Kitamura, Naoki Horikawa, Junzo Hamanishi, Masaki Mandai (Dept. Gynecol., Kyoto Univ., Sch. Med.)

**フェロトーシス抵抗性は上皮間葉転換と関連する**

古武 陽子、山口 建、北村 幸子、堀川 直城、濱西 潤三、万代 昌紀 (京都大・医・婦人科)

**P-1355 Development of novel microRNA replacement therapy with patient derived-exosome as a carrier**

Masaki Kobayashi, Kenjiro Sawada, Aasax Shimizu, Mayuko Miyamoto, Erika Naktuka, Michiko Kodama, Kae Hashimoto, Tadashi Kimura (Dept. Obstetrics &amp; Gynecol., Osaka Univ.)

**患者由来のエクソソームを用いた卵巣癌新規治療法の開発**

香林 正樹、澤田 健二郎、清水 亜麻、宮本 真由子、中塚 えりか、小玉 美智子、橋本 香映、木村 正 (大阪大・医・産婦人科)

## P14-21 Prostate cancer (1)

前立腺がん (1)

Chairperson: Takamitsu Inoue (Dept. Urology, Akita Univ. Grad. Sch. of Med.)  
 座長: 井上 高光 (秋田大・院医・腎泌尿器科学)

## P-1361 A new flavonoid-based agent: anticancer properties on docetaxel/cabazitaxel-resistant prostate cancer

Renato Nairo, Tomoyuki Makino, Suguru Kadomoto, Hiroaki Iwamoto, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami (Dept. Urol., Kanazawa Univ., Sch. Med. Sci.)

新規フラボノイド誘導体によるドセタキセル・カバジタキセル耐性前立腺癌細胞に対する抗腫瘍効果  
 内藤 伶奈人、牧野 友幸、門本 卓、若本 大旭、泉 浩二、角野 佳史、溝上 敦 (金沢大・泌尿器科)

## P-1362 Clinicopathological significance of claspin in prostate cancer

Takashi Babasaki<sup>1</sup>, Kazuhiro Sentani<sup>1</sup>, Go Kobayashi<sup>1</sup>, Yohei Sekino<sup>2</sup>, Naohiro Uraoka<sup>3</sup>, Naoya Sakamoto<sup>1</sup>, Masaki Shiota<sup>3</sup>, Naohide Oue<sup>1</sup>, Jun Teishima<sup>2</sup>, Akio Matsubara<sup>2</sup>, Wataru Yasui<sup>1</sup> (<sup>1</sup>Dept. Mol. Path., Hiroshima Univ., <sup>2</sup>Dept. Urology, Hiroshima Univ., <sup>3</sup>Dept. Urology, Kyushu Univ.)

前立腺癌における claspin の臨床病理学的分析

馬場崎 隆志<sup>1</sup>、仙谷 和弘<sup>1</sup>、小林 剛<sup>1</sup>、関野 陽平<sup>2</sup>、浦岡 直礼<sup>1</sup>、坂本 直也<sup>1</sup>、塩田 真己<sup>3</sup>、大上 直秀<sup>2</sup>、亭島 淳<sup>2</sup>、松原 昭郎<sup>2</sup>、安井 弥<sup>1</sup> (<sup>1</sup>広島大・院・分子病理学、<sup>2</sup>広島大・院・腎泌尿器科学、<sup>3</sup>九州大・院・腎泌尿器科学)

## P-1363 Shh-improved prostate stromal structure in the castrated mouse does not suppress proliferation of basal epithelial cells

Kenichiro Ishii<sup>1,2</sup>, Manabu Kato<sup>1</sup>, Masatoshi Watanabe<sup>2</sup>, Yoshiaki Sugimura<sup>1</sup> (<sup>1</sup>Dept. Nephro-Urologic Surg. & Andrology, Mie Univ. Grad. Sch. Med., <sup>2</sup>Dept. Oncologic Path., Mie Univ. Grad. Sch. Med.)

ソニック・ヘッジホッグによる間質リモデリングの改善は去勢下マウス前立腺基底上皮細胞の増殖を抑制しない  
 石井 健一朗<sup>1,2</sup>、加藤 学<sup>1</sup>、渡邊 昌俊<sup>2</sup>、杉村 芳樹<sup>1</sup> (<sup>1</sup>三重大・院医・腎泌尿器外科学、<sup>2</sup>三重大・院医・腫瘍病理学)

## P-1364 Analysis of micro RNA expression in anti-prostate cancer activity of magnetic iron oxide nanoparticles

Lisa Oshio<sup>1</sup>, Yasuhisa Nakagawa<sup>3</sup>, Masatoshi Watanabe<sup>3</sup>, Kazutoshi Iijima<sup>2</sup> (<sup>1</sup>Coll. Eng. Sci., Yokohama Natl. Univ., <sup>2</sup>Fac. Eng., Yokohama Natl. Univ., <sup>3</sup>Dept. Oncol. Pathol., Sch. Med., Mie Univ.)

磁性体ナノ粒子の抗前立腺癌活性における miRNA 発現の解析  
 大塩 里紗<sup>1</sup>、中川 泰久<sup>3</sup>、渡邊 昌俊<sup>3</sup>、飯島 一智<sup>2</sup> (<sup>1</sup>横浜国大・理工、<sup>2</sup>横浜国大・院工研院、<sup>3</sup>三重大・院医・腫瘍病理)

## P-1365 Targeting clusterin-associated proteins improve cellular sensitivity to taxane in prostate cancer

Ario Takeuchi, Masaki Shiota, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto (Dept. Urology, Grad. Sch. of Med. Sci., Kyushu Univ.)

前立腺癌においてクラスタリン関連タンパク質を標的とした治療はタキサン系薬剤の治療感受性を上昇させる  
 武内 在雄、塩田 真己、猪口 淳一、立神 勝則、江藤 正俊 (九州大・院医・泌尿器科)

## P-1366 Molecular mechanisms of AMPK mediated docetaxel-resistance in human prostate cancer

Tzyh-Chyuan Hour<sup>1</sup>, Pei-Shen Hou<sup>1,4</sup>, Chao-Yuan Huang<sup>2</sup>, Yeong-Shiau Pu<sup>2</sup>, Shu-Pin Huang<sup>3</sup>, Wen-Jeng Wu<sup>3</sup>, Chih-Pin Chuu<sup>5</sup> (<sup>1</sup>Dept. Biochem., College of Med., KMU, Kaohsiung, Taiwan, <sup>2</sup>Dept. Urology, NTUH, Taipei, Taiwan, <sup>3</sup>Dept. Urology, KMHU, Kaohsiung, Taiwan, <sup>4</sup>Grad. Inst. of Med., KMU, Kaohsiung, Taiwan, <sup>5</sup>Inst. of Cell. & System Med., NHRI, Miaoli, Taiwan)

## P14-22 Central nervous system tumors (2)

中枢神経系腫瘍 (2)

Chairperson: Mishie Tanino (Dept. Surg. Pathol. Asahikawa Med. Univ. Hosp.)  
 座長: 谷野 美智枝 (旭川医大・病院・病理)

## P-1367 Clinical significance of polyglutamylatation in primary central nervous system lymphoma

Naoki Shinojima, Kenji Fujimoto, Keishi Makino, Jun-ichiro Kuroda, Akitake Mukasa (Dept. Neurosurgery Kumamoto Univ. Hosp.)

中枢神経原発性悪性リンパ腫におけるポリグルタミル化の臨床的意義  
 篠島 直樹、藤本 健二、牧野 敬史、黒田 順一郎、武笠 晃文 (熊本大・病院・脳神経外科)

## P-1368 The miRNA signature constituted of miR-30d, miR-93, and miR-181b as promising prognostic markers in primary CNS lymphoma

Yasuo Takashima<sup>1</sup>, Atsushi Kawaguchi<sup>2</sup>, Yasuo Iwadata<sup>3</sup>, Hiroaki Hondoh<sup>4</sup>, Junya Fukai<sup>5</sup>, Koji Kajiwara<sup>6</sup>, Azusa Hayano<sup>1</sup>, Ryuya Yamanaka<sup>1</sup> (<sup>1</sup>Lab. Mol. Target Therapy Cancer, Kyoto Pref. Univ. Med., <sup>2</sup>Education & Res. Ctr. Community Med., Faculty Med., Saga Univ., <sup>3</sup>Dept. Neurosurg., Grad. Sch. Med. Sci., Chiba Univ., <sup>4</sup>Toyama Pref. Central Hosp., <sup>5</sup>Dept. Neurological Surg., Wakayama Med. Univ. Sch. Med., <sup>6</sup>Dept. Neurosurg., Grad. Sch. Med. Sci., Yamaguchi Univ.)

原発性中枢神経系リンパ腫において miR-30d, miR-93, および miR-181b からなるマイクロRNA シグネチャーは予後マーカーとなりうる  
 高島 康郎<sup>1</sup>、川口 淳<sup>2</sup>、岩立 康男<sup>3</sup>、本道 洋昭<sup>4</sup>、深井 順也<sup>5</sup>、梶原 浩司<sup>6</sup>、早野 あづさ<sup>1</sup>、山中 龍也<sup>1</sup> (<sup>1</sup>京都府医大・医・腫瘍分子標的治療学、<sup>2</sup>佐賀大・医・地域医療科学教育研究セ、<sup>3</sup>千葉大・医・脳神経外科、<sup>4</sup>富山県立中央病院、<sup>5</sup>和歌山県医大・医・脳神経外科、<sup>6</sup>山口大・医・脳神経外科)

## P-1369 Region-specific 5-hydroxymethylcytosine(5hmC) alteration affects the glioma malignant transformation

Taijun Hana<sup>1,2</sup>, Masashi Nomura<sup>1</sup>, Akitake Mukasa<sup>3</sup>, Shota Tanaka<sup>1</sup>, Genta Nagae<sup>2</sup>, Hiroyuki Aburatani<sup>2</sup> (<sup>1</sup>Univ. of Tokyo, Dept. Neurosurgery, <sup>2</sup>Univ. of Tokyo, RCAST, Genome Sci., <sup>3</sup>Kumamoto Univ., Dept. Neurosurgery)

領域特異的な 5-hydroxymethylcytosine (5hmC) の変動が Glioma 悪性転化に関与する

花 大洵<sup>1,2</sup>、野村 昌志<sup>1</sup>、武笠 晃文<sup>3</sup>、田中 将太<sup>1</sup>、永江 玄太<sup>2</sup>、油谷 浩幸<sup>2</sup> (<sup>1</sup>東京大・脳神経外科、<sup>2</sup>東京大・先端研・ゲノムサイエンス、<sup>3</sup>熊本大・脳神経外科)

## P-1370 Papaverine, an inhibitor of the HMGB1-RAGE interaction, suppresses glioblastoma

Mana Inada<sup>1,2</sup>, Akira Sato<sup>1</sup>, Mika Shindo<sup>1,3</sup>, Koichi Ichimura<sup>4</sup>, Fumiaki Uchiumi<sup>5</sup>, Sei-ichi Tanuma<sup>2</sup> (<sup>1</sup>Dept. Biochem., Fac. Pharm. Sci., Tokyo Univ. Sci., <sup>2</sup>Dept. Gene Regul., Fac. Pharm. Tokyo Univ. Sci., <sup>3</sup>Natl. Cancer Ctr. Hosp., <sup>4</sup>Div. Brain Tumor Translational Res., Natl. Cancer Ctr. Res. Inst., <sup>5</sup>Dept. Genomic Med., Res. Inst. Sci. Tech., Tokyo Univ. Sci.)

HMGB1-RAGE 相互作用の阻害剤であるパパペリンは神経膠芽腫を抑制する

稲田 愛<sup>1,2</sup>、佐藤 聡<sup>1</sup>、新藤 実香<sup>1,3</sup>、市村 幸一<sup>4</sup>、内海 文彰<sup>2</sup>、田沼 靖一<sup>5</sup> (<sup>1</sup>東京理大・薬・生化学、<sup>2</sup>東京理大・薬・遺伝子制御、<sup>3</sup>国立がん研セ・中央病院、<sup>4</sup>国立がん研セ・研・脳腫瘍連携、<sup>5</sup>東京理大・総研院・ゲノム創薬)

## P-1371 p53 Expression is a useful predictive marker for recurrence of meningioma

Atsufumi Nagahama<sup>1</sup>, Masakazu Yashiro<sup>2</sup>, Hiroki Morisako<sup>1</sup>, Takehiro Uda<sup>1</sup>, Takeo Goto<sup>1</sup>, Toshiro Takami<sup>1</sup>, Kenji Ohata<sup>1</sup> (<sup>1</sup>Dept. Neurosurgery Osaka City Univ. Grad. Sch. of Med., <sup>2</sup>Mol. Oncology & Therap. Dept. Osaka City Univ., Sch. Med.)

p53 の免疫組織学的所見における髄膜腫再発の検討

長濱 篤文<sup>1</sup>、八代 正和<sup>2</sup>、森迫 拓貴<sup>1</sup>、宇田 武弘<sup>1</sup>、後藤 剛夫<sup>1</sup>、高見 俊宏<sup>1</sup>、大畑 建治<sup>1</sup> (<sup>1</sup>大阪市大・院医脳神経外科、<sup>2</sup>大阪市大・院医腫瘍分子病態制御学)

## P-1372 Analysis of interaction of tumor cells with pericytes and endothelial cells in microenvironment of glioblastoma

Lei Wang<sup>1,2</sup>, Yuuki Ebisu<sup>1</sup>, Masumi Tsuda<sup>1,2,3</sup>, Shinya Tanaka<sup>1,2,3</sup> (<sup>1</sup>Dept. Cancer Pathol. Faculty of Med., Hokkaido Univ., <sup>2</sup>Global Institution of Collaborative Res. & Education (GI-CoRE), Hokkaido Univ., <sup>3</sup>Inst. for Chemical Reaction Design & Discovery (WPI-ICReDD), Hokkaido Univ.)

膠芽腫の血管周囲微小環境における腫瘍細胞と血管周皮細胞および血管内皮細胞との相互作用

王 磊<sup>1,2</sup>、戎 優樹<sup>1</sup>、津田 真寿美<sup>1,2,3</sup>、田中 伸哉<sup>1,2,3</sup> (<sup>1</sup>北海道大・医病理学講座腫瘍病理学教室、<sup>2</sup>北海道大・国際連携研究教育局 GI-CoRE, GSS、<sup>3</sup>北海道大・化学反応創成研究拠点)

## P14-23 Epithelial cancer and others

上皮性がん・その他

Chairperson: Michiie Sakamoto (Dept. Path., Keio Univ. Sch. of Med.)

座長: 坂元 亨宇 (慶應大・医・病理学)

## P-1373 Malignant mesothelioma patients with BAP1 and other germline mutations in relation to survival prognosis

Yoshie Yoshikawa<sup>1</sup>, Mitsuru Emi<sup>1,2</sup>, Masaki Ohmuraya<sup>1</sup>, Tomoko Hashimoto-Tamaoki<sup>1</sup> (<sup>1</sup>Dept. Genetics, Hyogo College of Med., <sup>2</sup>Univ. Hawaii Cancer Ctr.)

**BAP1** 等の遺伝子に生殖細胞系列変異を有する悪性中皮腫患者と予後  
吉川 良恵<sup>1</sup>、江見 充<sup>1,2</sup>、大村谷 昌樹<sup>1</sup>、玉置 (橋本) 知子<sup>1</sup> (兵庫医  
大・医・遺伝学、<sup>2</sup>ハワイ大・がんせ)

**P-1374 Delta-like 3 localizes to neuroendocrine cells and is a therapeutic target in gastrointestinal neuroendocrine malignancy**

**Kentarō Matsuo<sup>1</sup>, Kohei Taniguchi<sup>1,2</sup>, Hiroki Hamamoto<sup>1</sup>, Yousuke Inomata<sup>1</sup>, Takafumi Shima<sup>1</sup>, Kazuhisa Uchiyama<sup>1</sup>** (<sup>1</sup>Dept. General & Gastroenterological Surg., Osaka Med. College, <sup>2</sup>Translational Res. Program, Osaka Med. College)

**Delta-like 3 の発現様式および消化管内分泌細胞癌における治療的役割**

松尾 謙太郎<sup>1</sup>、谷口 高平<sup>1,2</sup>、濱元 宏喜<sup>1</sup>、猪俣 陽介<sup>1</sup>、島 卓史<sup>1</sup>、内山 和久<sup>1</sup> (<sup>1</sup>大阪医大・一般・消化器外科、<sup>2</sup>大阪医大・医・TR部門)

**P-1375 The novel therapeutic strategy targeting the mesenchymal phenotype by suppression of LSD1 in mesothelioma**

**Aditya Wirawan, Ken Tajima, Moulid Hidayat, Naohisa Matsumoto, Daisuke Hayakawa, Koichiro Kanamori, Kenta Izumi, Shoko Shimamura, Tetsuhiko Asao, Naoko Shimada, Yoichiro Mitsuiishi, Fumiyouki Takahashi, Kazuhisa Takahashi** (Dept. Resp Med., Juntendo Univ Grad Sch Med.)

**中皮腫における LSD1 を標的とした新たな治療法の検討**

Aditya Wirawan, 田島 健, Moulid Hidayat, 松本 直久, 早川 乃介, 金森 幸一郎, 和泉 研太, 嶋村 尚子, 朝尾 哲彦, 嶋田 奈緒子, 光石 陽一郎, 高橋 史行, 高橋 和久 (順天堂大・院医呼吸器内科学)

**P-1376 Increased expression and secretion of soluble (pro)renin receptor by anti-cancer agents in cultured cancer cells**

**Yurina Yokota, Koji Ohba, Moe Endo, Shigemitsu Sato, Kazuhiro Takahashi** (Dept. Endocrinol. & Appl. Med. Sci., Tohoku Univ. Grad. Sch. Med.)

**培養ヒト乳癌細胞及び培養ヒト肺癌細胞における抗がん剤による可溶性プロレニン受容体の発現と分泌の増加**

横田 柚梨菜、大場 浩史、遠藤 萌恵、佐藤 重光、高橋 和広 (東北大・医・内分泌応用医学分野)

**P-1377 Evaluation of CT texture features as prognostic markers in patients with laryngeal squamous cell carcinoma**

**Hanyue Xu<sup>1</sup>, Xuelei Ma<sup>2</sup>** (<sup>1</sup>West China Sch. of Med., Sichuan Univ., <sup>2</sup>State Key Lab. of Biotherapy, Sichuan Univ.)

**P-1378 Gut microbiome and metabolic profiling of opisthorchiasis hamster reveal the possible biomarkers for cholangiocarcinoma**

**Ornuma Haonon<sup>1,2,3</sup>, Zhigang Liu<sup>4</sup>, Anucha Puapairoj<sup>5</sup>, Porntrip Pinlaor<sup>2,6</sup>, Ubong Cha'on<sup>2,7</sup>, Jia V.Li<sup>4</sup>, Somchai Pinlaor<sup>1,2</sup>** (<sup>1</sup>Dept. Parasitology, Faculty of Med., Khon Kaen Univ., Thailand, <sup>2</sup>Chronic Kidney Disease Northeastern Thailand, Faculty of Med., Thailand, <sup>3</sup>Grad. school, Khon Kaen Univ., Thailand, <sup>4</sup>Faculty of Med., Imperial College London, UK, <sup>5</sup>Dept. Path., Faculty of Med., Khon Kaen Univ., Thailand, <sup>6</sup>Faculty of Associated Med. Sci., Khon Kaen Univ., Thailand, <sup>7</sup>Dept. Biochem., Faculty of Med., Khon Kaen Univ., Thailand)

## 15 Diagnosis

Room **P(B)** Sep. 26 (Thu.) 17:15-18:00

**E/J**

**P15-3 Diagnostic imaging**

画像診断

Chairperson: Kohei Sano (Lab. Biophys. Chem., Kobe Pharm. Univ.)

座長: 佐野 紘平 (神戸薬科大・薬品物理化学)

**P-1379 Development of convolutional neural network to classify glioma grading and its evaluation by Grad-CAM**

**Satoshi Takahashi<sup>1,2,3</sup>, Shota Tanaka<sup>3</sup>, Ryuji Hamamoto<sup>1,2</sup>, Wataru Takahashi<sup>4</sup>, Takahiro Nakamoto<sup>4</sup>, Erika Yamazawa<sup>3</sup>, Masamichi Takahashi<sup>3</sup>, Nobuhito Saito<sup>3</sup>** (<sup>1</sup>NCC, Dept. Mol. Modification & Cancer Biol., <sup>2</sup>RIKEN AIP center, <sup>3</sup>Dept. of Neurosurgery The Univ. of Tokyo Hosp., <sup>4</sup>Dept. of Radiology The Univ. of Tokyo Hosp., <sup>5</sup>NCC, Dept. of Neurosurgery)

**神経膠腫の悪性度分類を行う深層学習装置の作成と Grad-CAM によるその評価**

高橋 慧<sup>1,2,3</sup>、田中 將太<sup>3</sup>、浜本 隆二<sup>1,2</sup>、高橋 渉<sup>4</sup>、仲本 宗泰<sup>4</sup>、山澤 恵理香<sup>3</sup>、高橋 雅道<sup>3</sup>、斎藤 延人<sup>3</sup> (<sup>1</sup>国立がん研セ・がん分子修飾制御学分野、<sup>2</sup>理研・革新知能統合研究セ、<sup>3</sup>東京大・医・附属病院・脳神経外科、<sup>4</sup>東京大・医・附属病院・放射線科、<sup>5</sup>国立がん研セ・脳神経外科)

**P-1380 Synthesis and evaluation of radioiodinated nitroxide probe for lipid alkyl radicals**

**Toshihide Yamasaki, Kohei Sano, Masayuki Munekane, Takahiro Mukai** (Kobe Pharm. Univ.)

**脂質アルキルラジカルを標的とする放射性ヨウ素標識ニトロキシドプローブの合成と評価**

山崎 俊栄、佐野 紘平、宗兼 将之、向 高弘 (神戸薬大)

**P-1381 Development of cancer stromal targeting diagnostic method using anti insoluble fibrin antibody**

**Hirobumi Fuchigami<sup>1</sup>, Makoto Wakatsuki<sup>1,2</sup>, Masahiro Yasunaga<sup>1,2</sup>, Yasuhiro Matsumura<sup>1,2</sup>** (<sup>1</sup>Div. Developmental Therap., Natl. Cancer Ctr., <sup>2</sup>Grad. Sch. of Frontier Sci., Univ. of Tokyo)

**抗不溶性フィブリン抗体によるがん間質を標的としたイメージング剤の合成と評価**

山崎 俊栄、佐野 紘平、宗兼 将之、向 高弘 (神戸薬大)

**P-1382 Prediction of overall survival by the MRI radiomic signature in tongue cancer patients without distant metastasis**

**Xindi Song<sup>1</sup>, Xuelei Ma<sup>2</sup>** (<sup>1</sup>West China Sch. of Med., Sichuan Univ., <sup>2</sup>Dept. Biotherapy Oncology, West China Hosp. of Sichuan Univ.)

Room **P(B)** Sep. 26 (Thu.) 17:15-18:00

**E/J**

**P15-4 Development of novel biomarker of cancer (1)**

がんの新規バイオマーカーの探索 (1)

Chairperson: Katsuya Tsuchihara (Div. Translational Informatics, Exploratory Oncol., Res. & Clin. Trial Ctr., Natl. Cancer Ctr.)

座長: 土原 一哉 (国立がん研セ・先端医療開発セ・トランスレーションインフォマティクス分野)

**P-1383 M2 macrophages as a source of soluble PD-L1 in non-small-cell lung cancer**

**Koji Teramoto<sup>1</sup>, Tomoyuki Igarashi<sup>2</sup>, Hidetoshi Sumimoto<sup>1</sup>, Yataro Daigo<sup>1</sup>** (<sup>1</sup>Dept. Med. Oncol. & Cancer Ctr., Shiga Univ. Med. Sci., <sup>2</sup>Dept. Surg., Shiga Univ. Med. Sci.)

**非小細胞肺癌における M2 マクロファージによる可溶性 PD-L1 の意義**

寺本 晃治<sup>1</sup>、五十嵐 知之<sup>2</sup>、住本 秀敏<sup>1</sup>、醍醐 弥太郎<sup>1</sup> (滋賀医大・医・臨床腫瘍学、<sup>2</sup>滋賀医大・医・呼吸器外科)

**P-1384 Urine cfDNA reflects tumor genetic alterations, predicts muscle invasion and recurrence in urothelial bladder cancer**

**Yosuke Hirotsu<sup>1</sup>, Hitoshi Yokoyama<sup>2</sup>, Kenji Amamiya<sup>1</sup>, Kyoko Hosaka<sup>2</sup>, Hitoshi Mochizuki<sup>1,3</sup>, Toshio Oyama<sup>4</sup>, Masao Omata<sup>3,5</sup>** (<sup>1</sup>Genome Analysis Ctr., Yamanashi Central Hosp., <sup>2</sup>Dept. Urology, Yamanashi Central Hosp., <sup>3</sup>Dept. Gastroenterol., Yamanashi Central Hosp., <sup>4</sup>Dept. Path., Yamanashi Central Hosp., <sup>5</sup>Univ. of Tokyo)

**膀胱癌の尿中 cell free DNA は腫瘍ゲノムプロファイルを反映し、筋肉浸潤や再発予測に有用である**

弘津 陽介<sup>1</sup>、横山 仁<sup>2</sup>、雨宮 健司<sup>1</sup>、保坂 恭子<sup>2</sup>、望月 仁<sup>1,3</sup>、小山 敏雄<sup>4</sup>、小俣 政男<sup>3,5</sup> (<sup>1</sup>山梨県立中央病院・ゲノム解析セ、<sup>2</sup>山梨県立中央病院・泌尿器科、<sup>3</sup>山梨県立中央病院・消化器内科、<sup>4</sup>山梨県立中央病院・病理部、<sup>5</sup>東京大)

**P-1385 High-purity isolation method of rare cells for molecular analyses using microfluidic chip type cell sorter**

**Koichi Sato, Yasuhiro Koh, Mio Ikeda, Jun Oyanagi, Hiroki Ueda, Nobuyuki Yamamoto** (Int Med. III. Wakayama Med. Univ.)

**マイクロ流路チップ・セルソーターを用いた希少細胞高純度単離法の開発**

佐藤 孝一、洪 泰浩、池田 美央、小柳 潤、上田 弘樹、山本 信之 (和歌山県医大・第三内科)

**P-1386 Establishment of a diagnostic model PSA G-Index as a non-invasive secondary screening biomarker for prostate cancer**

**Yoshimi Haga<sup>1</sup>, Motohide Uemura<sup>2</sup>, Shusuke Akamatsu<sup>3</sup>, Kentaro Inamura<sup>4</sup>, Kengo Takeuchi<sup>4,5</sup>, Osamu Ogawa<sup>3</sup>, Norio Nonomura<sup>2</sup>, Koji Ueda<sup>1</sup>** (<sup>1</sup>Cancer Proteomics Group, JFCR, <sup>2</sup>Dept. Urology, Osaka Univ. Grad. Sch. Med., <sup>3</sup>Dept. Urology, Kyoto Univ. Grad. Sch. Med., <sup>4</sup>Div. Path., JFCR, <sup>5</sup>PPMT, JFCR)

**前立腺癌特異的 PSA 糖鎖構造の同定による新規な前立腺癌診断アルゴリズム PSA G-Index の構築**

芳賀 淑美<sup>1</sup>、植村 元秀<sup>2</sup>、赤松 秀輔<sup>3</sup>、稲村 健太郎<sup>4</sup>、竹内 賢吾<sup>4,5</sup>、小川 修<sup>3</sup>、野々村 祝夫<sup>2</sup>、植田 幸嗣<sup>1</sup> (<sup>1</sup>(公財)がん研・プロテオミクス解析グループ、<sup>2</sup>大阪大・医・泌尿器科、<sup>3</sup>京都大・医・泌尿器科、<sup>4</sup>(公財)がん研・病理部、<sup>5</sup>(公財)がん研・分子標的病理プロジェクト)



P-1387 **The significance of haptoglobin phenotype in an assay of fucosylated haptoglobin and its molecular mechanism**  
Koichi Morishita, Nami Ito, Sayaka Koda, Shinji Takamatsu, Yoshihiro Kamada, Eiji Miyoshi (Dept. Mol. Biochem. & Clin. Inv., Osaka Univ., Grad Sch. Med.)

フコシル化ハプトグロビン測定におけるハプトグロビン表現型の重要性とその分子機構の解明

森下 康一、伊藤 菜美、幸田 彩也加、高松 真二、鎌田 佳宏、三善 英知 (大阪大・医学系研究科・機能診断科学講座)

P-1388 **Establishment of non-viral detection method of Circulating tumor cells targeting telomerase activation**

Masahiro Takakura, Toshiyuki Sasagawa (Dept. Obstet. & Gynecol., Kanazawa Med. Univ.)

テロメラーゼ活性を標的とした非ウイルス的循環腫瘍細胞検出法の確立  
高倉 正博、笹川 寿之 (金沢医大・産婦人科)

P-1389 **Withdrawn**

Room P(B) Sep. 26 (Thu.) 17:15-18:00

E/J

P15-5 **Novel diagnostic tools (1)**

新しい診断技術 (1)

Chairperson: Hiroshi Fujiwara (Dept. Person. Cancer. Immunother., Mie Univ. Grad. Sch. Med.)

座長: 藤原 弘 (三重大・院医・個別化がん免疫治療学)

P-1390 **Innovation in cancer diagnosis by combining mass spectrometry and machine learning**

Sen Takeda (Dept. Anat. Cell Biol. Fac. Med. Univ. Yamanashi)

質量分析と人工知能を組み合わせた新たながん診断法の開発  
竹田 扇 (山梨大・医・解剖細胞生物学)

P-1391 **Tracing trifluridine in the DNA using anti-BrdU antibodies**

Hiroyuki Kitao<sup>1</sup>, Yoshiaki Fujimoto<sup>1,2</sup>, Ryota Nakanishi<sup>2</sup>, Mamoru Nukatsuka<sup>3</sup>, Kazuaki Matsuoka<sup>3</sup>, Teiji Takechi<sup>3</sup>, Takeshi Wakasa<sup>1,3</sup>, Makoto Iimori<sup>1</sup>, Hiroshi Saeki<sup>2</sup>, Eiji Oki<sup>2</sup>, Masaki Mori<sup>2</sup> (<sup>1</sup>Dept. Mol. Cancer Biol., Grad. Sch. Phar. Sci., Kyushu Univ., <sup>2</sup>Dept. Surg. Sci., Grad. Sch. Med. Sci., Kyushu Univ., <sup>3</sup>Transl. Res. Lab., Taiho Phar. Co. Ltd.)

抗BrdU抗体を用いたDNAに取り込まれたトリフルリジンの追跡  
北尾 洋之<sup>1</sup>、藤本 禎明<sup>1,2</sup>、中西 良太<sup>2</sup>、糠塚 守<sup>3</sup>、松岡 和明<sup>3</sup>、武知 貞士<sup>3</sup>、若狭 武司<sup>1,3</sup>、飯森 真人<sup>1</sup>、佐伯 浩司<sup>2</sup>、沖 英次<sup>3</sup>、森 正樹<sup>2</sup> (九州大・薬・抗がん剤育薬、九州大・医・消化器・総合外科、<sup>2</sup>大鵬薬品工業 (株)・育薬研)

P-1392 **A large cohort study to evaluate the cancer screening test measuring serum trace and major element: Metallo-balance**

Haruo Mikami, Yohko Nakamura, Miho Kusakabe, Hiroki Nagase (Chiba Cancer Ctr. Res. Inst.)

血清中の元素濃度バランスによるがんリスク診断法 (メタロバランス法) の有効性に関するコホート研究  
三上 春夫、中村 洋子、日下部 美帆、永瀬 浩喜 (千葉がんセンター 研)

P-1393 **Detection of activities of ubiquitin-conjugating enzymes in breast cancer cell membrane**

Kazuhide Miyamoto (Faculty of Pham. Sci, Himeji Dokkyo Univ.)

乳がん細胞膜中のユビキチン結合酵素活性の検出  
宮本 和英 (姫路獨協大・薬)

P-1394 **The optimal preanalytical conditions of gastrointestinal biopsy samples for next-generation sequencing**

Tomohiro Kamori<sup>1</sup>, Eiji Oki<sup>1</sup>, Qingjiang Hu<sup>1</sup>, Koji Ando<sup>1</sup>, Hiroshi Saeki<sup>2</sup>, Yoshinao Oda<sup>3</sup>, Masaki Mori<sup>1</sup> (<sup>1</sup>Dept. Surg. & Sci., Kyushu Univ., Grad. Sch. Med., <sup>2</sup>Dept. Gastrointestinal surg., Gunma Univ. Hosp., <sup>3</sup>Dept. Anat. Pathol. Pathol. Sci., Kyushu Univ., Grad. Sch. Med.)

NGS解析に供する消化管生検検体の適切なプレアナリシス条件についての検討

家守 智大<sup>1</sup>、沖 英次<sup>1</sup>、胡 慶江<sup>1</sup>、安藤 幸滋<sup>1</sup>、佐伯 浩司<sup>2</sup>、小田 義直<sup>3</sup>、森 正樹<sup>1</sup> (九州大・院・消化器・総合外科、<sup>2</sup>群馬大・病院・消化管外科、<sup>3</sup>九州大・院・形態機能病理学)

P-1395 **ABCG2 expression is related to 5-ALA photodynamic diagnosis (PDD) efficacy**

Noriko Kawai<sup>1,2</sup>, Yoshihiko Hirohashi<sup>1</sup>, Tomohide Shiroasaki<sup>1,2</sup>, Yuma Ebihara<sup>2</sup>, Teruhumi Kubo<sup>1</sup>, Munehide Nakatsugawa<sup>1</sup>, Takayuki Kanaseki<sup>1</sup>, Tomohide Tsukahara<sup>1</sup>, Satoshi Hirano<sup>2</sup>, Toshihiko Torigoe<sup>1</sup> (<sup>1</sup>Dept. Path., Sapporo Med. Univ., <sup>2</sup>Dept. Gastroenterological Surg. II, Hokkaido Univ.)

ABCG2発現は5-ALA PDD効率に關与する

河合 典子<sup>1,2</sup>、廣橋 良彦<sup>1</sup>、城崎 友秀<sup>1,2</sup>、海老原 裕磨<sup>2</sup>、久保 輝文<sup>1</sup>、中津川 宗秀<sup>1</sup>、金関 貴幸<sup>1</sup>、塚原 智英<sup>1</sup>、平野 聡<sup>2</sup>、鳥越 俊彦<sup>1</sup> (札幌医大・病理学第1講座、<sup>2</sup>北海道大・消化器外科教室 II)

## 17 Chemotherapy and endocrine therapy

Room P(B) Sep. 26 (Thu.) 17:15-18:00

E/J

P17-2 **Plutonium compounds, antimetabolites, alkaloids, others**  
プラチナ化合物・代謝拮抗薬・アルカロイド・その他

Chairperson: Tetsuo Mashima (Cancer Chemother. Ctr., JFCR)

座長: 馬島 哲夫 ((公財) がん研・化療セ)

P-1396 **p53 status and response to trifluridine-induced DNA replication stress**

Takeshi Wakasa<sup>1,2</sup>, Makoto Iimori<sup>1</sup>, Yuki Kataoka<sup>3</sup>, Eiji Oki<sup>3</sup>, Yoshihiko Maehara<sup>3</sup>, Masaki Mori<sup>3</sup>, Hiroyuki Kitao<sup>1</sup> (<sup>1</sup>Dept. Mol. Can. Biol., Grad. Sch. Pharm. Sci., Kyushu Univ., <sup>2</sup>Discov. & Preclin. Res. Div., Taiho pharm Co., Ltd., <sup>3</sup>Dept. Surg. Sci., Grad. Sch. Med. Sci., Kyushu Univ., <sup>4</sup>Kyushu Central Hosp.)

p53ステータスがトリフルリジン誘導性DNA複製ストレス応答に与える影響

若狭 武司<sup>1,2</sup>、飯森 真人<sup>1</sup>、片岡 裕貴<sup>2</sup>、沖 英次<sup>3</sup>、前原 喜彦<sup>4</sup>、森 正樹<sup>3</sup>、北尾 洋之<sup>1</sup> (九州大・院薬・抗がん剤育薬、<sup>2</sup>大鵬薬品工業 (株)・研究本部、<sup>3</sup>九州大・院医・消化器総合外科、<sup>4</sup>九州大・中央病院)

P-1397 **Analysis of antitumor effect of eribulin in BRAF mutant colorectal cancer**

Tomoyasu Yoshihiro<sup>1</sup>, Hiroshi Ariyama<sup>1</sup>, Koichi Akashi<sup>1</sup>, Eishi Baba<sup>2</sup> (<sup>1</sup>Dept. Med. & Biosystemic Sci., Kyushu Univ., <sup>2</sup>Dept. Oncol. & Social Med., Kyushu Univ.)

BRAF変異陽性大腸癌に対するエリ布林作用機序の解析

吉弘 知恭<sup>1</sup>、有山 寛<sup>1</sup>、赤司 浩一<sup>1</sup>、馬場 英司<sup>2</sup> (九州大・医・病態修復内科、<sup>2</sup>九州大・医・社会環境医学講座)

P-1398 **Cilastatin suppresses cisplatin-induced nephrotoxicity and enables to increase the dose of cisplatin for cancer therapy**

Masashi Arita<sup>1</sup>, Satoshi Watanabe<sup>1</sup>, Nobumasa Aoki<sup>1</sup>, Miho Takahashi<sup>1</sup>, Satoshi Shoji<sup>1</sup>, Koichiro Nozaki<sup>1</sup>, Kosuke Ichikawa<sup>1</sup>, Rie Kondo<sup>1</sup>, Shoji Kuwahara<sup>2</sup>, Junta Tanaka<sup>1</sup>, Toshiyuki Koya<sup>1</sup>, Akihiko Saito<sup>2</sup>, Tosiaki Kikuchi<sup>1</sup> (<sup>1</sup>Div. Respiratory & Infectious Diseases, Niigata Univ. Hosp., <sup>2</sup>Applied Mol. Med., Niigata Univ. Med. & Dent. Hosp.)

シラスチンによりシスプラチン腎症を抑制することでシスプラチン投与を増量できる

有田 将史<sup>1</sup>、渡部 聡<sup>1</sup>、青木 信将<sup>1</sup>、高橋 美帆<sup>1</sup>、庄子 聡<sup>1</sup>、野寄 幸一郎<sup>1</sup>、市川 純将<sup>1</sup>、近藤 利恵<sup>1</sup>、桑原 領治<sup>2</sup>、田中 純太<sup>1</sup>、小屋 俊之<sup>1</sup>、斎藤 亮彦<sup>2</sup>、菊地 利明<sup>1</sup> (新潟大・医歯学総合病院・呼吸器感染症内科、<sup>2</sup>新潟大・医歯学総合病院・機能分子医学)

P-1399 **Correlation between SLFN11 expression and DNA-damaging agent in gastric cancer**

Tsuyoshi Takashima<sup>1</sup>, Naoya Sakamoto<sup>1</sup>, Junko Murai<sup>2</sup>, Daiki Taniyama<sup>1</sup>, Kazuhiro Sentani<sup>1</sup>, Naohide Oue<sup>1</sup>, Wataru Yasui<sup>1</sup> (<sup>1</sup>Dept. Mol. Pathol., Hiroshima Univ., <sup>2</sup>Inst. for Advanced Biosci., Keio Univ.)

胃癌におけるSLFN11の発現とDNA障害型抗がん剤との相関

高島 剛志<sup>1</sup>、坂本 直也<sup>1</sup>、村井 純子<sup>2</sup>、谷山 大樹<sup>1</sup>、仙谷 和弘<sup>1</sup>、大上 直秀<sup>1</sup>、安井 弥<sup>1</sup> (広島大・院医歯薬保・分子病理、<sup>2</sup>慶應大・先端生命研)

P-1400 **Involvement of homologous recombination repair deficiency in cisplatin sensitization by 2-deoxy-D-glucose**

Yuka Okamoto, Akihiro Tomida (Div. Genome Res., Cancer Chemother. Ctr., JFCR)

2-デオキシ-D-グルコースによるシスプラチン高感受性化におけるDNA相同組換え修復欠損の関与

岡本 有加、富田 章弘 ((公財) がん研・化療セ・ゲノム)

P-1401 **Design and Synthesis of Cinnamic Acid Derivatives as Anticancer Agent**

Chawannuch Mudjupa (Dept. Pharm., Maharakham Univ.)

P-1402 **Cytotoxic Evaluation of Curcumin Structure Based-Boron Compounds against Breast Cancer Cells**

Dhanita Novitasari<sup>1</sup>, Adam Hermawan<sup>1,2</sup>, Febri Wulandari<sup>1</sup>, Rohmad Yudi Utomo<sup>1,2</sup>, Riris Istighfari Jenie<sup>1,2</sup>, Dyaningtyas Dewi Pamungkas Putri<sup>1,3</sup>, Muthi<sup>1</sup> Ikawati<sup>1,2</sup>, Ratna Asmah Susidarti<sup>1,2</sup>, Edy Meiyanto<sup>1,2</sup> (<sup>1</sup>CCRC Faculty of Pharm., UGM, Indonesia, <sup>2</sup>Dept. Pharm. Chemistry, Faculty of Pharm., UGM, Indonesia, <sup>3</sup>Dept. Pharmacology Clin. Pharm., Faculty of Pharm., UGM, Indonesia)